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"The history of modern knowledge is concerned in no small degree with 
man’s attempt to escape from his previous concepts. Within the present century we 
have seen physics liberated from the cramped philosophy of a rigid causality to the 
more fluid concept of probability. We are now witnessing a similar liberation of 
medical thought by the substitution of 'syndromes' for 'disease entities'...The 
'syndrome' has its philosophical basis not in specific disease factors but in a chain 
of physiological processes, interference with which at any point produces the same 
impairment of bodily function. The same syndrome may thus arise from many 
different causes. This newer view inspires a more catholic concept of aetiology and 
renders pointless many existing controversies. But the revision of medical thought 
entailed by its application has hardly begun."
\
Professor H.P. Himsworth, M.D., 
in an address to the Royal College of 
Physicians, March 1949.
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1-26, with the following additions:-
Aj Inhibitory adenosine receptor
ACTH Adrenocorticotropic hormone
AHO Albright Hereditary Osteodystrophy
BB/Wor Bio-Breeding diabetic rats
BSA Bovine serum albumin
C Catalytic unit of adenylate cyclase
cDNA Complimentary DNA
CGRP Calcitonin gene-related peptide
AChIR Human insulin receptor in which the fourteen C-terminal
amino acids have been removed 
CHO Chinese hamster ovary
CTC Copper-tartrate-carbonate
CTx Cholera toxin
D2 Inhibitory dopamine receptor
db "Diabetes" gene
DTT Dithiothreitol
EC50 Ligand concentration at which half-maximal stimulation is
achieved
EF-Tu Bacterial elongation factor-Tu
EGF Epidermal growth factor
fa  "Fatty" gene
GAP GTPase activating protein
GH Growth hormone
GHRH
GLUT
Gpp(NH)p
G-protein
GTPyS
5-HT
HEPES
IAPP
IAP
IC50
JDDM
IGF-I
IgG
lecat
^on
KRH
LDL
MAP-2
mRNA
NEM
NZO
ob
OGTT
\>2\ras
Growth hormone-releasing hormone 
Facilitative glucose transporter 
Guanylyl 5'-[Py-imido] diphosphate
Guanine nucleotide-binding regulatory protein (individual G- 
proteins defined in text)
Guanosine 5'-[3-0-thio] triphosphate 
5-hydroxytryptamine
4- (2-hydroxyethyl)-1 -piperazineethanesulphonic acid 
Islet amyloid polypeptide (amylin)
Islet-activating protein (pertussis toxin)
Ligand concentration at which half-maximal inhibition is 
achieved
Insulin-dependent diabetes mellitus 
Insulin-like growth factor-I 
Immunoglobulin G 
Catalytic rate constant
Rate constant for hormone receptor-mediated stimulation of
adenylate cyclase activity
Krebs-Ringer-Henseleit solution
Low density lipoprotein
Microtubule-associated protein-2
Messenger RNA
N-ethylmaleimide
New Zealand Obese mice
"Obese" gene
Oral Glucose Tolerance Test
Product from the ras family of genes coding for 21 kDa 
GTP-binding proteins
P2y Inhibitory purinergic receptor
PBS Phosphate-buffered saline
PCR Polymerase chain reaction
PDE Cyclic nucleotide phosphodiesterase
PDGF Platelet-derived growth factor
PGEX Prostaglandin Ej
PHP-Ia Pseudohypoparathyroidism type la
PIA N6-phenylisopropyladenosine
PKA Cyclic AMP-dependent protein kinase
PKC Ca2+- and phospholipid-dependent protein kinase
POS Phospho-oligosaccharide
PPHP Pseudo-pseudohypoparathyroidism
PTx Pertussis toxin (islet-activating protein)
Inhibitory receptor of adenylate cyclase
Rs Stimulatory receptor of adenylate cyclase
SDS Sodium dodecylsulphate
SDS-PAGE Sodium dodecylsulphate polyacrylamide gel electrophoresis
Spec. Ac. Specific activity
stz Streptozotocin
TEMED N, N, N1, N1 tetramethylethylenediamine
TGF-a Transforming growth factor-a
Tris Tris(hydroxymethyl)aminomethane
TSH Thyroid-stimulating hormone
c~fos, c-myc Proto-oncogenic proteins which form part of a 
growth factor-regulated transcription initiation j 
complex
TPA . Tetraphorbol acetate j
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SUMMARY
It is now well-established that many hormones regulate the metabolism of 
target cells by binding to receptors which can interact with specific members of a 
family of guanine nucleotide-binding regulatory proteins (G-proteins) which can 
in turn control the activity of various intracellular effector enzymes and ion 
channels. One such effector enzyme is adenylate cyclase which is controlled by 
stimulatory (Gs) and inhibitory (Gj) proteins. Both of these proteins are 
heterotrimers consisting of a-, P- and y-subunits, with the a-subunits conferring 
the abilities to interact with particular receptors and effectors. There are at least 
three members of the GjOC-subunit family of proteins, termed GjOC-1, GjOC-2 and 
Gj(X-3. The functional significance of this multiplicity is unknown although it 
has been suggested that GjOC-2 may be responsible for mediating the inhibition of 
adenylate cyclase activity in certain systems and that each of these proteins can 
regulate K+ channel opening.
Several reports have demonstrated that the regulation of adenylate cyclase 
activity is altered in membranes prepared from liver and adipose tissue isolated 
from animals which exhibit insulin resistance associated with diabetes mellitus 
and/or obesity. In particular, the functioning of Gj has been shown to be 
attenuated, as assessed by measuring the ability of the non-hydrolysable GTP 
analogue Gpp(NH)p (guanylyl 5'-[p,y-imido]diphosphate) to inhibit forskolin- 
stimulated adenylate cyclase activity. However, subsequent work in both liver 
and adipocyte membranes from chemically-induced Type I diabetic rats suggests 
that this lesion is restricted to an attenuation in the guanine nucleotide-dependent, 
receptor-independent inhibition of adenylate cyclase as receptor-dependent 
inhibitory effects are still present.
Liver plasma membranes prepared from genetically diabetic (dbldb) mice 
expressed reduced levels of GjOC-2? Gj(X-3 and p-subunits compared with 
membranes prepared from lean animals. However, these changes were
X X I I
associated with only a partial (40%) reduction in the ability of Gpp(NH)p to 
inhibit forskolin-stimulated adenylate cyclase activity. There was no alteration in 
the ability of either glucagon or NaF to stimulate adenylate cyclase activity, 
although the maximal stimulation elicited by the p-adrenergic receptor agonist 
isoproterenol was reduced by approximately 40% in membranes from diabetic 
animals compared with those from lean animals. However, membranes from 
diabetic animals were more sensitive to stimulation by increasing concentrations 
of Gpp(NH)p than those from lean animals. Also, whilst there was no alteration 
in the expression of either of the two forms of Gsa-subunits present in liver 
plasma membranes from diabetic animals compared with those from lean 
animals, membranes from the former were better substrates for cholera toxin- 
catalysed ADP-ribosylation compared with those from lean animals. In addition, 
the ability of pertussis toxin to catalyse the ADP-ribosylation of GjOC-subunits 
was severely attenuated in membranes from diabetic animals compared with those 
from lean animals. It is proposed that a reduced concentration of py-subunits in 
membranes from diabetic animals, following from the reduced levels of p- 
subunits, alters the equilibrium between holomeric and dissociated G-protein 
subunits such that dissociation is favoured: this would account for both the 
enhanced sensitivity to activation by Gpp(NH)p and the enhanced cholera toxin- 
catalysed labelling of Gsa-subunits in membranes from diabetic animals in the 
absence of any alteration in the expression of Gsa-subunits between lean and 
diabetic animals. This may also explain why the reduction in pertussis toxin- 
catalysed labelling of GjOC-subunits was slightly greater than the reductions in 
expression of GjOC-2 and GjOc-3.
Crude adipocyte membranes from diabetic (db/db) mice exhibited 
drastically reduced responses to increasing concentrations of isoproterenol, 
glucagon and secretin compared with membranes from lean animals. However, 
the response of adenylate cyclase to stimulation by both TSH and the wasp
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venom mastoparan were similar using membranes from either lean or diabetic 
animals. The range of differences suggest the existence of specific modifications 
in either individual receptor number or function. Consistent with the lesion lying 
at the level of individual receptors rather than the G-protein system was the 
absence of any difference in the expression of the two forms of Gsoc-subunits 
between membranes from lean and diabetic animals, or any difference in their 
functioning. This was deduced from observations showing that the maximal fold 
activation above basal activity attained using NaF, which activates adenylate 
cyclase via Gs, was the same in membranes from both lean and diabetic animals. 
With respect to inhibitory regulation, an enhanced maximal response to the 
adenosine receptor agonist PIA was noted, although the maximal inhibitory 
responses to PGEj and nicotinic acid were unaltered.
Adipocyte membranes from genetically Type II diabetic CBA/Ca mice 
exhibited an enhanced stimulatory response upon incubation with increasing 
concentrations of isoproterenol compared with that seen using membranes from 
lean animals. However, the response to glucagon, which produced a potent 
stimulation of adenylate cyclase activity in membranes from lean animals, was 
abolished in membranes from obese animals. In contrast, secretin elicited a 
similar increase in adenylate cyclase activity using membranes from either set of 
animals. Whilst the activity of adenylate cyclase was markedly increased in 
membranes from obese animals when assessed in the presence of either MnCl2 or 
forskolin, NaF- and GTP-stimulated adenylate cyclase activities were identical, 
as were the levels of expression of the two forms of Gsa-subunits were similar 
in membranes from both sets of animals: these anomalies are discussed with 
regard to a possible molecular mechanism. Guanine nucleotide-mediated 
receptor-independent 'tonic' inhibitory effects were present in membranes from 
lean and obese animals, as determined by measuring the abilities of Gpp(NH)p 
and GTP to inhibit forskolin- and isoproterenol-stimulated adenylate cyclase 
activities. However, whereas the ability of GTP to inhibit isoproterenol-
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stimulated adenylate cyclase activity was severely reduced in membranes from 
obese animals compared with those from lean animals, Gpp(NH)p was capable 
of inhibiting forskolin-stimulated adenylate cyclase activity by a similar degree in 
both lean and diabetic animals. Aj adenosine receptor-mediated inhibition of 
forskolin-stimulated adenylate cyclase activity was retained, and even slightly 
enhanced, in membranes from obese animals, although the maximal inhibitions 
elicited by PGEj and nicotine acid were unaltered. These changes in inhibitory 
regulation were accompanied by small reductions in the expression of G^oc-l, 
Gj(X-2 and Gj(X-3, in the absence of any alteration in the expression of p- 
subunits. It is suggested that a reduced 'tonic' inhibitory functioning of G| in 
adipocyte membranes from obese animals may account for the enhanced 
responsiveness of adenylate cyclase to stimulation by isoproterenol compared 
with membranes from lean animals. However, this functional defect would 
appear to be distinct from that which has been found in other rodent models of 
obesity, and possible molecular mechanisms by which it may arise are discussed.
X X V
CHAPTER 1 
Introduction
1.1 DIABETES MELLITUS & INSULIN RESISTANCE
1.1.1 INTRODUCTION
Diabetes mellitus is a complex disorder characterized by alterations in 
carbohydrate, lipid and protein metabolism resulting from a deficiency of insulin or 
of its cellular metabolic actions. As a function of time, these metabolic alterations 
lead to chronic developmental changes which manifest themselves as the classical 
side-effects of diabetes. These include retinopathies, renal failure, peripheral and 
autonomic neuropathy, occlusive peripheral vascular diseases and coronary artery 
diseases (Wilson & Reeves, 1986).
1.1.2 CLASSIFICATION OF DIABETES MELLITUS
Although the initial discovery, purification and commercial availability of 
insulin had an enormous impact on the treatment of diabetes and resulted in the 
saving of countless lives, it became clear to clinicians such as Himsworth (1949) 
that diabetes is a heterogeneous disease with more aetiologies than just insulin 
deficiency. He pointed out that the disease could be divided into 'insulin-sensitive' 
and 'insulin-insensitive' types, and postulated that the latter disease was not related 
to insulin deficiency (Himsworth, 1949). This hypothesis was later confirmed by 
measurements of plasma insulin concentrations by the radioimmunoassay of Yalow 
& Berson (1960): it was found that plasma from maturity-onset, non-ketotic 
diabetics contained insulin at concentrations which were, on average, greater than 
normal, suggesting that a resistance to insulin rather than its deficiency was 
responsible for this form of diabetes.
Although it is a heterogeneous disorder, diabetes mellitus can be classified 
into two major subtypes based on these initial observations (National Diabetes Data 
Group, 1979):-
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A Insulin-Dependent Diabetes Mellitus (IDDM)
Also known as Type I diabetes, this disease is characterized by the acute 
onset of hypoinsulinaemia, due to pancreatic p-cell damage, and an abrupt onset of 
symptoms such as a susceptibility to ketoacidosis. Sufferers are therefore 
dependent on the administration of exogenous insulin to prevent ketoacidosis and 
sustain life. It is also known as 'juvenile-onset' diabetes as the onset of symptoms 
usually occurs when patients are in their teens or early twenties. Approximately ten 
percent of all diabetics suffer from IDDM (National Diabetes Data Group, 1979).
In this disease, insulin resistance is not a major contributing factor to the 
complications of the disease: although it is present in newly diagnosed diabetics, it 
is readily alleviated once insulin treatment has begun (Kruszynska & Home, 1987). 
Any insulin resistance that does occur has most likely arisen from metabolic 
derangements of the diabetic state rather than any intrinsic target tissue defect in 
insulin action (Kruszynska & Home, 1987).
B Non-Insulin-Dependent Diabetes Mellitus (NIDDM)
Sufferers of Type II or non-insulin-dependent diabetes mellitus comprise 
approximately ninety percent of the diabetic population (National Diabetes Data 
Group, 1979). Thisibmi of diabetes is usually diagnosed in adulthood, hence the 
alternative term 'maturity-onset' diabetes. Unlike Type I diabetics, patients are not 
prone to ketosis and do not require the daily administration of insulin to sustain life, 
although in some cases insulin may be administered to treat persistent 
hyperglycaemia which does not respond to dietary control or anti-hyperglycaemic 
drugs ( Olefsky et al.t 1988).
Hyperinsulinaemia and target tissue resistance to insulin are characteristic 
features of NIDDM. Furthermore, greater than half the patients with NIDDM 
exhibit obesity which is also associated with hyperinsulinaemia and insulin 
resistance (Olefsky etal., 1988).
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As this thesis is concerned with defects associated with Type II diabetes, the 
rest of this section will be devoted to the discussion of the development and 
potential mechanisms of insulin resistance associated with this state. However, to 
discuss systematically mechanisms underlying insulin resistance, we need to have 
some concept of the normal mechanism by which insulin exerts its intracellular 
effects.
1.2 THE MECHANISM OF INSULIN ACTION
1.2.1 INTRODUCTION
Insulin exerts a variety of anabolic effects in its three principal target tissues 
which are liver, skeletal muscle and fat (Denton et al., 1981). Rapid effects of 
insulin include the stimulation of glucose uptake in skeletal muscle and fat, as well 
as the activation (e.g., glycogen synthase and pyruvate dehydrogenase) and 
inhibition (e.g., hormone-sensitive lipase) of specific regulatory enzymes (Denton 
et al., 1981). Slower responses to insulin include those involved in regulating cell 
growth, such as the induction of c-fos and c-myc, which may take many hours to 
be expressed (Mottola & Czech, 1984; Stumpo et al., 1988; Banskota et al.,
1989).
All these events are initiated by the binding of insulin to its receptor in the 
plasma membrane.
1.2.2 STRUCTURE & FUNCTION OF THE HUMAN INSULIN RECEPTOR
The structure of this receptor was initially determined by chemically cross- 
linking [1 2 5 I]insulin to its receptor, as well as by using biosynthetic and cell surface 
labelling techniques (Czech, 1985). It is an integral membrane glycoprotein with an 
approximate Mf=450kDa, composed of two a-subunits (Mr=130 kDa) and two P- 
subunits (Mj==95 kDa) which are linked by disulphide bonds (Figure 1.1) (Czech, 
1985). Affinity-labelling experiments using insulin derivatives predominantly
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Figure 1.1:
Diagrammatical Representation Of The Human Insulin Receptor
The top figure depicts the intron/exon structure of the human insulin 
receptor. The 22 exons, their intronic boundaries and the corresponding coding 
regions of the receptor are shown.
The bottom figure gives depicts a simple structural model of the human 
insulin receptor in the plasma membrane. The blocks represent known functional 
domains, some of which are encoded by specific exons. Important tyrosine 
residues, either autophosphorylation sites (1146,1150,1151) or a presumed site of 
interactions with other proteins (960) are indicated as 'Y*. Two possible signal 
transduction mechanisms are shown; a non-covalent interaction with a G-protein 
which then couples to a second messenger-generating enzyme (phospholipase) 
resulting in diacylglycerol (DAG) and POS formation from the hydrolysis of a 
phosphatidylinositolglycan (PIglycan), and the tyrosyl phosphorylation of 
endogenous insulin receptor substrates (S) is also shown.
The figures are taken from Olefsky (1990).
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affect the a-subunit, suggesting that this subunit is responsible for insulin binding 
(Massagud et al., 1981). However, even though two a-subunits are present per 
receptor molecule, the binding capacity of purified human insulin receptor is 
between 1 and 1.5 mol of insulin/mol of receptor (Petruzzelli et al., 1982): the 
reasons for this discrepancy are unknown.
cDNA clones encoding the human insulin receptor were initially isolated 
from a human placental cDNA library using synthetic oligonucleotide probes 
designed from N-terminal amino acid sequences obtained from the a -  and 13- 
subunits of purified human placental insulin receptor (Ullrich et al., 1985b; Ebina 
et al., 1985). More recently it has been shown that this cDNA is derived from a 
single insulin receptor gene of greater than 120 Kbases in size, composed of 22 
exons and which is located on the short arm of chromosome 19 (Seino et al.,
1989). As has been demonstrated for the low-density lipoprotein (LDL), platelet- 
derived growth factor (PDGF) and epidermal growth factor (EGF) receptors, the 
insulin receptor is a protein consisting of several specific functional domains, some 
of which are encoded by distinct exons within its gene (Gilbert, 1985; Williams, 
1989; Olefsky, 1990). Such a striking correlation between intron/exon structure 
and functionality suggests that such multidomain proteins have arisen by a series of 
exon shuffling and gene duplication events. Therefore, the insulin receptor can be 
seen as the product of a gene which may have evolved by the assembly of existing 
DNA sequences producing a novel gene. During the course of evolution, both gene 
rearrangements and degeneration of function at the protein level could have led to 
the overlap of functions across intron/exon boundaries (Olefsky, 1990).
The insulin receptor is synthesized as a single chain precursor containing 
either 1343 or 1355 amino acids preceded by a 27 residue signal sequence (Ullrich 
et al., 1985b; Seino & Bell, 1989). During processing and transport from the 
endoplasmic reticulum to the plasma membrane the signal sequence is removed, the 
sequence of basic amino acids joining the a -  and p-chains is cleaved,
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oligosaccharides are added at specific side-chains and acylation occurs (Czech, 
1985; Hedo et al., 1987): these events lead to the formation of an (ap) structure, 
the chains being linked by disulphide bonds. Two such processed monomers can 
associate with each other and form disulphide-linked dimers, (aP)2, which is the 
form of the mature receptor (Czech, 1985).
A Insulin Binding
Within each receptor molecule, the two a-subunits are identical and 
completely extracellular. They contain either 719 or 731 residues depending on the 
presence of a 1 2  amino acid insert which arises due to alternate splicing of exon 1 1  
within the receptor mRNA: such splicing appears to occur in a tissue-specific 
manner (Seino & Bell, 1989).
Within each a-subunit is a Cys-rich region which is critical for ligand 
binding (Ullrich et al., 1985b). A similar region has been identified within the 
ligand binding pockets of the EGF, PDGF and IGF-I receptors (Ullrich & 
Schlessinger, 1990). Interaction of the insulin molecule with other regions of the 
a-subunit has also been claimed, implying that these regions form a three- 
dimensional structure with the Cys-rich region to form the high-affinity binding 
site. The alternate splicing event within exon 11 has been shown to modify insulin 
binding affinity: inclusion of these residues produces a molecule with a 2- to 3-fold 
lower binding affinity for insulin (McClain et al., 1989b).
B Insulin-sensitive Tyrosyl Kinase Activity
The p-subunit of the human insulin receptor is a membrane-spanning 
protein containing 620 amino acids of which 403 residues are located in the 
cytoplasm and which are responsible for initiating insulin's effects in target tissues / 
(Ullrich et al., 1985b; Ebina et al., 1985). The most important finding made in 
recent years has been the identification of this portion of the insulin receptor as an
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insulin-sensitive tyrosyl kinase (Kasuga et al., 1982). Such a property has been 
identified in every cell-type that responds to insulin, and can also be demonstrated 
using solubilised receptors (Gammeltoft & Van Obberghen, 1986; Olefsky, 1990). 
This is a property shared by several growth factor receptors, including EGF, 
PDGF, TGFa, and IGF-I, as well as some oncogene products, such as src, ros 
and erb-B (Ullrich & Schlessinger, 1990). Therefore the insulin receptor has been 
assigned as a member of the src family of protein kinases (Ullrich et al., 1985b). 
In support of this hypothesis, analysis of the deduced amino acid sequence from the 
insulin receptor cDNA reveals the presence of an ATP-binding site (confirming 
biochemical studies by Shia & Pilch (1983)) as well as several Tyr residues which 
are capable of being autophosphorylated (Ullrich et al., 1985b; Ebina et al., 1985; 
Tavard et al., 1988).
Binding of insulin to the a-subunit induces a conformational change which 
relieves its inhibitory effect on the tyrosyl kinase activity of the p-subunit, and 
initiates a rapid cascade of autophosphorylation of the receptor on specific Tyr 
residues (White et al., 1988). Three Tyr residues (residues 1146, 1150 and 1151 
from the cDNA sequence of the original human receptor cDNA, which comprise 
"autophosphorylation domain A") are phosphorylated very rapidly after insulin 
binding and are the most important sites associated with an active receptor kinase 
(White et al., 1988; Tornqvist et al., 1987). Indeed, substitution of these Tyr 
residues for other amino acids causes a reduction in receptor kinase activity and 
compromises biological signalling with respect to glucose uptake (Ellis et al., 
1986a) but not with respect to insulin's mitogenic effects (Olefsky, 1990). 
However, mutation of the presumed ATP-binding site at Lys 1018 to Ala abolishes 
all cellular responses to insulin mediated by this receptor when it is transfected into 
rat fibroblasts (McClain et al., 1987). Two other Tyr residues in the C-terminal 
region of the molecule ( Tyr 1316 & 1322) are also thought to be important in 
mediating signal transduction by the receptor as they are also autophosphorylated 
after exposure of the receptor to insulin, although they are not phosphorylated as
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rapidly in the intact cell as domain A (Tavare et al., 1988).
Other studies on receptor constructs with either deletions or truncations 
which cause a loss in kinase activity also exhibit a loss of biological activity, further 
emphasizing the importance of the integrity of this property for signal transduction 
by the insulin receptor (Ellis et al., 1986b; Ellis et al., 1987). Experiments carried 
out on Rat-1 fibroblasts transfected with the ATP-binding site-defective human 
receptor (Lys 1018 substituted with Ala) have shown that although this receptor 
does not signal any of insulin's metabolic effects, the functioning of the native rat 
receptors is inhibited (McClain et al., 1987; Chou et al., 1987). The mechanisms 
by which this occurs are unclear: it is possible that both inactive rat/human receptor 
hybrids and mutant human receptors compete with the endogenous receptors for the 
next step in the signalling process (McClain et al., 1987; Chou et al., 1987).
C Post-Receptor Signal Transduction Mechanisms
As previously described, the insulin receptor can be thought of as a 
multidomain protein. Presumably some of these domains will be involved in 
mediating the interaction of the receptor with other cellular proteins. For example, 
one such domain may contain binding sites for substrates of the tyrosyl kinase 
activity of the receptor: these phosphorylated, activated proteins would then be able 
to participate in downstream signalling as direct effector units or coupling 
molecules. Several cellular substrates of the insulin receptor kinase have been 
identified in intact cells, yet they have only been identified by virtue of their 
molecular weights, for example ppl85. Their function and potential importance 
remain uncertain (Kahn & White, 1988).
The unambiguous identification of an insulin receptor substrate, or any 
protein capable of interacting productively with the insulin receptor, as a 
serine/threonine kinase or phosphatase which participates in the propagation of the 
observed phosphorylation cascade would greatly enhance our understanding of the
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mechanism of insulin action. Several kinases, such as microtubule-associated 
protein 2 kinase (MAP 2 kinase), raf and ribosomal subunit S6  kinase are all 
substrates of receptor tyrosyl kinases, with the MAP 2 kinase being of particular 
interest (Czech etal., 1988; Boulton et al., 1990b).
The activity of the MAP 2 kinase is stimulated by insulin and it is also 
capable of being activated by phosphorylation on Tyr residues in vitro (Ray & 
Sturgill, 1988). The fact that phosphorylation on Ser and Thr, as well as Tyr 
residues, is required for activation of MAP 2 kinase suggests that MAP 2 kinase 
activity is highly regulated, a property shared by other kinases intimately involved 
in phosphorylation cascades (raf, cdc2+) (Anderson et al., 1990). The cloning of 
the MAP 2 kinase from a Rat-1 fibroblast cDNA library showed this kinase to be 
highly homologous to two yeast Ser kinases (KSS 1 and FUS 3) which regulate the 
yeast cell cycle response to mating factors (Boulton et al., 1990a).
Other signalling molecules have been proposed to interact directly with the 
insulin receptor. These include specific G-proteins (Heyworth et al., 1985; 
Rothenberg & Kahn, 1988; Korn et al., 1987) which may either be 
phosphorylated on Tyr (O'Brien et al., 1987a & 1987b; Krupinski et al., 1988) or 
may interact directly with the receptor without being covalently modified 
(Rothenberg & Kahn, 1988; Luttrell et al., 1990). Such a G-protein may be 
capable of coupling to a phosphatidylinositol glycan-specific phospholipase C 
whose activity has been proposed to respond to insulin, leading to the release of a 
phospho-oligosaccharide (POS) 'mediator' and the accumulation of a specific 
diacylglycerol species (Saltiel, 1990; Standaert et al., 1988) which may activate a 
specific isoform of protein kinase C (Saltiel et al., 1987; Cooper et al., 1987; 
Heidenreich et al., 1990). Some evidence has suggested that the POS mediator 
can mimick the alterations in the Ser and Thr phosphorylation/dephosphorylation 
pattern observed on exposure of rat adipocytes to insulin (Alemany et al., 1987), 
although the exact loci of action of the mediator have not yet been fully
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characterized.
D Assignment Of Domains Of The Insulin Receptor With Function
The assignment of specific domains within the p-subunit responsible for 
interactions with specific signalling molecules or events has been attempted using 
molecular biological approaches (Olefsky, 1990; McClain, 1990): these findings are 
summarized in Figure 1.1. Two regions which have yielded particularly interesting 
information are the "Tyr 960 domain" and the C-terminal region of the P-subunit.
i Tvr 960 Domain
Unlike Tyr's 1146, 1150 and 1151, Tyr's 953, 960 and 972 are not 
autophosphorylated in the intact cell after exposure to insulin (Tavar6  et al., 1988) 
although Tyr 960 can be phosphorylated in truncated receptor constructs (White et 
al., 1988). However, mutation of Tyr 960 to a Phe residue can block the insulin- 
stimulated sensitization of glucose uptake when the mutant receptor is transfected 
into Chinese Hamster ovary (CHO) cells without affecting autophosphorylation or 
tyrosyl kinase activity towards exogenous substrates (White et a l,  1988). Whilst 
the region flanking Tyr 960 is conserved between the insulin and IGF-I receptors, 
similar sequences are not present in either the EGF receptor or v-ros, perhaps 
implying that this domain may specify interaction with a signalling mechanism 
which is common to insulin and IGF-I.
ii C-Terminal Domain
The most divergent cytoplasmic region amongst tyrosyl kinases is their 
hydrophilic C-terminal region: this is partially deleted in the oncogenic forms of v- 
erb-B and v-fms compared with their proto-oncogenic sequences, suggesting a 
potential role for this region in mediating specific responses (Ullrich et al., 1984; 
Ullrich et al., 1985a and b; Ullrich et al., 1986; Coussens et al., 1986). To this 
end, mutant human insulin receptors in which the C-terminal 43 amino acids are
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deleted (termed AChIR) have been studied after transfection into Rat-1 fibroblasts 
(McClain, 1990). The truncated receptor is normally synthesized and processed 
(McClain et al., 1988) and undergoes insulin-stimulated autophosphorylation in a 
normal fashion (Maegawa et al., 1988). Similarly, the truncated receptor is still 
capable of tyrosyl phosphorylating various exogenous and endogenous substrates 
(Maegawa et al., 1988). However, the ability of insulin to sensitize intracellular 
glucose uptake is severely attenuated, presumably because the necessary structural 
information required for this process has been deleted (Maegawa et al., 1988). 
This contrasts with an enhanced ability of insulin to mediate its mitogenic effects 
(measured by [3H]thymidine uptake) in cells transfected with the AChIR constructs 
(Thies et al., 1989). Hence, whilst the C-terminal domain may contain 
information critical for signalling the metabolic effects of insulin, absence of this 
domain also appears to relieve inhibitory constraints on insulin-stimulated 
mitogenesis (Thies et al., 1989).
A concept of domain-specific insulin receptor signalling is supported by 
other mutations which can induce both selective insulin resistance (Wilden et al., 
1990) and a differential regulation of various actions of insulin (Marshall, 1990). 
For example, one study demonstrated that mutation of Tyr 1146 to a Phe residue in 
the primary autophosphorylation site had no effect on metabolic signalling yet 
mitogenic signalling was attenuated (Wilden et al., 1990). However, more 
exhaustive studies are required to assign specific domains with putative effectors or 
substrates before any meaningful picture of the mechanism of insulin signal 
transduction can be drawn.
1.3 INSULIN-RESISTANT STATES
1.3.1 INTRODUCTION
Target tissue resistance to insulin is a characteristic feature of the Type II
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diabetic state. It can be defined as the metabolic state in which a physiologically 
relevant concentration of insulin produces a subnormal response (Olefsky et al.,
1988). Such resistance to insulin can involve any of its multiple metabolic effects, 
but the hormone's effects on glucose metabolism are the most frequently studied 
and this is most often monitored in humans by the oral glucose tolerance test 
(OGTT) which measures the clearance of glucose from the blood after ingestion of 
a concentrated glucose solution (DeFronzo, 1988)
The previous section's discussion of the mechanism of insulin action in the 
normal state demonstrates that insulin resistance can potentially result from a defect 
in any point within the mechanism of signal transduction by the insulin receptor, 
from the insulin binding event to the transport of glucose into muscle and fat cells. 
The development of an insulin-resistant state and the potential mechanisms by 
which this phenomenon occur will be discussed as they apply to humans. This will 
be followed by a description of the murine models of obesity used in this thesis and 
their relevance to the Type II diabetic state as it occurs in man.
1.3.2 DEVELOPMENT OF AN INSULIN-RESISTANT STATE
The maintenance of glucose homeostasis depends on three processes which 
must occur in a co-ordinated fashion: ingestion of glucose must stimulate insulin 
secretion by the pancreas which must result in peripheral glucose uptake by muscle 
and fat, and the suppression of glucose production by the liver. Hence, defects at 
the level of either the pancreatic P-cell, muscle (the tissue which accounts for the 
majority of glucose cleared from the blood) or liver can cause diabetes. DeFronzo 
(1988) has proposed that there are two primary defects responsible for the 
development of NIDDM: in some patients the primary defect is at the level of 
insulin secretion, whilst in others it lies at the level of tissue insensitivity to insulin. 
Whichever defect initiates the diabetic syndrome, the second abnormality will 
eventually develop as both defects must be present simultaneously for full
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expression of glucose intolerance (DeFronzo, 1988).
The major difficulty in attempting to determine the initial steps in the 
pathogenesis of NIDDM is that when patients are presented to a doctor, the defects 
in insulin secretion and insulin resistance are already present (DeFronzo et al.,
1983). However, two models which attempt to explain the development of 
NIDDM are outlined below:-
A "Failing Pancreas" Theory
In these NIDDM patients, the first phase of the insulin secretory response to 
hyperglycaemia is inadequate (Ward et al., 1984; DeFronzo et al., 1983). As a 
result, glucose concentrations remain elevated after glucose administration (Steiner 
et al., 1982) and this presents a continual stimulus to the p-cell such that high basal 
insulin secretion, and a resulting hyperinsulinaemia, is necessary to return glucose 
levels to normal. As the p-cell defect becomes progressively worse, and the 
diabetes more pronounced, the basal plasma insulin response, although elevated 
compared with normal subjects, becomes insufficient to return plasma glucose 
concentrations to normal, resulting in the development of fasting hyperglycaemia. 
This causes a constitutive elevation in basal insulin secretion and fasting 
hyperinsulinaemia ensues (DeFronzo et al., 1983; Faber & Damsgaard, 1984). 
Such a persistent hyperinsulinaemic state initiates a down-regulation of insulin 
receptors and the development of post-binding insulin resistance (Insel et al., 
1980; Garvey etal., 1986; Marangou et al., 1986).
Eventually, either as a result of the initial defect or p-cell exhaustion, the 
insulin response becomes absolutely deficient and fasting hyperglycaemia will 
persist due to excessive hepatic glucose output from the liver (Olefsky et al., 1985) 
and a further reduction in glucose clearance from the blood by skeletal muscle and 
fat tissues: this is the final clinical picture of a Type II diabetic patient.
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B "Resistant Receptor" Theory
In both diabetic and non-diabetic obesity, the plasma insulin response to 
oral and intravenous glucose is greater than for normal individuals (Felig et al.,
1974). It is thought that the disturbance in some of these patients is initiated by a 
cellular defect in insulin action. Initially, the insulin resistance is not sufficient to 
either impair glucose uptake by skeletal muscle or to increase hepatic glucose 
output. However, as the insulin resistance becomes more pronounced, peripheral 
glucose uptake becomes sufficiently impaired to induce hyperglycaemia, although 
hepatic glucose output remains normal due to the hyperinsulinaemia. The 
development of persistent hyperglycaemia exacerbates the hyperinsulinaemia which 
in turn causes down-regulation of insulin receptor number and function, thereby 
compounding the insulin resistance. In many patients the continual stimulation of 
p-cells due to hyperglycaemia causes a demise in p-cell function (DeFronzo, 1988). 
Such a sequence of events has been validated in several studies (Sims et al., 1973; 
Bevilacqua et al., 1985).
1.3.3 MECHANISMS OF INDUCTION OF DIABETES
There are several loci at which insulin resistance could potentially arise:-
A Secretion Of An Abnormal Insulin Molecule
This is a very rare syndrome. Only one such individual has been reported 
in the literature (Tager et al., 1979).
B Secretion Of An Incompletely Processed Insulin Molecule
This disease is termed familial hyperproinsulinaemia. Again, this is a very 
rare disease with only two families reported to exhibit this defect (Gabbay et al., 
1976; Kanazawa et al., 1978).
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C Circulating Insulin "Antagonists"
These may take several forms. For example, excessive secretion of other 
hormones in disease states can antagonize insulin's metabolic effects. Examples 
include Cushing's syndrome (excess cortisol secretion), acromegaly (growth 
hormone secretion) and pheochromocytoma (catecholamine secretion). Of 
particular interest is the increase in glucagon secretion observed in Type I diabetes 
which may contribute to the form of insulin resistance present in newly-diagnosed 
IDDM patients (Kruszynska & Home, 1987).
Anti-insulin or anti-insulin receptor antibodies can theoretically antagonize 
the binding of insulin to the a-subunits of the receptor, although these syndromes 
are very rare (Kurz & Nabarro, 1980; Kahn et al., 1981).
D Reduced Insulin Binding
Since the development of insulin resistance is initially associated with a 
hyperinsulinaemic state, one would expect a down-regulation of cell-surface insulin 
binding sites and a reduction in binding affinity to be induced. This has been 
observed in several cell types including adipocytes (Insel et al., 1980). However, 
since many target cells possess "spare receptors" for most of insulin's biological 
effects, the relation between receptor number and physiological effect is not simple. 
For example, in rat adipocytes, maximal insulin stimulation of glucose transport 
occurs when only 10% of the insulin receptors are occupied (Kono & Barham, 
1971; Olefsky, 1976), implying that 90% of the receptors are "spare". Hence, a 
successive reduction in the number of receptors is likely to shift the dose-response 
curve for insulin stimulation of glucose transport to the right, i.e. the sensitivity to 
insulin will be compromised but not the maximal response: only when greater than 
90% of the receptors are lost will there be a reduction in the maximal response 
(Olefsky, 1976). Such a situation contrasts with liver, where only 10% of the total 
complement of insulin receptors are spare when insulin binding is compared with
15
activation of glycogen synthesis (Gammeltoft et al., 1978; Gammeltoft, 1984). It 
has been suggested that these tissue-specific binding kinetics are a result of 
adaptation to different concentrations of insulin in the portal and extraportal 
circulations (Gammeltoft & Van Obberghen, 1986).
E Post-B inding Defects
In NIDDM, only part of the insulin resistance is accounted for by a 
reduction in insulin binding to its receptor: the major component has been attributed 
to a post-binding defect(s) (Kolterman et al., 1981; Bolinder et al., 1982). Two 
insulin-stimulated events which have been intensively studied with respect to 
potential defects in NIDDM are the tyrosyl kinase activity of the receptor (both 
autophosphorylation and modification of exogenous substrates) and glucose 
transport in skeletal muscle and fat (Olefsky etal., 1988).
i Genetic Defects In Insulin Receptor Function
The types of patients most studied with respect to insulin receptor kinase 
functioning are those diabetics whose symptoms are severe and which arise due to 
genetic defects (Reddy & Kahn, 1988; Taylor et al., 1990). Diseases arising from 
such defects include type A insulin resistance (Kahn et al., 1976), lipoatrophic 
diabetes (Rossini & Cahill, 1979) and leprechaunism (Rosenberg et al., 1980). 
Numerous studies on insulin receptors in different tissues from patients with these 
syndromes have shown there to be multiple insulin receptor aberations within each 
disease, including reduced binding associated with reduced expression of the 
receptor as well as autophosphorylation defects which vary in severity between 
patients (reviewed by Reddy & Kahn (1988)).
A variety of insulin-resistant patients have been studied by Taylor et al. 
(1990) and shown to exhibit a heterogeneous range o f’defects. Mutations in the 
insulin receptors isolated from these patients can produce any alteration from a 
reduced binding capacity, impaired processing leading to reduced functional
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receptor number and reduced expression, as well as impaired tyrosyl kinase 
activity: the same alteration in function can arise from different patients exhibiting 
mutations in different parts of the insulin receptor (Taylor et al., 1990). However, 
whilst such studies are illuminating from the point of elucidating putative functions 
of various domains of the insulin receptor, they have limited relevance to the most 
common form of insulin resistance associated with NIDDM and obesity.
ii Regulatory Defects In Insulin Receptor Function
Insulin resistance associated with NIDDM and obesity is distinct from the 
defects in insulin receptor function described above. Firstly, the degree of severity 
of the insulin-resistant state varies widely between different individuals, unlike the 
above syndromes which are all severe. Secondly, the common forms of insulin 
resistance are reversible to some degree, as the resistance may be alleviated by 
fasting and weight loss (Bar et a l , 1976; Freidenberg et al., 1988), suggesting 
the existence of a readily-reversible regulatory defect.
The insulin resistance of NIDDM patients is associated with a reduced 
insulin-stimulated tyrosyl kinase activity of the receptor, with respect to 
autophosphorylation and tyrosyl phosphorylation of cellular substrates, in 
adipocytes (Freidenberg et al., 1987; Sinha et al., 1987; Thies et al., 1990) and 
hepatocytes (Caro et al., 1986) compared with non-diabetic counterparts. Studies 
on skeletal muscle have been less clear, with autophosphorylation in lean, obese 
and obese-diabetic groups being similar, yet kinase activity using exogenous 
substrates in vitro was reduced in the NIDDM patients (Caro et al., 1987; Arner 
et al. 1987). Studies on adipocyte insulin receptors from NIDDM patients have 
shown that the reduced autophosphorylation observed is probably due to a decrease 
in the proportion of receptors capable of undergoing autophosphorylation (Olefsky 
et al., 1988). The mechanism by which this occurs is unknown, although several 
possibilities have been proposed.
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It has been suggested, on the basis of both direct (Karasik et al., 1990) and 
indirect evidence (Houslay, 1989; van der Werve & Massillon, 1990) from studies 
on rodent models of obesity and insulin resistance, that there may be altered 
regulation of insulin receptor function by protein kinase C (PKC). Protein kinases 
A and C are capable of phosphorylating the insulin receptor, resulting in a 
dimunition of. insulin binding and insulin-stimulated autophosphorylation 
(Stadtmauer & Rosen, 1986; Takayama et al., 1988). Phorbol esters can also 
regulate insulin receptor internalization in some cell types (Hayachi et al., 1987). 
The regulation of insulin receptor function has received particular attention by virtue 
of the findings from studies investigating the regulation of hepatic insulin receptor 
functioning from 72 hour-starved insulin-resistant rats (Karasik et al., 1990). A 
drastic reduction in insulin-stimulated autophosphorylation of the receptor was 
noted, and was found to be associated with an increased PKC activity in both 
membrane and cytosolic fractions in livers from starved animals (Karasik et al., 
1990). It was suggested that an increase in the Ser/Thr phosphorylation by an 
enhanced PKC activity attenuated insulin receptor functioning (Karasik et al.,
1990).
In contrast, it has been noted in myocytes and hepatocytes from genetically 
obese Zucker rats that there is a reduced ability of hormone- or phorbol ester- 
stimulated PKC to inactivate glycogen synthase activity compared with their lean 
littermates (van der Werve et al., 1987; van der Werve & Massillon, 1990). This 
contrasts with the conclusions of Bushfield et al. (1990b) who observed a 
phosphorylation and inactivation of the inhibitory regulatory protein of adenylate 
cyclase, GjCX-2, in obese Zucker rat hepatocytes and ascribed this phenomenon to a 
constitutively elevated PKC activity. It is possible that the processes studied by 
these two groups of investigators are regulated by distinct PKC isoforms which are 
differentially regulated by the insulin-resistant state. In relation to this, it has been 
noted that both liver and skeletal muscle from genetically obese Zucker rats contain
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elevated levels of ^ «-l,2 -diacylglycerol compared with lean controls, which may 
result in the selective down-regulation or persistent activation of certain PKC 
isoforms (Turinsky et al., 1990).
1.3.4 INSULIN-STIMULATED GLUCOSE TRANSPORT
Facilitative diffusion of glucose across the plasma membrane is 
characteristic of virtually all animal cells. Diffusion is mediated by a family of 
facilitative glucose transporter glycoproteins which display considerable homology 
with one another in their primary sequences, but exhibit distinct tissue-specific 
patterns of expression. The family consists of five different gene products, 
designated GLUT 1 to GLUT 5 based on the chronological order of publication of 
the cDNA sequences (Bell et al., 1990). The basic characteristics and tissue 
distribution of these isoforms are detailed in Table 1.1. The transporters share a 
conserved presumed membrane topography of twelve transmembrane-spanning a- 
helices (Gould & Bell, 1990).
Insulin stimulates glucose uptake from the blood by enhancing the 
facilitative transport of glucose into skeletal muscle, heart and fat tissues (Gould & 
Bell, 1990). This is achieved by the translocation of specific transporter species 
from an intracellular vesicular pool to the plasma membrane (Cushman & Wardzala, 
1980; Suzuki & Kono, 1980). In isolated rat adipocytes, exposure to insulin 
results in a 20- to 30-fold increase in the rate of glucose transport across the plasma 
membrane (Gibbs et al., 1988). This is achieved by the translocation of GLUT 1 
and GLUT 4 to the plasma membrane, with GLUT 4 accounting for the vast 
majority of the insulin-stimulated transport in both fat (Zorzano et al., 1989) and 
skeletal muscle (Kern etal., 1990).
As previously mentioned, peripheral insulin resistance is one of the major 
pathophysiological disorders of the Type II diabetic state. As this is associated with 
a reduced insulin stimulation of glucose utilization in skeletal muscle, the glucose 
transport system is a potential locus for this insulin resistance as glucose uptake
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Table 1.1:
Family Of Human Facilitative Glucose Transporters
The table shows a list of the facilitative glucose transporters 
cloned thus far from the human genome, their size, tissue distribution and 
chromosomal locations.
The table is adapted from Gould & Bell (1990).
Common
Name
No. Of 
Amino Acids
Major Sites Of: 
Expression
Chromosomal
Location
GLUT 1 492 Fetal tissues, brain, 1
kidney & colon
GLUT 2 524 Liver, P-cell, kidney & 3
small intestine
GLUT 3 496 Many tissues 1 2
GLUT 4 509 Skeletal muscle, heart 17
& adipocytes
GLUT 5 501 Small intestine 1
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appears to be the rate-limiting step for glucose utilization in muscle (Morgan et al., 
1961). Any defect in insulin-stimulated glucose transport could potentially arise 
from perturbations in three processes: insulin receptor signal transduction 
(previously discussed), translocation of GLUT 1 and/or GLUT 4 to the plasma 
membrane or a reduced transport capacity of GLUT 1 or GLUT 4. Recent studies 
have demonstrated that induction of the Type I diabetic state in rats is associated 
with a drastic reduction in expression of GLUT 4, but not GLUT 1, in adipocytes 
(Berger et al., 1989; Sivitz et al., 1989) and skeletal muscle (Garvey et al., 1989) 
with expression of the GLUT 4 transporter in adipocytes being regulated by the 
hypoinsulinaemia but not the hyperglycaemia (Sivitz et al., 1990). In contrast, 
studies on GLUT 4 expression in various tissues from genetically Type II diabetic 
(idb/db) mice showed that reduced insulin-stimulated glucose transport in skeletal 
muscle (Chan & Tatoyan, 1984) was not associated with a reduced expression of 
GLUT 4 in diabetic animals compared with lean controls (Koranyi et al., 1990).
Numerous studies on insulin-stimulated glucose transport in adipocytes 
from Type II diabetic humans have been carried out by Olefsky and co-workers 
(Olefsky et al., 1988). NIDDM patients exhibit drastically reduced levels of low 
density microsomal- and plasma membrane-associated glucose transporters as 
measured by D-glucose-inhibitable cytochalasin B binding measurements (Olefsky 
et al., 1988). There also appears to be an impairment in the translocation of 
transporters to the plasma membrane as the rate at which maximal activation of 
glucose transport is achieved is reduced in NIDDM patients compared with non­
diabetic controls (Molina et al., 1989). Another possible mechanism for reduced 
transport in NIDDM sufferers is modification of the glucose transporter proteins: 
this has been implicated by a reduced affinity of glucose transporters for 
cytochalasin B in adipocytes from diabetic patients (Olefsky et al., 1988). 
However, it is important to emphasize that, compared with skeletal muscle, adipose 
tissue is an inconsequential depot for circulating glucose and that GLUT 4 may be
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differentially regulated in muscle in these insulin-resistant states (Ferrannini et al., 
1985; Mueckler, 1990).
Considering the rapid increase in the understanding of the proteins involved 
in glucose transport over the last three years, it is now necessary to determine the 
contribution of each of the glucose transporter subtypes (GLUT 1 or GLUT 4) in 
determining the reduced transport capacity in diabetic patients and by what 
mechanisms these changes occur.
Genetic studies are also underway in several labs in an attempt to determine 
a possible linkage between altered GLUT genes and the development of NIDDM: 
two obvious candidates are GLUT 2 (liver and P-cell transporter) and GLUT 4 
(fat and muscle). Initial studies with GLUT 1 (ubiquitous tissue distribution) have 
produced conflicting results, with one group suggesting a linkage between a genetic 
variation in GLUT 1 and a susceptibility to NIDDM and others failing to observe 
such a relation in different populations (Bell et al., 1990). Similar studies on 
GLUT 4 have also shown there to be no association of a modified gene with 
susceptibility to NIDDM (Bell et al., 1990). However as susceptibility to NIDDM 
is complex and polygenic in nature, any relation between altered glucose transporter 
genes and susceptibility to NIDDM will not be a simple one.
1.3.5 INDUCTION OF INSULIN RESISTANCE BY AMYLIN
Recently, it has been noted that islet amyloid polypeptide (IAPP or amylin), 
which is the major peptide component of pancreatic amyloid deposits found in 
diabetics, can induce insulin resistance in vitro and in vivo (Leighton & Cooper,
1990). Maximally effective concentrations of amylin, and the related calcitonin 
gene-related peptide (CGRP), can inhibit basal and insulin-stimulated glucose 
uptake into rat soleus muscle (Leighton & Cooper, 1988) and BC3 HI myocytes but 
not rat adipocytes (Molina et al., 1990). As the major glucose transporter isoform 
in BC3 HI myocytes which translocates in response to insulin is GLUT 1 and not
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Table 1.2:
Rodent Models Of Type II Diabetes Mellitus And Obesity
SINGLE GENE MUTANTS 
Obese (ob/ob) mouse 
Diabetic (db/db) mouse 
Zucker (fa/fa) rat 
Obese Yellow (Avy) mouse
POLYGENIC INHERITANCE 
Chinese hamster 
NZO mouse 
KK mouse 
Djungarian hamster 
South African hamster 
Pbb/Ld mouse 
CBA/Ca mouse
HYBRIDS
Wellesley hybrid mouse
ACQUIRED 
High fat-fed rat 
High fructose-fed rat
Spiny mouse (partial genetic susceptibility)
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GLUT 4 (Calderhead et al., 1990), amylin may be responsible for reducing basal 
glucose transport activity in skeletal muscle. It also remains to be determined what 
range of circulating physiological amylin concentrations is present in diabetics, and 
what relation this bears to the concentrations used in the studies carried out with the 
peptide thus far (Leighton & Cooper, 1990).
1.4 RODENT MODELS OF TYPE II DIABETES MELLITUS 
& INSULIN RESISTANCE
1.4.1 INTRODUCTION
Several different rodent models of Type II diabetes and insulin resistance 
associated with obesity have been developed to study the metabolic perturbations 
characteristic of insulin-resistant states: some of these are listed in Table 1.2. Only 
the two models of obesity used in this thesis will be described in detail.
1.4.2 THE GENETICALLY DIABETIC (db/db) MOUSE
"Diabetes" (db) is a single gene mutation on chromosome 4 initially 
observed in a C57BL/KsJ mouse strain at the Jackson Laboratory, Maine, U.S.A. 
(Hummel et al., 1966). On this background, which is characteristic of the mice 
used in this thesis, the gene produces marked hyperglycaemia, hyperphagia, 
obesity and atrophy of pancreatic P-cells. Inheritance of the diabetes syndrome is 
autosomal recessive with complete penetrance.
Hyperinsulinaemia in these animals is detectable from as early as 10 days of 
age and after 4 weeks the animals are profoundly diabetic, although a transient 
hypoinsulinaemia is detectable before the hyperinsulinaemic state prevails (Coleman 
& Hummel, 1974). In this state the obese diabetic animals can rapidly, gain weight 
so that after 6  weeks of age they weigh 50% more than pair-fed lean controls and 
substantially more if they are allowed ad libitum access to food (Cox & Powley, 
1977). During the hyperinsulinaemic phase of their life, the P-cells degranulate and
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secrete insulin at greatly enhanced rates compared to normal animals until the cells 
die and fail to secrete insulin in response to glucose. This initiates the final 
hypoinsulinaemic phase of the syndrome when the animals become ketotic and die.
The etiology of this syndrome has yet to be defined. Coleman & Hummel 
(1974) have suggested that a defect in insulin secretion initiates the the syndrome 
and that insulin resistance eventually follows in a manner similar to that described 
for the "Failing Pancreas" model of NIDDM development in humans. Insulin 
resistance has been noted in liver, where insulin binding is reduced (Soil et al.,
1975) and gluconeogenesis is non-suppressible (Chan et al., 1975), and in skeletal 
muscle where insulin-stimulated glucose uptake is reduced (Chan & Tatoyan,
1984). The role of other hormones in contributing to the observed insulin 
resistance is unknown: glucagon secretion is elevated throughout the life of a 
diabetic mouse due to increased pancreatic A-cell number (Laube et al., 1973) and 
the secretion of thyroid hormones is normal, although steroid metabolism is 
severely perturbed (Leiter, 1990).
The activities of several insulin-sensitive enzymes involved in hepatic and 
adipose tissue lipogenesis are increased in diabetic animals compared with controls 
(Chan & Exton, 1977; Coleman & Hummel, 1967). Furthermore, an impaired 
mobilization of fat in response to lipolytic hormones has been observed by several 
investigators (Steinmetz et al., 1969; Yen et al., 1970). Presumably these 
phenomena cause the accumulation of triglyceride and the associated obesity. 
These factors will be discussed in more detail in Chapter 4.
1.4.2 THE GENETICALLY DIABETIC CBA/CA MOUSE
The CBA/Ca mice used in this thesis were obtained from the University of 
Bristol Medical School, Bristol, U.K. They were derived from an inbred colony in 
which approximately 80% of males exhibit a maturity onset diabetic syndrome, 
consisting of hyperphagia, hyperinsulinaemia, hypertriglyceridaemia, obesity and
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impaired glucose tolerance (Connelly & Tabemer, 1989). Onset of the syndrome 
occurs between the ages of twelve and sixteen weeks, although the afflicted mice 
have a similar life expectancy to that of non-diabetic animals (Connelly & Tabemer, 
1989). The background of the CBA syndrome is unknown, but presumably 
susceptibility does not involve an environmental component as the obese male mice 
are kept under identical conditions as their lean littermates (Connelly & Taberner,
1989).
Since this colony of mice has been developed recently, only limited 
biochemical studies have been performed thus far. Insulin binding studies, 
performed on liver plasma membranes from lean and obese animals, have 
demonstrated that the numbers of high- and low-affinity insulin binding sites are 
reduced by some 40% in obese animals compared with their lean littermates 
(Taberner & Connelly, 1991). Considering the directly proportional relationship 
between insulin receptor number and insulin action in liver (Gammeltoft et al.> 
1978; Gammeltoft, 1984), this may partially contribute to the insulin resistance 
these animals exhibit. Insulin resistance has also been noted with respect to the 
ability of insulin to exert anti-lipolytic effects in brown and white adipose tissues 
(Mercer etal., 1991)
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1.5 HISTORICAL PERSPECTIVES ON G-PROTEIN 
REGULATION OF SIGNAL TRANSDUCTION
In 1956, Earl Sutherland first recognized the importance of the heat-stable 
compound adenosine 3', 5'-cyclic monophosphate (cyclic AMP) in mediating the 
activation of glycogen phosphorylase by glucagon in rat liver (historical summary 
by Sutherland, 1972). This observation gave rise to the concept of an extracellular 
hormonal "first messenger" activating an effector enzyme which produces relatively 
large amounts of an intracellular "second messenger". Subsequent studies on the 
hormonal sensitivity of cyclic AMP formation demonstrated that occupation of a 
hormone receptor by a suitable agonist induces a conformational change in the 
catalytic unit of adenylate cyclase thereby activating it and increasing the rate of 
formation of cyclic AMP from ATP. Therefore hormone-dependent adenylate 
cyclase functions as an allosterically regulated enzyme, the receptor occupying the
status of a regulatory site (Robison et al., 1967).
The importance of a guanine nucleotide binding regulatory component, or
G-protein, was first suggested by a requirement for GTP in the activation of 
adenylate cyclase by glucagon in rat liver plasma membranes (Rodbell et al., 
1971b). This was associated with an ability of GTP to reduce the specific binding 
of glucagon to its receptor (Rodbell et al., 1971a). Further research demonstrated 
that this effect was specific for agonists and was a consequence of reduced affinity 
for receptor (Maguire et al., 1976). The agonist dependence of the effect of 
guanine nucleotides on ligand binding to p-adrenergic receptors was shown by 
Cassel and Selinger to be related to their ability to stimulate a catecholamine- 
sensitive GTPase activity in turkey erythrocyte membranes (Cassel & Selinger,
1976).
From these early studies, the basic properties of G-protein-linked systems 
were determined. Thus G-protein-linked systems stimulate a specific protein by 
interacting with it such that bound GDP dissociates allowing GTP to bind and
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activate the protein: hydrolysis of GTP to GDP initiates deactivation. The 
correlation of receptor occupancy by an agonist with GDP release leads to the 
negative heterotropic effect of guanine nucleotides on agonist binding.
Subsequent research over 15 years has shown G-proteins to be general 
intermediates in many hormone-sensitive signal transduction pathways. The 
number of receptors involved is vast and includes those for biogenic amines 
(catecholamines, muscarinic receptors for acetylcholine), autocoids (prostaglandins, 
leukotrienes), peptide hormones (glucagon), neurotransmitters (opioids) and the 
photoreceptor rhodopsin. However, relatively few effector enzymes are known to 
be regulated by G-proteins: adenylate cyclase and the retinal cyclic GMP-specific 
phosphodiesterase have been intensively studied, but other effectors include a 
phosphoinositide-specific phospholipase C, phospholipase A2 and some ion 
channels (Bimbaumer etal., 1990).
Recent research has also demonstrated that G-protein-linked signalling 
pathways are not restricted to mammalian systems. For example, in 
Saccharomyces cerevisiae G-proteins are involved in both the activation of 
adenylate cyclase and the "pheromone response", which results in yeast cells 
mating. Both of the proteins involved exhibit strong structural and functional 
homologies with their mammalian counterparts (Levitzki, 1988; Fields, 1990).
1.6 STUCTURES & FUNCTIONS OF G-PROTEIN SUBUNITS
1.6.1 INTRODUCTION
To describe adequately both structures and mechanisms of G-protein action 
it must be appreciated that G-proteins are heterotrimeric species with subunits 
designated a , p and y  in order of decreasing molecular weight. Each protein is 
distinguished by virtue of its a-subunit which confers the abilities to bind GTP and 
interact with receptor and effector. The p- and y-subunits bind to the a-subunit but
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can dissociate from it as a py complex after activation of the G-protein by the 
appropriate receptor under suitable conditions: p- and y-subunits are only separated 
under conditions were they are denatured.
Certain details about G-protein structure have been gleaned from molecular 
biological approaches, which have resulted in the cloning of several G-protein 
subunits, and from X-ray crystallographic structures of the bacterial elongation 
factor EF-Tu (Jurnak, 1985) and more recently the crystal structure of c-Ha-ras 
p21 (deVos et al., 1988; Pai et al., 1990). Therefore we are at a stage where 
nearly all the G-protein a-subunits purified to date have been cloned, expressed and 
their primary structures determined. In the following section, the properties of the 
major G-protein subunits thus far cloned will be described. This will be followed 
by a discussion of the 'Gavg* a-subunit proposed by Bourne and co-workers 
(Masters et al., 1986), and modified by Johnson and colleagues (Osawa et al.,
1990), which attempts to unify these studies to produce a 'predicted' secondary 
structure containing important structural features common to all members of the G- 
protein family.
1.6.2 THE MAJOR MAMMALIAN G-PROTEIN ALPHA-SUBIJNITS
A The a-subunits Of Gs
The stimulatory guanine nucleotide-binding regulatory protein, Gs, was first 
identified by its ability to stimulate adenylate cyclase activity. The original tissue 
source used for the isolation of Gswas rabbit liver (Northup et al., 1980) and on 
purification, two oligomeric proteins were obtained containing differing a-subunits 
(apparent Mr of 45 and 52 kDa) and indistinguishable P-subunits. A cDNA 
corresponding to Gsa  was isolated initially from a bovine brain cDNA library using 
an oligonucleotide probe with a nucleotide sequence taken from a region conserved 
in G0a  and the a-subunit of transducin (Harris et al., 1985). Anti-peptide antisera 
raised against deduced amino acid sequences taken from the isolated cDNA
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nucleotide sequence recognised proteins of the appropriate molecular weight in 
Western blotting studies, and were identified as Gsa-subunits by the failure to find 
both messenger RNA and protein in the Gsa-deficient S49 cyc~ murine lymphoma 
cell line (Harris et al., 1985). Subsequent expression of the cDNA from bovine 
brain, as well as Gsa  cDNA's isolated from bovine adrenals and rat brain, verified 
these observations (Robishaw et al., 1986a and b; Itoh et al., 1986). Northern 
and Western blotting studies have shown the protein to be ubiquitous in mammalian 
tissues.
The original cDNA clone for Gsa  encoded a protein of 394 amino acids 
with a corresponding molecular weight of 46 kDa. However expression in either 
COS-m6 cells or in E. coli under the control of bacterial promoters produces the 
52 kDa form, thus suggesting that the molecular weight of this subunit in SDS- 
PAGE gels is anomalous (Robishaw et al., 1986a and b). The situation is further 
complicated by the studies of Bray et al. (1986) which revealed four different Gsa  
cDNA's in human brain, one of which corresponded to the original cDNA isolated 
by Harris etal. (1985): these cDNA’s have been designated Gsa-1 to 4. Gsa-1 
and Gsa-3 are identical except that Gsoc-3 lacks a stretch of 45 nucleotides. Gsa-2 
and Gsa-4  have 3 additional nucleotides (CAG) to Gsa-1 and Gsa-3 which are 
located at the 3' end of the 45 nucleotide stretch.
The isolation and characterisation of the human Gsa  gene provided an 
explanation for the origin of the four messenger RNA species (Kosaza et al.,
1988). The human Gs gene is composed of 13 exons and 12 introns which extend 
approximately 20 kilobases and it maps to chromosome 20 in the human genome 
(Blatt et al.y 1988). Comparing the exon-intron organisation of the gene with the 
predicted functional domain structure of Gavg > various exons can be putatively 
assigned certain functions. Exons 1 and 2 may code for the GTPase activity, whilst 
exon 9 contains a conserved Asp 223 which may form a salt bridge with the Mg2+ 
ion bound to the p-phosphate of GDP. Therefore, exchange of GDP for GTP may
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displace the surrounding residues, causing a GTP-dependent conformational 
change in the hydrophilic region of residues 230-238 in exon 9. A consensus 
sequence sequence Asn-Lys-X-Asp is found in exon 11: a similar sequence in EF- 
Tu was found by X-ray crystallographic analysis to be adjacent to the guanine ring 
ofGDP(Jurnak, 1985).
These regions are common amongst all G-protein a-subunits, but exons 4 
and 5 encode a region which is heterogeneous amongst G-protein subunits, while 
exon 3 is unique to Gsa . Figure 1.2 shows how the four different Gsa  mRNA 
species are derived from the differential splicing of a single primary RNA 
transcript, utilizing GT-TG donor/acceptor splice sites as well as the more usual 
GT-AG sites. These splicing events allow for the potential expression of four 
Gsa-subunits per cell. Two of these (Gsa-1 and Gsa-2) will contain an extra 14 
amino acids from residues 72 to 85 (corresponding to the inclusion of exon 3 from 
the gene). Also Gsa-2 and Gsa-4 contain an extra Ser residue compared with 
Gsa-1 and Gsa-3 respectively due to splicing events causing the inclusion of the 
CAG nucleotide sequence in their mRNAs (Kozasa et al., 1988).
In native membranes, relative amounts of the various isoforms of Gga  vary: 
while some tissues contain only 45 kDa or 52 kDa forms, multiple forms exist in 
most tissues (Mumby et al., 1986). Studies on partially-purified preparations of 
Gsa  demonstrated that both forms can mediate hormonal stimulation of adenylate 
cyclase (Sternweis et al., 1981) although some preliminary studies have suggested 
that there may be quantitative differences in the extent to which both forms can 
activate the enzyme (Kaslow et al., 1979; Larner & Ross, 1981). Kinetic 
measurements of GDP release and rates of GTP hydrolysis by recombinant 45 kDa 
and 52 kDa Gsa-subunits purified from E. coli expression systems have shown 
that while both forms have similar kcat (GTPase) values, the larger form releases 
GDP more rapidly. Hence, under basal conditions, a greater proportion of the 
larger form is GTP-bound and active with respect to stimulation of adenylate
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Figure 1.2:
Origin Of Four Gsa-Subunit mRNA Species
The Gsa-subunit gene is shown in the centre. Exons 2 and 4 are shown by 
open boxes while exon 3 is depicted as a solid box. Nucleotide sequences of exon- 
intron boundaries are shown, as are the consequences of the alternate splicing 
events on the amino acid sequence. Figure is taken from Kozasa et al. (1988).
g a g
G I u Gl y G lu
G s o — 1 ( 2*3 * 4 )
lC AGT GAG
G l u  G ly Sc r  G lu
Gsa —2 (2*3*4*)
G so 
G e n e  —
EXON 2 EXON 3
'GTA CTG
CAG
EXON 4 
TGAG
G s a - 3 ( 2 * 4 )
GA T GAG
A s p  G I u
G sa-4(2*4’)
GA C AGT GAG 
Asp Ser G t u
32
cyclase in both S49 eye cells and with the purified enzyme in detergent (Graziano 
et al., 1989). The demonstration of a similarly increased hormone receptor- 
dependent rate of GDP dissociation of the larger form of Gsa  would also be of 
considerable interest. However it must be appreciated that in these experiments 
recombinant Gsa  had a much lower affinity (5- to 10-fold) for the adenylate cyclase 
catalytic unit compared with purified rabbit liver Gsa  under the same conditions, 
and so results with recombinant molecules may not be extrapolated to the situation 
in the plasma membrane.
B The a-subunits Of Gj
The inhibitory guanine nucleotide-binding regulatory protein, Gi? was first 
identified as a 41 kDa substrate for ADP-ribosylation catalysed by the islet- 
activating protein (IAP) from the whooping cough bacterium Bordetella pertussis, 
or pertussis toxin. It was first purified from rabbit liver and human erythrocytes 
using a very similar protocol to that employed for purification of Gs (Bokoch et 
al., 1983; Codina et al., 1983). Like Gs, GA was purified as an oligomer 
containing an a-subunit distinct from Gsa , but apparently identical p-subunits 
(Manning & Gilman, 1983). The functional attributes of Gi were deduced by 
reconstituting the purified protein with S49 lymphoma and platelet membranes 
which resulted in the inhibition of adenylate cyclase activity (Katada et al., 1984a, 
b and c).
However, the heterogeneity of pertussis toxin substrates observed in several 
tissues, including b r a i n  (Milligan & Klee, 1985) and fat (Rapiejko et al., 1986), 
suggested that there may be several isoforms of this protein and that this inhibitory 
function may not be specific for one form of Gj. Indeed, the possibility that 
different G^s control other pertussis toxin-sensitive signalling events, such as 
activation of phospholipases C and A2, has produced an area of intense research but 
its discussion is beyond the scope of this thesis.
Nakada et al. (1986) isolated a G| cDNA by purifying a 41 kDa pertussis
toxin substrate from bovine brain and using the sequences of the trypsin-digested 
peptides to generate oligonucleotide probes. The cDNA isolated contains nucleotide 
sequences which correspond to all the tryptic peptide sequences, and codes for a 
protein of 354 amino acids with a calculated molecular weight of 40.4 kDa. This 
protein has been designated Gja-1, as it was the first Gj protein to be cloned, and 
corresponding cDNA species have subsequently been isolated from rat C6 glioma 
cells and human cDNA libraries (Didsbury et al., 1986; Itoh et al., 1986). 
Immunological studies suggest that GjOC-1 is most abundant in brain and less 
widely distributed in peripheral tissues (Brann et al., 1987). The gene for GjCX-1 
maps to chromosome 7 of. the human genome (Blatt et al., 1988).
The screening of a rat C6 glioma cDNA library with an oligonucleotide 
probe containing a nucleotide sequence corresponding to an amino acid sequence of 
"purified" rat brain G ja led to the isolation of 2 cDNA clones (Itoh et al., 1986). 
One corresponded to rat GjOC-1, which differs in sequence from bovine GjOC-1 by 2 
amino acid residues. The other clone encoded a 355 amino acid protein which 
differed significantly (11%) from the GjOt-1 clone, and was termed G ft-2. This 
encodes for a protein of predicted Mr=40.1 kDa. Molecular biological studies 
showed that the G|0c-2 gene maps to chromosome 3 in humans (Blatt et al., 1988). 
Northern and Western blotting studies have also demonstrated the expression of 
this protein in several peripheral tissues, including liver, kidney, heart and white 
adipose tissues (Suki et al., 1987).
cDNA clones for a Gjtx-3 protein were initially isolated by 2 groups from 
human HL-60 cell and human liver cDNA libraries (Didsbury & Snyderman, 1987; 
Suki et al., 1987). GjCt-3 cDNA has since been cloned from rat C6 glioma cell, rat 
olfactory and human T-lymphocyte cDNA libraries (Beals et al., 1987; Jones & 
Reed, 1987; Itoh et al., 1988). These species code for a protein with a deduced 
Mr=40.5 KDa. Subsequent Northern and Western blotting analyses have shown 
the mRNA for this species to be present in many peripheral tissues, including liver,
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heart, kidney and white adipose tissues (Didsbury & Snyderman, 1987; Mitchell 
et al., 1989). The human Gja-3 gene has been mapped to chromosome 1 (Blatt et 
a l , 1988).
Between each of GjOC-1 , 2 and 3 there is a very strong conservation of 
overall structure. There is also a striking conservation of sequence between each Gi 
subtype (more than 98% homology) between rat, mouse, bovine and human 
proteins (Itoh et al., 1988). Such a strong conservation of sequence may reflect 
evolutionary pressure to maintain the specific functioning of each G  ^gene product. 
One interesting point is that the homologies between the three Gj species are higher 
than that between rod and cone transducins (Gta-1 and Gta-2) (Lerea et al.,
1986). Considering that Gta-1 and Gta-2 activate the same effector, whereas the 
GjOc's probably interact with several different ones depending on the cell-type, the 
degree of homology is quite remarkable.
As with Gsa-subunits, different tissues express particular combinations of 
GiOc-subunits, as determined by Western blotting analysis of various tissues using 
antisera specific for each of the three GjCX-subunits. For example, while rat liver 
expresses only GjOC-2 and GjOC-3, white adipose tissue expresses all three Gja- 
subunits (Suki eta l., 1987; Mitchell e ta l , 1989).
The isolation of genes for the three Gj species was achieved by Itoh et al. 
(1988), initially using a rat GjCt-2 probe on a human genomic DNA library under 
conditions of low stringency. The resulting clones were used for restriction 
analysis and Southern hybridisation at high and low stringencies, and isolation of 
the three G^a genes. Both GjCC-2 and 3 consist of eight exons and seven introns. 
G ft-2  contains an additional exon in the 3' flanking region but this does not code 
for amino acids. The positions of the exon junctions in the cDNA sequences were 
found to be identical even though intron lengths were different between each gene.
Comparison between the exon-intron structure of the GjOt genes and the 
predicted domain structure reveals some interesting relationships. Whereas exons
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1, 2, 5, 6 and 7 are fairly conserved between different Ga-subunits, exons 3, 4 and 
8 show the greatest structural divergence. In particular, residues 80-130 in exons 3 
and 4 show a very significant sequence diversity within the Gja-subunits, implying 
a role of this region in specifying effector interactions. The heterogeneous C- 
terminal domain encoded by exon 8, which contains the Cys residue ADP- 
ribosylated by pertussis toxin, is thought to be involved in mediating G-protein 
contact with the appropriate receptor (Masters et al., 1986; see later).
C The a-subunits Of Transducin, Gt
Gt, or transducin, was first purified from bovine retina at about the same 
time as Gs was being purified. It is easily isolated, being the major component of 
retinal rod outer segment (ROS) disc membranes, and large amounts (mg 
quantities) can be obtained (Kuhn, 1980). This facilitated the manufacture of 
polyclonal antisera and determination of enough partial amino acid sequence data to 
generate probes, allowing isolation of Gta  cDNA seqences (Hurley et al., 1984; 
Lochrie et al., 1985; Yatsunami et al., 1985). Two cDNA clones (Gta-1 and 
Gta-2) were isolated which differ by approximately 20% in their respective primary 
sequences. Whereas Gta-1 cDNA encodes for a protein of 350 residues, Gta-2 
codes for 354 amino acids (Yatsunami et al., 1985; Lochrie et al., 1985). Both 
Gta 's  contain Arg 174 and Cys 347 residues which can be ADP-ribosylated by 
cholera and pertussis toxins respectively (VanDopeffl/., 1984a and b). Anti­
peptide antisera raised against sequences specific for each Gta  demonstrated that 
Gta-1 was located exclusively in rod outer cell segments whereas Gta-2  was 
expressed only in cone cells (Lerea et al., 1986). The two Gta-subunits were 
found to be the products of two separate genes located on human chromosomes 3 
(Gta-1) and 1 (Gta-2) (Blatt et al., 1988). Both subtypes are presumed to activate 
the cyclic GMP-specific phosphodiesterase effector enzyme of visual signal 
transduction.
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D Other G-Protein Subunits
i The a-subunit Of Go
G0 was first identified by Sternweis & Robishaw (1984) as the predominant 
pertussis toxin substrate in bovine brain: it was designated "o" for "other" to signify 
its distinction from Gj. Like G j, Gs and Gt, it exists as a heterotrimer of a-, p- 
and y-subunits. Several lines of biochemical evidence suggested the existence of 
two forms of G0a. These were confirmed by molecular biological studies leading 
to cDNA cloning and determination of deduced primary sequences. G0a-subunit 
cDNA's have been cloned from several mammalian tissues, including rat brain (Itoh 
et al., 1988), heart (VanDongen et al., 1988), neuroepithelium (Jones & Reed,
1987) and bovine retina (VanMeurs et al., 1987). Tissue expression studies show 
that GQa-subunits are expressed at relatively high levels in brain and retina 
compared with heart, but are not expressed in liver (Brann et al., 1987). Bovine 
G0a  (GQa - l)  contains 354 residues, the same number as GQoc-2. Their primary 
sequences are identical up to position 248: thereafter 26 amino acids are different. 
It has been proposed by Hsu et al. (1990) that G0a-1 and 2 arise due to the 
alternative splicing of a single G0a  transcript. Unlike other G-protein subunits, the 
gene for G0a  has not yet been mapped to a chromosome in the human genome.
The function of G0 is unknown although it has been proposed by different 
groups to control distinct processes in certain cell types. These include opiate- 
induced Ca2+ channel opening in neural cell lines (Hescheler et al., 1987), and 
activation of phospholipase C in oocytes from Xenopus laevis (Moriarty et al., 
1990). One important finding made recently is that the activity of G0 is regulated 
by a GAP protein (designated 'GAP-43') which stimulates binding of GTPyS to 
G0a  (Strittmatter et al., 1990). GAP-43 is intimately involved in neural axonal 
growth and it is capable of interacting with the N-terminal region of GQa , the 
region thought to be involved in mediating receptor/G-protein interaction
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(Strittmatter et al., 1990; Masters et al.> 1986). In particular, a consensus amino 
acid sequence containing two Cys and two basic residues is found in many G- 
protein-linked receptors as well as GAP-43 and the wasp venom mastoparan 
(Strittmatter et al., 1990).
ii The a-subunit Of Golf
Considering the ubiquity of receptor/G-protein/effector mechanisms for 
mediating intracellular responses from extracellular ligands, it is not surprising to 
find that many oderants initiate their effects by binding to specific receptors on 
specialized neuronal olfactory membranes which couple to G-proteins and 
subsequent second messenger generation (Pace et al., 1986; Sklar et al., 1986). 
In particular, cyclic AMP is capable of opening the ion channels which initiate the 
oderant-stimulated nerve impulse in olfactory neurones, suggesting a model where 
oderant-induced elevation of intracellular cyclic AMP levels precedes the cyclic 
AMP-dependent depolarization of the sensory neurone (Nakamura & Gold, 1987).
However, as most of the Gsa-subunit mRNA in olfactory tissue is derived 
from non-neuronal cells (Jones et al., 1988), it seemed likely that a distinct G- 
protein was responsible for the activation of adenylate cyclase in olfactory 
neurones. Such a protein was identified by the screening of a rat olfactory tissue 
cDNA library with a degenerate oligonucleotide probe directed towards a conserved 
region of the G-protein GTP-binding domain (Jones & Reed, 1989). Amongst the 
clones isolated were some which hybridized weakly with a Gsa  probe: the protein 
encoded by the open reading frame of these clones was termed G0if(X (Jones & 
Reed, 1989). Although the deduced amino acid sequence of the clones consisted of 
381 amino acids which shared a significant identity (88%) with Gsa , one important 
difference was the absence of the 45-base exon whose alternative splicing results in 
the different molecular weight forms of Gsa  observed in many tissues (Bray et al.,
1986). Northern blot analysis showed that Golfa-subunit mRNA species of 3.5
38
and 2.7 kbases in size were expressed exclusively in olfactory epithelia, specifically 
in sensory neurones as determined by immunocytochemical experiments using a 
polyclonal antibody raised against a unique Golfa-subunit sequence (Jones & Reed,
1989). Expression of the Golfa-subunit clone in S49 e y e  kin~ cells demonstrated 
that activation of adenylate cyclase could be achieved by expression of the cloned 
protein (Jones & Reed, 1989).
iii The a-subunit Of Gz
A cDNA clone for the a-subunit of Gz was initially isolated by screening a 
bovine retinal cDNA library with bovine rod Gta  cDNA under conditions of low 
stringency (Fong et al., 1988). An identical clone was isolated from a human 
genomic library using cDNA clones obtained from a rat C6 glioma cell cDNA 
library. Subsequent screening of a rat brain cDNA library with the human Gza  
genomic clone isolated a rat Gza  clone of similar sequence (Matsuoka et al.,
1988). The deduced amino acid sequence consisted of 355 amino acids (Mr=40.8 
kDa) exhibiting a particularly strong homology with the G ja proteins (66-67% 
identity in sequence with G ja-1, G ja-2 and G ja-3) although not strong enough 
to be part of that separate subfamily (Gja-subunits exhibit 85-94% identity 
between each other). Northern and Western blotting analyses have shown that Gza  
is expressed in retina, brain, adrenal gland, kidney and liver, but not testis, lung or 
spleen (Fong et al., 1988). The gene for Gza  maps to human chromosome 22 
(Blatter^/., 1988).
A particularly interesting deviation from classical G^a characteristics is the 
absence of a Cys residue 4 residues from the C-terminus which is the site for ADP- 
ribosylation by pertussis toxin on G ^ - and G0a-subunits.
The purification of several 40 kDa pertussis toxin-insensitive G-protein a- 
subunits from bovine brain (Pang Sc Stemweis, 1990) and the molecular cloning of 
additional G-protein subunits using PCR (Strathmann et al., 1990) suggests that a 
family of such proteins exist which may either be responsible for pertussis toxin-
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insensitive signalling events or which may have other functions.
1.6.3 ASSIGNMENT OF FUNCTIONAL DOMAINS ON G-PROTEIN ALPHA
SUBUNITS
The absence of a crystal structure for any of the mammalian Ga-subunits 
prompted Bourne and co-workers to predict the secondary structure of a composite 
G-protein a-subunit ("ocavg") from the deduced amino acid sequences of Gja-1, 
Gta-1, Gta-2, G0a  and Gsa  as well as the crystal structure of bacterial elongation 
factor EF-Tu (Masters et al., 1986). The model defines three putative functional 
domains surrounding a hydrophobic guanine nucleotide-binding domain (Figure 
1.3). The evidence assigning these domains with specific functions will now be 
discussed.
A Guanine Nucleotide-Binding Domain
Four short stretches of amino acid sequence which are conserved amongst 
all G-protein a-subunits, EF-Tu and p21m‘s are presumed to form the guanine 
nucleotide-binding domain. The crystal structures of EF-Tu (Jumak, 1985) and 
GTP-bound p2 lras (Pai et al., 1990) show these sequences to be located at turns 
between an a-helix and a strand of p-pleated sheet and have been designated A, C, 
E and G, after the assignments of p21/us and EF-Tu by Halliday (1984).
Region A, corresponding to residues 47-53 of a avg, contains a Gly-4X-Lys 
consensus sequence. In EF-Tu, these residues comprise a loop which is adjacent to 
the a- and P-phosphoryl groups of bound GDP (Jumak, 1985). The importance of 
this region in guanine nucleotide binding is further suggested by two observations. 
Firstly, mutation of Gly 12 in p2 \ras (corresponding to Gly 49 in a  „) to any 
other amino acid produces a molecule with reduced GTPase activity and an
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Figure 1.3:
Diagram m atical Representation Of A G-Protein Alpha-Subunit 
('aavg')
This figure is taken from Bourne et al. (1988) and represents a composite 
G-protein a-subunit, a avg. The GDP-binding domain is adapted from that of EF- 
Tu (Jurnak, 1985) and the GDP molecule (G=guanine ring, R=ribose, 
P=phosphoryl) nestles in a pocket formed by turns joining p-pleated sheets and a- 
helices. The rest of the molecule depicts a predicted secondary structure which is 
described in the text. Residues conserved amongst different a-subunits are 
represented by the corresponding single letter amino acid code, and numbers refer 
to their positions in a avg. Asterisks represent locations of tryptic cleavage sites. 
Sites of a s mutations and ADP-ribosylation sites are also indicated.
D om ain  II
enhanced transforming capacity (Bishop & Varmus, 1985). Secondly, replacement 
of the Lys residue in p2 \ras reduces the protein's affinity for GTP and GDP 
without altering the specificity of nucleotide binding (Sigal et al., 1986).
Region C, corresponding to residues 225-228 in a avg, has the signature 
sequence Asp-2X-Gly. In EF-Tu, the Gly begins a turn away from the bound 
GDP whilst the Asp group forms a salt bridge with the Mg2+ ion co-ordinated with 
the p-phosphoryl group of GDP (Jumak, 1985). Presumably replacement of GDP 
with GTP causes a conformational change which may result in the displacement of 
C and the predicted adjacent a-helix (residues 229-238 in a avg) on the surface of 
the molecule.
Region E is a hydrophobic region which forms a partial pocket for the 
guanine ring of GDP in EF-Tu, and which is highly conserved within G-protein a- 
subunits.
Region G forms a turn at the end of a P-strand which fixes the position of 
the guanine ring of GDP in EF-Tu. Asn 294 in a avg may interact with the keto 
substituent of the ring while the next Asp residue (Asp 297 in cxavg) binds the 2- 
amino group (Jurnak, 1985).
B Domain I (residues 1-41)
The hydrophilic portion of a avg has the predicted structure of an 
amphipathic a-helix, and several lines of evidence implicate its involvement in 
controlling binding to py-subunits. Tryptic cleavage of the amino-terminal 18 
residues of Gta-1 (corresponding to residues 1-25 of a avg) abolishes its ability to 
bind to photolysed rhodopsin and py-subunits (Fung & Nash, 1983). Subsequent 
work has shown this effect to be due exclusively to the reduced ability of Gta-1 to 
bind to py, which results in the abolition of the ability of pertussis toxin to catalyse 
the ADP-ribosylation of Cys 346 near the C-terminus of the molecule (Navon & 
Fung, 1987). Similar results were obtained by Neer et al. (1988) using 2 pertussis
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toxin substrates purified from bovine brain, a 41 and a 39 (GjCX-1 and G0a). In 
addition, they showed that trypsin treatment had no effect on the intrinsic GTPase 
activity of the a-subunits. Construction of G|a-2/Gsa-subunit chimeras containing 
N-terminal regions from GjCC-2 attached to a Gsa-subunit has also demonstrated 
that the N-terminal region is involved in Py interactions and GDP dissociation
independently from GTPase and effector activation (Osawa et al.y 1990).
Presumably the charged portion of the amphipathic helix in this region
controls py binding, and so we might expect a large degree of homology between j 
the (j-protein a-subunits: that this is not the case is therefore surprising. ! 
However, it is important to note that EF-Tu and p21ras do not contain residues 
corresponding to amino acids 1-41 of a avg and neither binds py.
Another potentially important function of this domain may be to attach the 
relatively hydrophilic a-subunit to the plasma membrane after dissociation from Py. 
In particular,! G^a-1 to 3, G0a, Gza , Gta  but not Gsa  have been shown to be
N-myristylated on the Gly residue at their amino termini in a human astrocytoma 
cell line and when transiently expressed in COS-7 cells (Buss et al.y 1987; Mumby 
et al.y 1990): site-directed mutagenesis of these a-subunits or substitution of 
myristate with a less hydrophobic analogue affects a-subunit subcellular 
distribution within the cell. Successful reconstitution of the myristylated protein 
into phospholipid vesicles has an absolute requirement for Py-subunits, so this 
modification may promote the attachment of a-subunit to py, consistent with the 
predicted function of this domain (Jones et al.y 1990).
C Domain II (residues 60-208)
Different a-subunits can interact with py-complexes from various G-protein 
sources, but their interactions with effector systems are rather more specific. 
Therefore any domain in a avg involved in contact with an effector enzyme should 
be of variable sequence and should be involved in contact which is regulated in a 
guanine nucleotide-dependent manner. For a avg, the amphipathic P-pleated sheets
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and a-helices between regions A and C of the guanine nucleotide binding site may 
fit these criteria. Between EF-Tu, p21ras and the G-protein a-subunits, this region 
varies considerably in length, being as small as 18 amino acids (p21ras) up to the 
108 amino acids calculated for a avg. In EF-Tu this region participates in the GTP- 
dependent binding of amino acyl tRNA, while in p21ras this region has been 
identified as the binding site of "GTPase activating protein" (GAP) which regulates 
the ability of p21ras to hydrolyse GTP and which may be its effector (McCormick,
1989).
Within this domain, residues 128-156 of a avg exhibit the greatest variability 
and may conceivably account for the specificity of a-subunit/effector interactions, 
although the basic secondary structure is probably conserved. This secondary 
structure is most likely to consist of amphipathic helices located on the surface of 
the protein with effector specificity probably depending on unique distributions of 
charges within the helices (Masters et al., 1986).
Residues 200-220 of a avg comprise a region of p-pleated sheets whose 
sequence is highly conserved amongst the a-subunits. Such conservation, and the 
likelihood of GTP-dependent changes in conformation in this region, has raised the 
possibility that this region may be an alternative py contact site to domain I, 
although this hypothesis lacks any direct evidence. This region also contains the 
Arg residue (Arg 203 in ocavg) which is ADP-ribosylated by cholera toxin in Gsa, 
Gta-1 and 2 and, under suitable conditions, the G ^-subunits (Owens et al., 
1985). This modification results in the dissociation of GTP-bound a-subunit from 
Py and the persistent activation of the a-subunit due to the abolition of its GTPase 
activity.
1.3.4. Domain III (residues 298-396)
Domain III lies between region G of the guanine nucleotide-binding site and 
the C-terminus of ocavg, and has a predicted secondary structure consisting largely
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of p-pleated sheets attached to a C-terminal a-helix. Several lines of evidence have 
suggested an involvement of this region in coupling the G-protein to its receptor. 
Firstly, ADP-ribosylation of Gta-1, Gta-2, and the Gja-subunits by pertussis 
toxin on a Cys residue which is 4 amino acids away from the C-terminus (Cys 392 
in a avg) prevents interaction with photolysed rhodopsin and inhibitory receptors 
respectively (Van Dop et al., 1984a; Ui et al., 1984). One possible explanation 
for this effect is that the incorporated ADP-ribose group sterically hinders 
interaction of this domain with the receptor. Other evidence has come from 
molecular biological studies on mutant Gsa-subunits expressed in S49 lymphoma 
cells. Adenylate cyclase activity in S49 unc mutant cells responds normally to 
ligands acting on Gsa  directly (Gpp[NH]p or A1F4' for example) but is incapable of 
responding to stimulatory receptor agonists such as those acting at p-adrenergic and 
prostaglandin Ej receptors. This is associated with the abolition of the ability of 
guanine nucleotides to reduce agonist binding to p-adrenergic receptors (Haga et 
al., 1977; Bourne et al., 1982). Preparation of cDNA libraries from wild type 
and unc mutant S49 cells, and the use of a restriction fragment from murine Gsa  
cDNA as a probe, led to the isolation of cDNA sequences encoding approximately 
70% of the Gsa  open reading frames from both cell types. While the wild type 
nucleotide sequences gave a deduced amino acid sequence identical to that of 
normal murine Gsa , Gsa  cDNA from the unc cells had a single base mutation 
resulting in the replacement of an Arg residue with a Pro at residue 372, 6 residues 
from the C-terminus. Construction of a complete recombinant Gsa unc cDNA 
containing the Pro mutation and expression of the mutant in S49 cyc~ cells 
reproduced all the characteristics of the unc phenotype with respect to its regulation 
of adenylate cyclase (Sullivan et al., 1987). Presumably substitution of Arg 372 
for a Pro residue in the predicted C-terminal a-helix will introduce a kink in the 
helix as well as alter the distribution of charge in this region, hence preventing 
interaction with receptor.
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Another study by the same group examined the properties of a GgOc/GjOC-2 
chimeric a-subunit expressed in S49 eye' cells (Masters et al., 1988). This 
chimera contained the N-terminal 212 amino acids of G ft-2 (i.e. domains I and II) 
attached to the 160 C-terminal residues of murine Gsa  (i.e. domain III). One 
surprising but important finding from this study was that the chimeric G-protein 
was capable of stimulating adenylate cyclase even though it contained the presumed 
effector binding site of G^a-2. Therefore it is possible that structural features of 
domain III may be involved in regulating effector interactions, although which 
particular sequences are important within the 160 amino acids of Gsa  in the chimera 
are unknown. However it must be noted that swapping domain III of G ft-2  for the 
corresponding region of Gsa  could impair the functioning of the rest of the 
molecule and lead to erroneous assignment of function to a given domain. Another 
important finding from this work was that stimulation of adenylate cyclase activity 
by this chimera was similar to that mediated by wild type Gsa  and it was concluded 
that the ability of Gsa  to interact with receptor resided within the C-terminal 160 
amino acids of Gsa  in the chimera.
Indeed the abilities of the p-adrenergic receptor and rhodopsin to 
discriminate between different G-protein a-subunits in vitro also seems related to 
differences in the latter's C-termini. Activated rhodopsin is capable of stimulating 
the GTPase activity of Gta - 1  and 2 as well as G0a  and G ja but not Gsa . 
Similarly, the p-adrenergic receptor can stimulate the GTPase activity of Gsa  more 
efficiently than any other G-protein, consistent with the C-terminal region of Gsa  
being distinct from those of Gja, G0a  and Gta  (Cerione et al., 1985; Asano et 
a l., 1984). Also in support of the assignment of this domain in mediating 
interaction with receptors has been the abilities of specific antisera raised against C- 
terminal peptides of G-protein a-subunits to block hormone-stimulated events. For 
example, an antiserum raised against the C-terminal decapeptide sequence of Gsa  
reduces isoproterenol stimulation of adenylate cyclase activity in turkey erythrocytes 
without disrupting the ability of the antiserum to immunoprecipitate Gsa .C
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complexes (Simonds et al., 1989a). Similarly, antibodies raised against the C- 
terminal decapeptide of GjOt-2 attenuate receptor-dependent inhibition of adenylate 
cyclase activity in human platelet membranes (Simonds et al., 1989b).
However, it is important to stress that there may be at least one more site of 
receptor/G-protein contact other than the C-terminus. This has been demonstrated 
by studies on purified a 2-adrenergic receptors reconstituted with GjOt, GQa  and 
Gta ,  where agonist-stimulated GTP hydrolysis was not observed for Gta  even 
though the C-terminal regions of these three proteins are virtually identical (Cerione 
et al., 1986).
1.6.4 BETA-SUBUNITS
On purification of Gs, Gj and Gt, similar 35 kDa proteins were found to be 
associated with the more distinctive a-subunits. Peptide maps of these p-subunits 
from Gs, Gj and Gt yielded identical patterns, and the use of several anti-transducin 
antisera in Western blotting studies could not discriminate between P-subunits of 
different G-proteins (Manning & Gilman, 1983; Hildebrandt et al., 1985; 
Gierschik et al.y 1985). They are associated with smaller y-subunits in vivo and 
these py-complexes appear to be functionally interchangeable; for example, py- 
subunits from Gj can interact with Gt to reconstitute rhodopsin-stimulated GTPase 
activity (Kanaho et al., 1984). However, evidence is now accumulating which 
suggests that p-subunits are structurally heterogeneous proteins. Although the p- 
subunit of Gt migrates as a single 36 kDa band on SDS-PAGE gels, the subunits 
for other G-proteins run as a 36/35 kDa (P j/P 2) doublet under suitable 
electrophoretic conditions (Sternweis & Robishaw, 1984). Moreover, antisera 
raised against a synthetic peptide with an amino acid sequence corresponding to a 
region of GJ3 recognizes only pj (Evans et al.y 1986). A cDNA clone for GtP 
was isolated from a bovine retinal cDNA library by Sugimoto et al. (1985) and 
was found to code for a protein of 340 amino acids (Mr=37.4 kDa). Northern
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hybridization experiments with the isolated cDNA recognized 2 bands of 1.8 and 
3.3 kbases in RNA from brain, liver and retinal tissues, suggesting multiple forms 
(Tagahashi et al., 1985). Another cDNA was subsequently isolated from bovine 
brain, bovine adrenal and human myeloid leukemia (HL-60) cell cDNA libraries 
(Fong et al., 1987). This cDNA also codes for a protein of 340 residues 
(Mr=37,329) which is 90% identical in predicted amino acid sequence with the 
protein encoded by human and bovine pj cDNAs. The issue has been further 
complicated by the cloning of a p3 cDNA sequence from a retinal cDNA library by 
Levine et al. (1990). Screening of bovine and human retinal cDNA libraries with a 
probe corresponding to residues 61-75 of the amino acid sequence of bovine pj 
resulted in the isolation of the distinct P3 cDNA. As for pj and P2, the P3 cDNA 
codes for a protein of of 340 amino acids (Mr=37.2 kDa) whose size on 
electrophoretic gels is unknown as the cDNA has not yet been expressed. Northern 
blotting of human retinal RNA with a probe corresponding to a unique region of the 
3' untranslated region of human P3 cDNA recognised 2 bands, suggesting that 
there are two p3 mRNA species arising from alternative splicing of a single gene 
product (Levine et al., 1990). Data from several laboratories have shown that 
these subunits are derived from 3 non-allelic genes located on human chromosomes 
1 (Pi)> 7 (p2) and 12 (P3) (Blatteral., 1988; Levine e ta l., 1990).
Deduced amino acid sequences of human pj- and p2-subunits differ only in 
34 (10%) out of 340 residues, with these differences representing conservative 
changes in the N-terminal half of the molecule. In contrast, human p3 differs from 
Pj by 17% and from P2 by 19%, with both conservative and divergent changes 
throughout the sequence (Levine etal., 1990). The relationship between sequence 
divergence and functional interactions with a- and y-subunits, as well as hormone 
receptors, has yet to be elucidated.
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1.6.5 GAMMA-SUBUNITS
Y-subunits remain tightly associated with p-subunits throughout G-protein 
purification, and they can only be separated from one another by denaturation. The 
y-subunit of Gt was recognized as a 5 kDa band on SDS-PAGE gels early in its 
purification (Fung et al., 1981) whereas its association with Gj and G s was 
delayed because of its poor staining (Hildebrandt et al., 1984). The primary 
sequence of Gty's have been deduced from both cDNA isolation and protein 
chemistry (Yatsunami et al., 1985; Ovchinnikov et al., 1985). Gtyhas 74 amino 
acid residues (Mj=8.4 kDa) and is very hydrophobic although it contains a large 
proportion of acidic residues. Two-dimensional peptide mapping of bovine and 
frog Gty produces similar patterns, but different from the pattern observed with 
human erythrocyte Gsy and bovine brain Gjy, suggesting that Gty is an isoform 
distinct from that of other G-proteins (Hildebrandt et al., 1984). A y-subunit 
cDNA has been cloned from a bovine adrenal cDNA library which codes for a 71 
amino acid peptide of estimated Mj=7.85 kDa (Robishaw et al., 1989). This was 
shown to be distinct from the y-subunits present in brain and retina (Robishaw et 
al., 1989). The nature of y-subunit diversity has been further complicated by the 
recent isolation of cDNA's encoding several more distinct y-subunits (Gautam et 
al., 1990).
An important observation made recently is that the y-subunit of Gt can alter 
the ability of the a-subunit to interact with activated rhodopsin. Fukada et al. 
(1990) were able to separate bovine retinal Gtpy-subunits into Gtpy-1 and GtPy-2 
components. GDP-bound Gta-subunits have a higher affinity for the latter and, 
moreover, GtPy-2 is capable of enhancing by approximately 30-fold the 
metarhodopsin II-stimulated binding of GTP to Gta  compared with Gtpy-1. This 
is associated with the presence of a farnesyl (polyisoprenyl) group and a methyl- 
ester at the C-terminal Cys residue of Gty-2; these post-translational modifications 
are absent from Gty-1 (Fukada et al., 1990). Unlike the proposed function of the 
similar modification in p21ras proteins (Hancock et al., 1989), the farnesylation
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event does not seem to be involved in promoting membrane attachment as Gtpy-2 is 
easily extracted in soluble form. Such a polyisoprenylation event has recently been 
shown to occur on the bovine adrenal G-protein y-subunit after expression of the 
appropriate cDNA in COS cells and after translation in vitro with a rabbit 
reticulocyte lysate (Maltese & Robishaw, 1990).
The potential importance of these modifications on y-subunits from other 
mammalian G-proteins has yet to be determined, although it has been observed that 
a similar polyisoprenylation event on STE18, the y-subunit equivalent of a yeast G- 
protein involved in the pheromone-mating response (Gm), is essential for 
membrane association and proper functioning (Finegold et al., 1990).
1.7 G-PROTEIN-LINKED RECEPTORS
1.7.1 INTRODUCTION
G-protein-linked receptors encompass the largest group of hormone and 
drug receptors known. This receptor family includes those for amines 
(catecholamines, acetylcholine, serotonins), small peptides (vasopressin, oxytocin, 
tachykinins), proteins (glucagon, luteinizing hormone) and the 'light receptor' 
rhodopsin. It is highly likely that this family will expand to include other sensory 
receptors.
Based on the purification to apparent homogeneity of the adrenergic receptor 
subtypes, limited protein sequences were obtained which allowed the synthesis of 
oligonucleotide probes for cloning studies. As a result, the last 5 years has seen the 
elucidation of the primary structures of several members of this receptor family by 
recombinant DNA technology (Figure 1.4). Among these are included some of the 
adrenergic ( a lf o^, pj, P2  and p3), muscarinic acetylcholine (mj to m5), serotonin 
(5-HT) and tachykinin receptor subtypes. Deduced amino acid sequences have 
shown that these receptors are homologous proteins, exhibiting variability within a
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Figure 1.4:
Diagrammatical Representation Of A G-Protein-Linked Receptor
The figure shows the amino acid sequence and predicted membrane- 
spanning topography of the human p2-adrenergic receptor and is taken from 
O'Dowd et al. (1989). Potential sites of N-linked glycosylation are shown (CHO) 
as is Cys341, which may be palmitoylated in vivo.
E X T R A C E L L U L A R  S U R F A C E
C Y T O P L A S M I C  S U R F A C E
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common structural framework (Lefkowitz et al.y 1989).
1.7.2 HORMONE-RECEPTOR TOPOGRAPHY &STRUCTURE
A Membrane Spanning Regions
All the G-protein-linked receptors thus far cloned share a conserved 
structure and presumed membrane topography. The major feature of their deduced 
amino acid sequences are the 7 hydrophobic segments predicted by hydropathy 
analysis, each containing 24-28 amino acids, which are long enough to span the 
plasma membrane as a series of a-helices. These presumed membrane-spanning 
regions are connected by a series of extracellular and cytoplasmic loops, of which 
the third cytoplasmic loop varies most between different receptor types (O'Dowd et 
a l., 1989). Between all the G-protein-linked receptors thus far cloned, 
conservation of sequence is greatest in the membrane spanning regions (40-50% 
between members of the adrenergic receptor subfamily; 20-30% between adrenergic 
and muscarinic receptors).
It is important to note, however, that the predicted membrane spanning 
topography has not yet been unequivocally proven for any of these receptors. Its 
existence rests on the 7-helical structure obtained from the high resolution electron 
diffraction pattern for the bacteriorhodopsin molecule in the purple membrane of 
Halobacterium halobium (Henderson & Unwin, 1975). A similar structure has 
been proposed for mammalian rhodopsin on the basis of circular dichroism, infra 
red circular dichroism and neutron diffraction studies (Applebury & Hargrave,
1987). A similar structure for the adrenergic receptors has also been proposed but 
on the basis of limited proteolysis studies (Dohlman et al.y 1987).
In bacteriorhodopsin, three of the helices seem to be tilted, suggesting a 
structural requirement for the interlocking of amino acid side chains from adjacent 
helices. Results with rhodopsin, which could be extrapolated to other hormone
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receptors, have shown that there are Pro residues in some helices which could 
induce kinks of the sort observed for the bacteriorhodopsin molecule (Michel-Villaz 
et al., 1979).
B Ligand Binding Sites
Comparing the transmembrane sequences of the muscarinic and adrenergic 
receptors, the majority of amino acids found exclusively in one or other of the 
receptor types are located on the side of the helices closest to the extracellular 
surface (67% for adrenergic receptors and 64% for muscarinic receptors) (O'Dowd 
et al., 1989). It has been proposed that this may reflect the unique ligand binding 
characteristics of these receptor types.
Presumably the cluster of a-helices within the membrane form a pocket 
within which a ligand binding site exists, as is the case for rhodopsin where the 
retinal chromophore is buried and surrounded by the seven helices (Stryer, 1986). 
Mutagenesis studies have demonstrated that highly conserved Asp residues at 
positions 79, 113 and 130 of the human P-adrenergic receptor are essential for 
normal agonist binding (Strader et al., 1988). In particular, residues 113 and 130 
may be important in forming a negative counterion for the protonated amino group 
of the catecholamine moiety (Strader et al., 1988).
Hydrophilic cytoplasmic and extracellular regions appear, in general, not to 
affect this function, although the second extracellular loop of the P-adrenergic 
receptor contains several highly conserved Cys residues which may be important in 
disulphide bridge formation. Site-directed mutagenesis studies have demonstrated 
that deletion of these residues causes the loss of ligand binding (Dixon et al., 1987; 
Lefkowitz et al, 1989).
The construction of chimeric receptors has also provided information 
on the nature of ligand binding. If one constructs p2-adrenergic receptor chimeras 
containing progressively larger proportions of a 2-adrenergic receptor spreading 
from the N-terminus and expresses the chimeras in Xenopus oocytes, or
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transiently in COS-7 cells, progressive changes in agonist binding affinity occur. 
Binding patterns intermediate between a 2 and p2 characteristics are observed, and 
binding affinities for all agonists are reduced, suggesting an inability to form a 
stable ligand binding site structure (Kobilka et al., 1988). However, with respect 
to antagonist binding, one can construct a chimera which consists of the appropriate 
o^-adrenergic receptor sequence attached to the fifth, sixth, and seventh membrane- 
spanning and C-terminal regions of the P2-adrenergic receptor, and still retain p2- 
adrenergic receptor antagonist binding characteristics. Conversion of the seventh 
membrane-spanning region to an a 2-adrenergic sequence restores a 2-antagonist 
binding properties, confirming the importance of this region in this process 
(Kobilka et al., 1988).
Localization of specific residues within the membrane-spanning regions 
with probable importance in ligand binding agrees with data obtained from a 
biochemical approach using affinity and photoaffinity ligands (Dohlman et al., 
1988; Wong e ta l ,  1988).
C G-Protein-Coupling Region
The major function ascribed to the cytoplasmic domain of the adrenergic and 
related receptors is the agonist-dependent coupling with a specific G-protein. 
Specific cytoplasmic regions have been implicated by biochemical and site-directed 
mutagenesis studies as well as by expression of chimeric receptors in Xenopus 
oocytes or transient expression in COS-7 cells.
Whereas amino acid substitutions in the first and second cytoplasmic loops 
have no effect on coupling with effector (O'Dowd et al., 1989), the third 
cytoplasmic loop and the C-terminus have been directly implicated for both 
rhodopsin and the human p2-adrenergic receptor (Takemoto et al., 1985; Strader 
et al., 1987). Several studies have shown that either deletion or substitution of 
amino acids in the C-terminal tail causes a marked reduction in agonist-stimulated
54
adenylate cyclase activity (O'Dowd et al., 1989). In particular, Strader and 
collegues demonstrated that deletions in either the amino or carboxy ends of of the 
third cytoplasmic loop uncouple the hamster P2-adrenergic receptor from cyclase 
stimulation (Strader et al.t 1987). Residues in the amino terminal end of of the C- 
terminal tail are also important in this coupling process (O'Dowd et al., 1989). 
The assignment of this domain in G-protein coupling has been challenged by 
Rubenstein e ta l . (1987) examining the interaction of Gs with partially digested 
turkey erythrocyte P2-adrenergic receptor in phospholipid vesicles. Nevertheless, 
evidence accumulated from the construction and expression of chimeric receptors 
implicating the third cytoplasmic loop and the C-terminal tail is convincing. For 
example, a hybrid receptor containing the fifth and sixth transmembrane regions 
with the interconnecting 3rd cytoplasmic loop of the p2-adrenergic receptor within 
an a 2-adrenergic receptor exhibits a 2 binding characteristics yet activates cyclase 
with classical c^-adrenergic specificity. This implies that swapping of the third 
cytoplasmic loop connecting transmembrane helices 5 and 6 confers the ability to 
interact with Gs and stimulate cyclase (Kobilka et al., 1988). This region is highly 
conserved amongst receptors which couple to the same G-protein, although more 
work is required to determine the generality of these sequences and the 
conformational requirements for G-protein interaction within them.
It has also been shown that the third cytoplasmic loop contains amino acid 
sequences containing Cys residues and basic residues which are conserved amongst 
many different receptor subtypes as well as mastoparan, a wasp venom which 
activates G-proteins (Strittmatter et al., 1990; Higashijima et al., 1988). One of 
these Cys residues must be palmitylated for proper functioning of the p-adrenergic 
receptor (O'Dowd et al., 1989) and such a modification may be essential for the 
functioning of other receptors as well as GAP-43, which is a peripheral membrane 
protein capable of interacting with G0 (Strittmatter et al., 1990). Indeed, a 
acylation/deacylation cycle could potentially be an important mechanism for
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regulating receptor functioning.
1.8 THE CATALYTIC UNIT OF ADENYLATE CYCLASE
1.8.1 PURIFICATION
Of the five components involved in the dual regulation of hormone- 
stimulated generation of cyclic AMP at the plasma membrane, least is known about 
the catalytic unit. Biochemical evidence suggests the existence of several isoforms 
which have molecular weights between 150 and 180 kDa (Pfeuffer et al., 1985; 
Mollner & Pfeuffer, 1988). Purification of adenylate cyclase to homogeneity from 
bovine brain using a forskolin-agarose affinity step produces a 120 kDa 
glycoprotein (Pfeuffer et al., 1985). Polyclonal antisera raised against this 
glycoprotein recognized a protein of the appropriate molecular weight in solubilized 
brain membranes and was able to precipitate adenylate cyclase activity from 
detergent solutions containing the partially-purified enzyme (Mollner & Pfeuffer,
1988). This 120 kDa form of adenylate cyclase binds tightly to calmodulin, a 
property which has been used to further purify the protein after the forskolin- 
affinity stage (Minocherhomjee et al., 1987). Indeed, the activity of this isoform 
of adenylate cyclase can be stimulated on binding Ca2+-calmodulin (Katada et al.,
1987). py-subunits can competitively inhibit the enzyme by binding to the Ca2+- 
calmodulin complex, thereby preventing its interaction with and activation of the 
catalytic unit (Katada et al., 1987). The addition of purified, activated Gs further 
enhances activation by Ca2+-calmodulin (Harrison et al., 1989).
1.8.2 PRIMARY STRUCTURE
Isolation of cDNA sequences encoding the primary sequence of the 
calmodulin-sensitive form of adenylate cyclase was achieved by screening a bovine 
brain cDNA library using a probe constructed from the amino acid sequence of a 
peptide obtained after exhaustive tryptic digestion of adenylate cyclase purified from
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bovine brain (Krupinski et al.t 1989). When one of the isolated clones was used 
as a probe in Northern blotting analysis of bovine brain mRNA at high stringency, 
a single band of 11.5 kbases in size was visualized. The deduced amino acid 
sequence of the isolated cDNA's encoded a molecule with an estimated molecular 
weight of 124 kDa containing several potential glycosylation sites. Hydropathy 
analysis showed the protein to consist of two large cytoplasmic domains attached to 
the plasma membrane by two sets of six transmembrane a-helices. The 
cytoplasmic domains contained regions of similarity with each other as well as with 
sequences from soluble and membrane-bound guanylate cyclases (Krupinski et al., 
1989). Moreover, the similarity between the proposed structure and topography of 
adenylate cyclase with other G-protein-linked effectors, such as dihydropyridine- 
sensitive Ca2+ channels and K+ channels, suggested that such proteins have similar 
motifs within which limited variability produces different functions (Krupinski et 
al., 1989).
Putative Ser residues have been identified which may be substrates for the 
observed PKC-catalysed phosphorylation and sensitization of adenylate cyclase 
observed in frog erythrocytes (Krupinski et al., 1989; Yoshimasa et al., 1987). 
The regions of the protein involved in the interactions with Gs, Gj, calmodulin and 
the region involved in forming the inhibitory P-site have yet to be assigned.
1.9 DUAL REGULATION OF ADENYLATE CYCLASE
1.9.1 INTRODUCTION
As previously described, hormone-sensitive adenylate cyclase is a 
multicomponent system consisting of five functional units (Figure 1.5):-
i The stimulatory receptor, of which the p-adrenergic receptors are the most 
thoroughly characterised. Other examples include those for glucagon,
57
Figure 1.5:
Dual Regulation Of Adenylate Cyclase Activity
Figure depicts how the activity of the adenylate cyclase catalytic unit is 
regulated by a stimulatory (Gs) and inhibitory (G^ G-protein. The activities of Gs 
and Gi are regulated by their interaction with appropriate receptors; after binding of 
the appropriate agonists, Rs couples to Gs, and R-t couples to G^
Stimulatory Agonist
4
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adrenocorticotropic hormone (ACTH), thyroid-stimulating hormone (TSH) and 
secretin.
ii The stimulatory guanine nucleotide-binding regulatory protein, Gs .
iii The inhibitory receptor, homologous in structure to its stimulatory counterpart.
iv The inhibitory guanine nucleotide-binding regulatory protein, Gj. Unambiguous 
identification of the isoform(s) responsible for mediating inhibition of adenylate 
cyclase activity is still lacking.
v The catalytic unit (C) responsible for generating cyclic AMP from ATP.
It has been observed that the mechanisms of information transfer between 
receptors and G-proteins are highly conserved, presumably reflecting similar 
structural motifs present within the bewildering number (eighty to date) of different 
receptors coupled to various G-proteins and effectors (Birnbaumer et al., 1990). 
The intensively studied P-adrenergic receptor/Gs and rhodopsin/transducin systems 
have provided the basis for understanding the interactions involved, although 
different cells appear to exploit the same basic mechanisms to their own advantage.
1.9.2 STIMULATION OF ADENYLATE CYCLASE ACTIVITY
A Hormone-Sensitive Activation/Deactivation Cycle Of Gs_ _________
Studies on the interactions of Gs with p-adrenergic receptors in 
phospholipid vesicles (Pederson & Ross, 1982) and isolated membranes (Levitzki,
1986) have revealed the essential features of their interactions (Figure 1.6):-
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Figure 1.6:
Regulatory Cycle Of G-Protein Activation/Deactivation
Figure depicts the mechanism by which a receptor catalyses the activation of 
a G-protein and the possible reaction sequences in which a receptor mediates the 
release of GDP from the ap y  heterotrimer, promotes the binding of GTP and 
triggers the activation of the heterotrimer before a possible dissociation of a*-GTP 
from py. GTP-bound a-subunits activate the appropriate effector enzyme, a 
process which is turned-off by the intrinsic GTPase activity of the a-subunit, 
allowing the reassociation of a-GDP with py to initiate another cycle. R^=receptor 
with high affinity for agonist; R^receptor with lower affinity for agonist; 
G*=activated heterotrimeric G-protein; a*=activated a-subunit; P^inorganic 
phosphate.
Figure is taken from Bimbaumer (1990).
GDP GTP
* G T P
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i Agonist-occupied receptors, in concert with intracellular Mg2+, stimulate the rate 
of dissociation of GDP from the guanine nucleotide-binding site on the a-subunit 
of the apy  heterotrimeric G-protein. In the absence of activated receptor, GDP 
only dissociates very slowly (1-5 minutes) (Brandt & Ross, 1985).
ii Agonist-occupied receptors stimulate GTP binding, even when the nucleotide 
binding site is empty. Therefore the life-span of the the "open" G- 
protein/receptor/agonist complex is short as physiological GTP concentrations (100 
|iM) are sufficient to saturate Gs (KmGTP is approximately 1 jiM.) and so the 
nucleotide readily binds to Gs (Bimbaumer et al., 1985).
This nucleotide exchange on the a-subunit described in steps "i" and "ii" 
requires the presence of the Py-complex: in its absence, there is little effect of 
receptors on the a-subunit (Weiss eta l., 1988; Florio & Stemweis, 1989)
iii Binding of GTP precedes a Mg2+- and temperature-dependent activation of Gs 
such that the a-subunits become capable of complexing with and activating the 
adenylate cyclase catalytic unit, increasing the kcat for MgATP by approximately 
200-fold (Northup et al, 1983). The importance of Mg2+ ions in the G-protein 
activation process was determined by Iyengar & Birnbaumer (1982) who found that 
the addition of glucagon to rat liver plasma membranes increases the affinity of the 
system for Mg2+ by three orders of magnitude (from a millimolar to a 
physiologically relevant micromolar range) and enhances the maximal activation of 
adenylate cyclase by GTPyS.
iv The intrinsic GTPase activity of Gsa  hydrolyses GTP to GDP, causing 
deactivation of cyclase. The resulting GS-GDP complex is then free to interact with 
another agonist-occupied receptor to re-initiate the cycle. Thus hormones stimulate 
a GTPase activity not by increasing the km  for GTP hydrolysis, but by increasing 
the number of molecules with GTP bound.
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These events explain the basic properties of hormone-stimulated adenylate 
cyclase. In particular, the importance of the GTPase reaction in turning off the 
cycle was suggested by three observations. Firstly, non-hydrolysable GTP 
analogues (Gpp(NH)p and GTPyS) generate a persistently active enzyme as they 
block the hydrolytic "turn-off" step. Secondly, cholera toxin-catalysed ADP- 
ribosylation of Gsa  abolishes its GTPase activity and results in the persistent 
activation of adenylate cyclase. Thirdly, a hormone-stimulated GTPase activity has 
been demonstrated in several systems, including turkey erythrocyte (Cassel & 
Selinger, 1976; Cassel et al., 1977) and human platelet (Houslay et al., 1986) 
membranes as well as for purified p-adrenergic receptors and Gsa  reconstituted 
into phospholipid vesicles (Cerione et al., 1984).
B The Role Of Hormone-Bound Receptor
The first amplification step in hormonal signalling is at the receptor/Gs 
interaction because the hormone-bound receptor functions as an exchange catalyst 
to activate several Gs molecules. Like conventional enzymes, agonist-bound 
receptors exhibit a higher affinity for the transition state (nucleotide-free Gs) than 
for the product (GTP-bound Gs). The catalytic nature of this interaction was 
demonstrated most unequivocally for the p-adrenergic receptor in turkey 
erythrocyte membranes (Tolkovsky & Levitzki, 1978) and reconstituted in 
phospholipid vesicles with purified Gs (Pederson & Ross, 1982). Similar results 
were also obtained for the glucagon receptor in rat liver plasma membranes 
(Houslay et al., 1980). It was found that a progressive decrease in the number of 
stimulatory receptors reduces the rate of adenylate cyclase activation without 
affecting the maximum specific activity attainable with agonist and Gpp(NH)p, i.e. 
the rate of cyclase activation by Gs (kon) is linearly related to the concentration of 
agonist-bound receptorr These observations led to the formulation of the collision-
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coupling theory of adenylate cyclase activation whereby a hormone-bound receptor 
makes a transient contact with a GS.C complex (Tolkovsky &Levitzki 1978). Such 
a model accounts for the observed kinetics in membranes and reconstituted 
systems, which include the linear dependence of kon with the concentration of 
hormone-bound receptor, a non co-operative dependence of kQn with hormone 
concentration, and first order activation of adenylate cyclase activity by Gpp(NH)p 
and hormone (Pederson & Ross, 1982; Tolkovsky & Levitzki, 1978). Inactivation 
of C in membranes treated with N-ethylmaleimide, or reconstitution of the P- 
adrenergic receptor with purified Gs in the absence of C, demonstrated that these 
kinetic properties were not dependent on its presence (Iyengar & Birnbaumer, 
1982; Pederson & Ross, 1982).
D The Effects Of Guanine Nucleotides On Agonist Binding
The capacity of a hormone to activate adenylate cyclase in isolated 
membranes is absolutely dependent on the presence of guanine nucleotides and 
Mg2+. This observation came not from studies of adenylate cyclase activation but 
from studies on the interaction of glucagon with its receptor in liver plasma 
membranes. It was found that guanine nucleotides (present as contaminants of the 
ATP used in the adenylate cyclase assays) cause a reduction in the affinity of the 
receptors for glucagon (Rodbell et al., 1971a). The search for a functional 
consequence of these effects led to the discovery of guanine nucleotide-mediated 
regulation of adenylate cyclase (Rodbell et al., 1971a and b; Birnbaumer & Yang, 
1974). Subsequently the importance of this phenomenon in G-protein activation 
has been extensively studied for many receptor subtypes linked to adenylate cyclase 
activation, particularly the P-adrenergic receptor (Maguire et al., 1976), as well as 
the rhodopsin/ transducin system of visual signal transduction (Pfister et al., 
1983).
Diffusion:of an agonist to within a few molecules diameters of its receptor
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induces their interaction. The resulting free energy of binding is used to alter 
receptor conformation to a form which has a high affinity for the heterotrimeric G- 
protein with an unoccupied guanine nucleotide binding site on its a-subunit 
(Wessling-Resnick et al, 1987). Thus, activated receptors not only transfer the 
energy of binding to promote GDP release, but also hold open the guanine 
nucleotide binding site to allow GTP binding (Birnbaumer et al., 1980; May & 
Ross, 1988). Once bound, the affinity of the receptor for the G-protein decreases 
and the two species dissociate from one another, thereby reducing the high affinity 
binding of agonist to receptor to a level commensurate with the energy used to 
activate the G-protein. However, in the absence of guanine nucleotides one can 
measure the receptor/G-protein association quite easily.
As previously stated, agonist-occupied receptors behave as catalysts, and as 
such have a high affinity for their transition state (the nucleotide-free heterotrimer). 
Presumably antagonist-bound receptors cannot bind more tightly than unoccupied 
receptors to the transition state. By binding with equal efficacy to different G- 
protein conformations, antagonist-occupied receptors would not alter the 
equilibrium between these conformations, and antagonist binding therefore would 
become insensitive to guanine nucleotides (Maguire et al., 1976; Lefkowitz et al., 
1976). Alternatively, it is possible that antagonist-bound receptors can bind more 
tightly to non-transition state forms of Gs which would be stabilised by antagonist 
binding. Such antagonists exhibit a negative intrinsic activity and inhibit basal 
activity (Costa & Herz, 1989). Partial agonists are capable of forming high affinity 
guanine nucleotide-sensitive complexes with Rs receptors in a manner which is 
positively and linearly correlated with their abilities to activate cyclase by increasing 
the kon (Birnbaumer et al., 1985) •
E G-Protein Activation
 Activation of a G-protein requires the induction of a conformational change
which allows the a-subunit to interact with and modify the activity of its effector.
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The structural changes underlying these steps are poorly understood but 
presumably the effects of guanine nucleotides on receptor/G-protein interactions 
reflect these conformational changes. As agonist/receptor complexes bind tightly to 
the ap y  (nucleotide-free) transition state but not to the substrate (apy-GDP) or 
product (apy-GTP), the high affinity binding of Rs to Gs, or the linked function of 
high affinity binding of agonist to receptor, are disrupted by GDP, GTP or their 
analogues. However, whereas GTP promotes activation of Gs, GDP prevents their 
intreraction. Therefore, if GDP binds to Gsa, the aPy-GDP complex will leave the 
receptor exactly as it arrived whereas if GTP binds, the G-protein will alter its 
conformation such that it can now activate adenylate cyclase and can only interact 
with the receptor again after GTP hydrolysis (Higashijima et al., 1987).
It has been suggested (Bourne et al., 1991) that the ability of the receptor to 
preferentially bind the aPy heterotrimer (Fung & Nash, 1983; Florio & Sternweis,
1989), coupled with the preference of Py to bind GDP-bound rather than GTP- 
bound a-subunits, means that hormone receptors catalyse the replacement of GDP 
with GTP instead of the other way round. This is because the dissociation of py 
from GTP-bound a-subunits prevents further interaction with the receptor thereby 
avoiding receptor-mediated release of GTP.
Molecular biological and functional studies of a mutant H21a Gsa  protein 
have attempted to analyse the mechanisms of G-protein activation (Bourne et al., 
1988). The mutant exhibits a single amino acid difference compared with wild type 
G sa , adjacent to the GTP-binding site, resulting in the divorce of guanine 
nucleotide-sensitive agonist binding from adenylate cyclase activation. Presumably 
this results from the mutation preventing the Mg2+-dependent change in 
conformation which would allow the a-subunit to activate C. A similar separation 
of agonist binding and cyclase stimulatory effects of guanine nucleotides occurs in 
the absence of Mg2+, supporting the hypothesis that a Mg2+-dependent activation 
step is impeded in the H21a mutant (Higashijima et alT, T987X
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The nature of the conformational transitions which occur after GTP binding 
are controversial. When purified detergent-solubilised G-proteins bind GTPyS, 
dissociation into Gsoc-GTPyS and py complexes is promoted: GDP stabilizes the 
holomeric form (Gilman, 1984; Florio & Sterweis, 1989). These observations led 
to the proposal of a model whereby hormone-stimulated GTP binding to Gs leads to 
the dissociation of a Gga-GTP complex which then associates with and activates C. 
Upon GTP hydrolysis, the Gsa-GDP complex dissociates from C and can 
preferentially reassociate with Py since it has a higher affinity for the latter than 
Gsa-GTP (Gilman, 1987). Hence Py competes with C for Gsa . Therefore one 
potential mechanism for cyclase inhibition is Gj dissociation producing elevated 
levels of py-subunits which can bind Gsa  molecules, making them less accessible 
to C and thereby causing inhibition. In this respect, it is noteworthy that Gga-GTP 
binds more tightly to py than GjCX-GTP (Pang & Stemweis, 1989).
However, Levitzki and co-workers have provided evidence which suggests 
that Gs remains tightly bound to C throughout the activation cycle and that it may 
not even dissociate into subunit complexes upon binding of GTP (Levitzki, 1990). 
Firstly, the mechanism proposed implies a "shuttling" of Gga  from holomeric Gs to 
C which is incompatible with the observed kinetics of cyclase activation in isolated 
membranes and reconstituted systems (Tolkovsky et al., 1982). Secondly, very 
little dissociation of G-proteins has ever been observed in the presence of GTP 
(Huff & Neer, 1986). Finally, it is possible to extensively purify GDP-bound and 
Gpp(NH)p-preactivated C from turkey erythrocytes and bovine brain at low 
detergent/protein ratios such that p-subunits co-purify stoichiometrically with C and 
the associated Gsa-subunit (Arad et al., 1984; Marbach e t «/., 1990). High salt 
washing of the forskolin affinity column to which this complex is bound results in a 
final forskolin-eluted product devoid of p-subunits, demonstrating the high salt 
sensitivity of the a/Py interaction (Marbach et al., 1990).
--------- Despite the controversy and ignorance surrounding the conformational
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changes occurring, it is accepted that the G-protein activation cycle provides a 
second amplification step after the Rs/Gs catalytic interaction. This is because the 
rate constant of GTP hydrolysis (approximately 10 per minute at 37°C) is 100-times 
less than the turnover number of the cyclase catalytic unit (approximately 1000 per 
minute). Therefore the events from agonist binding to activation of C result in a 
10xl00=1000-fold amplification factor (Levitzki, 1988).
1.9.3 INHIBITION OF ADENYLATE CYCLASE ACTIVITY
Proof that Gs and G- were independent molecules under the separate 
control of GTP and hormone receptors came initially from studies which 
demonstrated that Rs receptor-mediated GTP hydrolysis was additive to the activity 
stimulated by R{ receptors (Bitonti et al., 1980; Aktories & Jakobs, 1981). The 
subsequent purification and reconstitution of Gs and Gj with appropriate receptors 
confirmed these observations in isolated membranes (Kurose et al., 1986).
Just as stimulation of adenylate cyclase activity by appropriate receptors 
appears to be ubiquitous, inhibition of adenylate cyclase activity also seems to be a 
universal phenomenon. Examples of inhibitory receptors which activate Gj to 
inhibit adenylate cyclase activity include oc2-adrenergic receptor subtypes and 
muscarinic acetylcholine receptor subtypes, as well as receptors for angiotensin II, 
dopamine (D2 class), purinergics (P2y class) and adenosine (Aj class) to mention a 
few examples. The receptor-dependent activation/deactivation cycle of G{ is veiy 
similar to that of Gs but unlike Rs receptors, Rj receptors do not appear to enhance 
G{ activity by increasing its affinity for Mg2+ because under basal conditions, G{ 
already has an affinity for Mg2+ which is within the micromolar range (Hildebrandt 
& Bimbaumer, 1983). However like Rs receptors, agonist-bound R{ receptors are 
capable of catalysing nucleotide exchange at the a-subunit, as has been 
demonstrated in platelet and adipocyte membranes (Michel & Lefkowitz, 1982; 
Murayama & Ui, 1984). Similarly, GTP, GDP and their analogues exhibit 
virtually identical effects on the binding of agonists to R{ receptors as they do for Rs
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receptor agonists (Birnbaumer et al., 1985). One important difference is that 
pertussis toxin-catalysed ADP-ribosylation of G^a-subunits within holomeric Gj 
prevents formation of the high affinity nucleotide-free transition state, thereby 
inhibiting guanine nucleotide exchange and abolishing Gj function (Sunyer et al.,
1988).
A Proposed Inhibitory Mechanisms
As for Gs, studies on purified, ionic detergent-solubilised receptors and G- 
proteins led to the proposal of a subunit dissociation model to account for the 
observed non-competitive inhibitory effects of Gj on adenylate cyclase activity 
(Gilman, 1984). Such a model assumes that Gsa  and py are in continual 
equilibrium and that binding of GTP promotes a dissociated state whilst GDP 
stabilizes the holomeric form (Katada et al., 1984a, b and c). Similarly, Gj 
molecules are presumed to dissociate into their constituent Gja and py-subunits. 
Since Py-subunits appear to be functionally interchangeable, and Gj is expressed in 
a 5- to 10-fold excess over Gs in most tissues, (Gilman, 1987) elevated levels of 
free py-subunits released by Gj dissociation will tend to increase the proportion of 
Gs molecules in the holomeric form by a Mass Action effect (Katada et al., 1984a, 
b and c).
However, as a dissociation model cannot account for the observed kinetics 
of adenylate cyclase stimulation, Levitzki and co-workers have proposed a 
modification of this hypothesis which assumes the permanent association of Gsa  
and C that was used to account for Gs-mediated activation of C described in the 
previous section (Marbach et al., 1990; Levitzki, 1990). The finding that py-^ 
subunits remain tightly associated with Gpp(NH)p-preactivated C places doubts on 
the ability of py to inhibit cyclase by binding to Tree' Gsa  (Marbach et al., 1990), 
and leaves GjOc as the dominant inhibitory species. Whereas GjOC.C interactions are 
not readily observable with purified components inphospholipid vesicles, they
68 0
must occur in S49 eye" cells to account for the observed inhibitory effects of 
somatostatin and guanine nucleotides on forskolin-stimulated activity as there is no 
Gs present (Hildebrandt & Bimbaumer, 1983; Hildebrandt & Kohnken, 1990). 
The fact that Gj function, but not Gs function, may be preferentially uncoupled in 
certain systems using heparin (Willuweit & Aktories, 1987) suggests that its 
interaction with C involves weaker forces than those involved in GS.C interaction: 
hence the lack of an inhibitory effect of GAa  on C in reconstituted systems even 
though Ri receptor-mediated activation of Gj can be observed (Smigel, 1986). 
Nevertheless, interaction between G| and GS.C has been detected in S49 lymphoma 
membranes by measuring P-adrenergic receptor binding affinity after treatment of 
membranes with pertussis toxin (Marbach et al., 1988). Such experiments 
demonstrated that pertussis toxin pre-treatment reduced receptor affinity by 
approximately five-fold compared with untreated membranes, an effect not 
observed in S49 e y e  cells (no Gsa  present) or turkey erythrocyte membranes (no 
Gj present). This suggested to the authors that Gj can interact more efficiently with 
C when C is complexed to Gs. The nature of these interactions is unknown 
(Marbach etaL, 1988).
One argument against a role of Py-subunits in mediating inhibition is that 
activation of any G-protein will result in cyclase inhibition. However, preferential 
inhibition by py of basal and forskolin-stimulated activity rather than hormone- 
stimulated activity in S49 e y e  cells suggests that effects of these subunits on 
cyclase activity may not be artefactual or trivial, and a model has been proposed 
which tries to account for their inhibitory effects (Hildebrandt & Kohnken, 1990). 
These workers have proposed that a preferential inhibition of basal activty by Py- 
subunits arises due to their ability to bind to GDP-bound Gsa-subunits, thereby 
preventing exchange of GDP for GTP and subsequent activation. This assumes 
that a 'free' GDP-bound Gsa-subunit can exist, and that the rate of nucleotide 
exchange ofthis species is greater than for holomeric G[. Hence, the main function
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of py-subunits would be to suppress basal activity thereby allowing any hormone 
working through any G-protein to inhibit basal adenylate cyclase activity, but only 
hormones working through Gj could inhibit hormone-stimulated cyclic AMP 
production (Hildebrandt & Kohnken, 1990). If this is the case, the importance of 
this basal inhibition of adenylate cyclase activity in different tissues depends on the 
amounts of free py-subunits in excess of Gsa , perhaps accounting for the variation 
in potency of exogenously added py in causing inhibition of adenylate cyclase in 
different systems (Hildebrandt & Kohnken, 1990; Higashijima et al., 1987).
2.9.3 EFFECTS OF ENVIRONMENT ON RESPONSIVENESS
Once a ligand has bound to its receptor, the activated complex must initiate a 
response. Since agonist-bound receptor complexes have a lifespan of only a few 
seconds, G-protein activation must be rapid so that the initial response is amplified 
by the activation of many G-proteins. Rapid activation of several G-proteins is 
achieved in several ways. Firstly, the dissociation of the G-protein from the 
receptor after the binding of GTP liberates the receptor so that it can activate another 
G-protein: this receptor recycling maximizes its catalytic efficiency. Secondly, 
receptors and G-proteins interact at the surface of a membrane and not free in 
solution, i.e. they are diluted in two rather than three dimensions, which increases 
the probability that they will interact with each other in a productive manner 
(Liebman et al., 1987). This advantage will be counteracted to some degree by the 
relatively slow rate of lateral diffusion of receptors in the lipid bilayer compared to 
the situation in free solution. A comparison between vertebrate and invertebrate 
rhodopsin molecules also emphasizes the importance of membrane fluidity in 
regulating these interactions. Whereas vertebrate rhodopsin is highly mobile 
compared with most membrane proteins (Poo & Cone, 1974), squid rhodopsin is 
tightly embedded in microvilli (Foster, 1980). These differing environments may 
explain why a single photobleached vertebrate rhodopsin molecule can activate up 
to 500 transducins, whilst the invertebrate protein can only activate 8 transducins
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(Stryer, 1986; Kirkwood et al., 1989).
The rate of activation of an effector enzyme by a GTP-bound G-protein 
would be expected to depend more on cytoplasmic conditions than membrane 
conditions as none of the G-protein subunits are thought to be transmembrane 
species, and this has been shown to be the case for transducin-mediated activation 
of the retinal cyclic GMP-specific phosphodiesterase (Chabre, 1987). It has also 
been shown that the rate of p-adrenergic receptor- but not fluoride-mediated 
stimulation of adenylate cyclase activity is profoundly affected by alterations in 
membrane fluidity (Hanski et al., 1979). The advantages of restricting interactions 
between signalling proteins to the membrane are not lost because G-proteins are 
membrane-bound, yet an additional benefit may be a faster transfer of information 
between G-protein and effector in the cytosol, which is rather less viscous than the 
plasma membrane. As yet, the assumption that the diffusion rates of 
transmembrane receptors and catalytic units within the membrane might limit the 
rates of activation or inhibition of adenylate cyclase activity has not been thoroughly 
tested experimentally.
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1.10 REGULATION OF HORMONAL RESPONSIVENESS
1.10.1 STIMULATION OF ADENYLATE CYCLASE
The stimulation of second messenger generation by G-protein-linked 
receptors is under tight control from the regulatory mechanisms of the cell. This is 
manifested in the phenomenon of refractoriness or desensitization, which is defined 
as a continual temporal reduction in responsiveness observed despite the continuous 
presence of agonist at constant intensity. As intracellular cyclic AMP levels are the 
sum of three continuous processes (synthesis, degradation and export of cyclic 
AMP) it is possible that regulation at any of these points could account for the 
observed plateau in intracellular cyclic AMP levels observed after prolonged 
exposure to a stimulatory agonist. As both intracellular and extracellular levels of 
cyclic AMP plateau after exposure to a stimulatory agonist, cyclic AMP export 
cannot account for the observed desensitization (Shear et al., 1976). Similarly, the 
observed cyclic AMP-induced increases in PDE activity at the level of increased 
gene transcription (Swinnen et al.y 1989) are not rapid enough to account for the 
observed plateau, and the effect also occurs in the presence of PDE inhibitors 
(Shear et al., 1976). Instead, the bulk of the desensitization arises due to the 
attenuation of cyclic AMP synthesis
Desensitization of the p-adrenergic receptor has been most thoroughly 
characterised with respect to its activation of adenylate cyclase activity, and two 
processes are thought to be involved in its development: a rapid uncoupling of the 
receptor from the G-protein and receptor sequestration, followed by receptor down- 
regulation leading to a reduced receptor number (Collins et al., 1990)
A Receptor/G-Protein Uncoupling & Receptor Sequestration
As previously mentioned in Section 1.7, the receptor/G-protein-linked 
systems are very homologous TcTthe rhodopsin/transducin system. In the latter
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case, a rhodopsin kinase is capable of specifically phosphorylaiing 'bleached* 
rhodopsin molecules, thereby uncoupling them from transducin and homologously 
desensitizing the response (Kuhn & Wilden, 1987). An analagous enzyme, the p- 
adrenergic receptor kinase (PARK) has been identified, purified to apparent 
homogeneity and cloned (Benovic et al., 1987; Benovic et al., 1989). The 
activity of this protein kinase is dependent on the presence of agonist-occupied p2- 
and o^-adrenergic receptors, and it is capable of phosphorylating the former to a 
stoichiometry of 8 mol phosphate per mole of receptor (Dohlman et al., 1987). 
For the P2-adrenergic receptor, most of the phosphorylated Ser and Thr residues 
are within the C-terminal tail of the receptor as carboxypeptidase Y treatment of 
reconstituted pARK-phosphorylated receptor removes most of the incorporated 
phosphate (Dohlman et al., 1987).
Although phosphorylation by pARK reduces receptor function, an 
additional factor is required for the full expression of these effects (Benovic et al.,
1987). Again, this is analogous to the rhodopsin system where phosphorylation of 
at least one more Ser on the third cytoplasmic loop of rhodopsin is required before 
the binding of arrestin, a soluble 48 kDa protein which binds to phosphorylated 
rhodopsin and prevents its interaction with transducin (Stryer, 1986). Considering 
the ubiquity of G-protein-linked systems, it is not surprising that an analogous 
protein, termed Parrestin, has been shown to exist for the p-adrenergic receptor/Gs 
system and a family of such proteins may exist for other systems in which 
desensitization mechanisms have not yet been fully characterized (Benovic et al., 
1987; Lohse e ta l., 1990b).
The cloning of pARK also resulted in the isolation of another homologous 
yet distinct clone, raising the possibility of the existence of pARK isoenzymes and 
perhaps a family of related molecules (Benovic et al.y 1989). The fact that 
muscarinic receptors have clusters of Ser and Thr residues at their C-termini might
indicate that a similar kinase(s) are involved in an analogous homologous
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desensitization mechanism (Peralta et al., 1987). Indeed, this is given further 
credence by the finding that PARK is capable of phosphorylating muscarinic 
receptors in an agonist-dependent fashion (Kwatra et al., 1989)
The P-adrenergic receptor also contains two consensus sequences for 
phosphorylation by cyclic AMP-dependent protein kinase (PKA): one site is within 
the third cytoplasmic loop, the other within the C-terminal tail (Blackshear et al.,
1988). Presumably these are the sites which are responsible for the heterologous 
desensitization elicited by Rs agonists in cells expressing several types of Gs-linked 
receptors (Hausdorff et al., 1990). As with pARK, the rate of phosphorylation of 
the p2-adrenergic receptor by PKA is increased by agonist occupancy of the 
receptor (Bouvier et al., 1987).
Using specific inhibitors of pARK and PKA, Lohse et al.( 1990a) have 
tried to assess the contribution of these kinases to the initial rapid uncoupling of the 
P-adrenergic receptor from adenylate cyclase after agonist exposure. At low 
agonist concentrations, approximately 90% of the desensitization response is due to 
equal contributions from PKA- and pARK-catalysed phosphorylation of the 
receptor. However, at higher doses of agonist, receptor sequestration becomes a 
significant component of the desensitization pathway. Therefore the contribution 
from each of these different mechanisms in the final desensitization response is 
intimately related to agonist concentration (Lohse et al., 1990a).
A consensus sequence for protein kinase C also exists and has been shown 
to be phosphorylated in an agonist-independent manner, providing a potential 
means of 'cross-talk' between the inositol lipid and cyclic AMP signalling 
pathways, allowing one pathway to regulate the other (Bouvier et al., 1987). 
Similarly, it is possible for PKA to phosphorylate the otj-adrenergic receptor in an 
agonist-independent manner, thus regulating the function of the latter (Bouvier et 
al., 1987).
Currently very little is known about the mechanisms of receptor 
dephosphorylation and resensitization of responsiveness, although latent
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phosphatase 2A can catalyse the dephosphorylation of purified hamster p2- 
adrenergic receptor which has been phosphorylated by pARK in vitro (Yang et 
al., 1988). Also, the subcellular distribution of latent phosphatase 2A parallels that 
of p-adrenergic receptor phosphatase described in frog erythrocytes (Sibley et al., 
1986).
B Receptor Down-Regulation
Down-regulation leads to the irreversible reduction of receptor number and 
an associated reduction in agonist-stimulated adenylate cyclase activity (Lefkowitz 
& Caron, 1988). From studies with mutated P-adrenergic receptors which have 
been transfected and expressed in p-adrenergic receptor-deficient cells, as well as 
studies on transfected DDTj MF-2 smooth muscle cells, PKA appears to play an 
important role in the control of down-regulation (Collins et al., 1990).
In cells expressing human p2-adrenergic receptors with a single mutation 
(Ser to Ala) in either one or both of the PKA phosphorylation sequences, P- 
adrenergic receptor down-regulation proceeded with an initial delay, but after 
several hours the down-regulation rate paralleled that of cells transfected with the 
wild type receptor (Collins et al., 1990). Hence, factors other than PKA- 
dependent phosphorylation of receptor are required for down-regulation to occur. 
Treatment of wild type and mutant receptor-transfected cells with forskolin or 
dibutyryl cyclic AMP causes identical reductions in the levels of p-adrenergic 
receptor mRNA. This reduction occurs in the absence of a promoter sequence, and 
must therefore result from a post-transcriptional event such as destabilisation of p- 
adrenergic receptor mRNA (Bouvier et al., 1989; Hadcock et al., 1989).
Recent evidence has also implicated two Tyr residues in the C-terminal tail 
of the p-adrenergic and other receptors in controlling down-regulation. Site- 
directed mutation of these Tyr residues to Ala's has no effect on receptor
sequestration but drastically reduces down-regulation, providing more evidence that
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these events are probably controlled by distinct mechanisms (Vaiiquette et al.,
1990).
1.10.2 GLUCAGON RECEPTOR DESENSITIZATION
Glucagon desensitization has been studied intensively in rat and chick 
hepatocytes: both systems exhibit distinct regulatory constraints on glucagon 
activation of adenylate cyclase activity. Unlike the p-adrenergic receptor system, a 
heterologous desensitization follows a homologous desensitization process 
(Premont & Iyengar, 1988; Premont & Iyengar, 1989). Whereas the homologous 
phase occurs over a relatively small time course (complete within 5 minutes), the 
heterologous phase, as monitored by fluoride-stimulated adenylate cyclase activity, 
takes longer (approximately 30 minutes) to reach completion (Heyworth & 
Houslay, 1983; Premont & Iyengar, 1988). Removal of glucagon within 30 
minutes rapidly restores normal coupling of glucagon receptors to Gs.
In rat hepatocytes, angiotensin II, Arg-vasopressin and TPA can mimic the 
desensitization response, implying a role for PKC-catalysed phosphorylation of 
some component of the adenylate cyclase complex in mediating the desensitization 
response (Houslay, 1986). Indeed, it has been claimed that glucagon itself is also 
capable of eliciting a small stimulation of PIP2  breakdown, resulting in the sn-1,2- 
diacylglycerol production which may initiate the PKC-mediated desensitization 
event (Wakelam et al., 1986). This contrasts with the situation for chick 
hepatocytes where only cyclic AMP and its analogues can mimick the refractory 
response, a property not displayed by rat hepatocytes (Houslay, 1986).
1.10.3 PHOSPHORYLATION OF G-PROTEIN SUBUNITS
One obvious potential mechanism by which cells could rapidly adapt their 
hormonal responsiveness is by rapidly altering the functional status of a relevant G-
protein by phosphorylation. This may result in either a heterologous desensitization
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or supersensitization of a given second messenger event.
In vitro studies have shown that purified human insulin receptor is capable 
of phosphorylating on Tyr a mixture of bovine brain G^a and G0a  when in their 
GDP-bound state (Krupinski et al., 1988; O'Brien et al., 1987a). However, 
insulin-stimulated phosphorylation of G ja has not been observed in intact rat 
hepatocytes (Rothenberg & Kahn, 1988; Pyne et al., 1989) and so the functional 
significance of these in vitro studies is unclear.
Ser/Thr phosphorylation of G-protein a-subunits has been noted by several 
investigators. In particular, Jakobs et al. (1985) initially claimed that a 2- 
adrenergic receptor-mediated inhibition of adenylate cyclase in platelets was 
attenuated by treatment with TPA which was thought to stimulate the PKC- 
catalysed phosphorylation of G ^ . Since these initial observations, other workers 
have shown that Gza  may also be phosphorylated in platelets in response to 
thrombin, which stimulates inositol phospholipid metabolism (Carlson et al.,
1989).
In rat hepatocytes, G ^-2  can be specifically phosphorylated by hormones 
which elevate cyclic AMP and ^w-l,2-diacylglycerol levels, resulting in the 
activation of PKA and PKC respectively (Bushfield et al., 1990a). Whereas pure 
PKC can elicit a similar phosphorylation event on isolated hepatocyte membranes 
in vitro, pure PKA cannot, implying that PKA cannot phosphorylate G^a-2 
directly but is required for the activation of a kinase which can. The inability of 
pure PKA to phosphorylate GAa  in vitro has been noted by others (Premont & 
Iyengar, 1989). In rat hepatocytes, these phosphorylation events abolish the ability 
of guanine nucleotides to inhibit adenylate cyclase activity: as it is possible to lose 
this effect while retaining receptor-dependent inhibition (Strassheim et al., 1990), 
phosphorylation may enhance the sensitivity of adenylate cyclase to stimulation by 
stimulatory agonists such as glucagon.
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1.10.4 HORMONAL INHIBITION OF ADENYLATE CYCLASE
Relatively few studies have investigated the mechanisms by which 
inhibitory regulation of adenylate cyclase is modified in response to persistent 
agonist exposure. Chronic (6 day) infusion of rats with the Aj adenosine receptor 
agonist PIA causes a reduction in expression of Gja-1 and G^a-2 and an increased 
expression of Gsa  without causing any alteration in the levels of GjCX-3 in 
adipocyte membranes from treated animals compared with controls: these changes 
in expression are not accompanied by any alterations in the abundance of the 
mRNA species encoding these proteins (Longabaugh et al.y 1989). A 60% 
reduction in the number of adenosine receptors is also observed, with a greater 
proportion of the receptors existing in a low affinity state in the PIA-treated animals 
(Longabaugh et al.y 1989). With respect to the kinetics of adenylate cyclase 
regulation, PIA treatment leads to a progressive reduction in the ability of this 
ligand to inhibit adenylate cyclase activity while basal and forskolin-stimulated 
activities are increased compared with controls. Presumably the reduced expression 
of GiOC-subunits and an increased expression of Gsa-subunits produces elevated 
adenylate cyclase activity by relieving a tonic inhibitory input and potentiating a 
stimulatory input. Similar results have been obtained by treating isolated rat 
adipocytes in primary culture with PIA (Green, 1987).
Chronic treatment of S49 cells in culture with either isoproterenol or 
forskolin causes a time-dependent increase in expression of GjOC-2 and a small 
reduction in expression of Gsa  (Hadcock et al.y 1990).' ‘These changes arise due 
to an increased transcription of G ft-2  mRNA, and a reduced stability of Gsa  even 
though the abundance of its mRNA is slightly increased. (Hadcock et al.y 1990). 
Presumably these alterations in G-protein subunit expression account for the 
increased inhibition of forskolin-stimulated adenylate cyclase activity by 
somatostatin in forskolin- and isoproterenol-treated cells. The alterations in 
expression of Gxa-2 required the presence of a functional PKA activity as S49 kin
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cells are unable to regulate expression of this protein when exposed to isoproterenol 
or forskolin under the same conditions as the wild type cell line (Hadcock et al.,
1990).
The mechanisms by which the mRNA's for different G-protein subunits are 
regulated are not fully understood at present, but the rapid increase in GjOC-2 mRNA 
observed in treated S49 cells may be due to the presence of a cyclic AMP- 
responsive element in the 51 non-coding region of the GjOC-2 gene which could be 
activated on exposure of the cells to stimulatory agents. This provides a means by 
which one arm of dually regulated adenylate cyclase can control the functioning of 
the other arm (Brann et al., 1987; Hadcock et al., 1990).
1.11 REGULATION OF ADENYLATE CYCLASE IN
PATHOLOGICAL STATES
1.11.1 ALTERED THYROID STATUS
A Hypothyroidism
It has been recognized for many years that thyroid hormones can regulate 
catecholamine-stimulated lipolysis in adipocytes, with a hypothyroid state leading to 
triglyceride accumulation and obesity (Debons & Schwartz, 1961). This is 
achieved by regulating the number and function of p-adrenergic receptors coupled 
to the stimulation of adenylate cyclase (Stiles et al., 1984) and by modulating the 
expression of specific G-protein subunits (Milligan et al., 1987; Rapiejko et al.,
1989).
Fat cells from chemically-induced hypothyroid rats exhibit a drastically 
reduced response of adenylate cyclase to catecholamine stimulation (Malbon et al., 
1978) as well as an enhanced inhibitory response to inhibitory adenosine receptor 
agonists (Malbon et al., 1985; Saggerson, 1986). These observed changes in
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hormonal sensitivity are accompanied by an uncoupling of the P-adrenergic receptor 
from Gs without any change in expression of Gs (Milligan & Saggerson, 1990; 
Rapiejko et al., 1989; Malbon et al., 1984). However, the response of 
hypothyroid membranes to stimulation by either ACTH or glucagon is relatively 
unaffected (Saggerson, 1986). An increased abundance of Gja-1 and Gfn-2 was 
observed in hypothyroid animals as determined by pertussis toxin-catalysed ADP- 
ribosylation in vitro (Malbon et al., 1985) and immunoblotting (Milligan et al., 
1987; Rapiejko et al., 1989), although GjCX-1 and GjOc-2 mRNA levels are 
unaltered between hypothyroid and euthyroid animals (Rapiejko et al., 1989). An 
increased expression of G ja-3 has also been observed in adipocytes from 
hypothyroid animals by immunoblotting (Milligan & Saggerson, 1990). 
Immunoblotting studies have also shown there to be increased levels of pj- and p2- 
subunits in adipocyte membranes prepared from hypothyroid animals, which is 
associated with elevated amounts of their mRNA species (Rapiejko et al., 1989). 
Human studies, although showing a general decreased effectiveness in lipolysis in 
hypothyroid patients, have shown that there are no alterations in G-protein 
expression. It is possible that the patients used exhibited enough genetic variability 
to mask any changes that occur in the wider population of hypothyroid individuals 
(Ohisalo & Milligan, 1989).
Preliminary studies have also shown that the hypothyroid state causes a 
similar potentiation of the inhibitory regulation of adenylate cyclase in synaptosomal 
membranes prepared from rat brain (Mazurkiewicz et al., 1989). Whether this is 
due to the same alterations in G-protein expression as those occuring in fat cells is 
unknown.
B Hyperthyroidism
Hyperthyroidism is associated with a potentiated lipolytic response causing 
an elevated accumulation of cyclic AMP in response to catecholamines (Deykin & 
Vaughn, 1963; Malbon et al., 1978). These changes may be explained by the
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reduced levels of GjCX-1, GfL-2 and P-subunits, as well as the slightly increased 
abundance of Gsa-subunits seen in adipocytes from hyperthyroid animals 
compared with euthyroid controls (Ros et al., 1988; Rapiejko et al., 1989). 
Presumably these changes enhance cyclic AMP accumulation by reducing the tonic 
inhibitory effect of Gj on adenylate cyclase activity as well as slightly potentiating 
the stimulatory input from Gs. As with the hypothyroid animals, only p-subunits 
exhibited a co-ordinate reduction in the expression of their mRNA species 
(Rapiejko et al., 1989), perhaps suggesting one point of permissive regulation of 
adenylate cyclase activity by thyroid hormones at the level of controlling P-subunit 
mRNA (Rapiejko et al., 1989).
1.11.2 ALBRIGHT HEREDITARY OSTEODYSTROPHY (AHOl
AHO is a disorder inherited as an autosomal dominant trait (Van Dop et al., 
1984c), and is characterized by symptoms which include round facies, short 
stature, subcutaneous ossification and obesity (Levine et al., 1988). Most AHO 
sufferers also exhibit pseudohypoparathyroidism type la (PHP-Ia), a state 
characterized by mental retardation, impaired olfaction and a resistance to 
parathyroid hormone and other ligands capable of stimulating adenylate cyclase 
activity in many tissues (Farfel & Friedman, 1986; Weinstock etal., 1986; Levine 
et al., 1983a). Presumably this is due to the drastically reduced functioning of 
Gsa  detected in all tissues thus far examined from PHP-Ia sufferers (Downs et al., 
1983; Farfel et al., 1982; Levine et al., 1983b). AHO patients with normal 
hormone responsiveness are termed pseudo-pseudohypoparathyroidism sufferers 
(PPHP) (Albright et al., 1952).
The autosomal dominant nature of the PHP-Ia characteristics suggested that 
the molecular lesion is at the level of one of the Gsa  genes in the human genome. 
Fibroblasts and erythrocytes from all AHO patients examined, whether PHP-Ia or
t
PPHP sufferers, have reduced levels of Gsa  protein compared with normal
subjects and all but three of these also had correspondingly reduced levels of Gsoc 
mRNA (Levine et al., 1988). The lack of any differences in the genomic DNA 
restriction maps between normal and AHO patients rules out the possibility of large 
deletions, substitutions or re-arrangements within the Gsa  gene being responsible 
for the observed reduced mRNA levels, but it does not exclude the possibility of 
small changes within the gene or its promoter region (Levine et al., 1988). At 
present it is not known whether Gga  mRNA synthesis or processing is defective in 
these individuals.
The nature of the defect in the three PHP-Ia patients in the study by Levine 
et a/.(1988) with normal Gsa  mRNA levels but reduced Gsa  protein is also 
unknown.
1.11.3 GROWTH HORMONE-SECRETING PITUITARY TUMOURS
Growth hormone releasing hormone (GHRH) is a peptide which interacts 
with receptors on pituitary somatotroph cells causing the elevation of intracellular 
cyclic AMP levels, resulting in uncontrolled somatotrophic cell proliferation and 
growth hormone (GH) secretion (Billestrup et al., 1986). Measurement of 
adenylate cyclase activity in GH-secreting pituitary tumours from a subset of 
patients showed there to be a marked elevation of cyclic AMP levels which were not 
responsive to further stimulation by GHRH (Vallar et al., 1987). Several lines of 
evidence implicated the existence of a constitutively active Gsa  molecule in such 
individuals: these included a hyper-responsiveness of adenylate cyclase to activation 
by Mg2+, elevated Gs activity as measured by complementation of Gsa-deficient 
S49 eye" cell membranes, and the inabilities of cholera toxin, Gpp(NH)p and NaF 
to elicit further activation of adenylate cyclase activity (Vallar et al., 1987).
In four patients examined by Landis et al. (1989), two different mutations 
in Gsa  were observed: three tumours replaced Arg 201 with a Cys or His residue, 
and one tumour had a Gin 227 to Arg substitution. Construction of Gsa  molecules
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with the appropriate mutations and expression in S49cyc" cells reproduced the 
same perturbed kinetics of adenylate cyclase stimulation as observed in the tumour 
cells (Landis et al., 1989).
The Gin 227 mutation occurs in a region of Gsa  within the GTP-binding 
domain (Masters et al., 1986) and as for the corresponding residue in p21ras 
(residue 61), substitution to another amino acid results in the severe attenuation of 
the kcat (GTPase) of the molecule (Landis et al., 1989; Barbacid, 1987). Mutation 
of Arg 201 to a Cys or His residue produces a molecule with properties that are 
similar to those of wild type Gsa which has been ADP-ribosylated on Arg 201 by 
cholera toxin (Landis et al., 1989). This Arg residue is within domain II of Gsa  
(Masters et al., 1986), a domain that is lacking in both p2 \ras proteins and EF-Tu. 
Unlike G-proteins, the GTPase activity of these smaller molecules is regulated by 
their interaction with other proteins (GAP and a programmed ribosome 
respectively). Therefore it has been proposed that domain II acts as an 'intrinsic 
GAP' within Gsa thereby accounting for the higher intrinsic GTPase activity 
compared to the p2 \ras proteins (Landis et al., 1989). Substitution of Arg 201 
abolishes this GAP activity and causes the accumulation of GTP-bound Gsa  
(Graziano & Gilman, 1989; Masters etal., 1989).
The existence of constitutively active Gsa  molecules responsible for tumour 
promotion begs the question of their unambiguous identification as 'gsp oncogene' 
products. They resemble dominantly acting oncogenes in several respects, 
including their abilities to i mimics a growth factor response (GHRH in this case), 
the existence of oncogenic mutations exclusively in tumour DNA and the dominant 
expression of the gsp molecules with respect to wild type Gsa  (Landis et al., 
1989). However, it is not yet known whether expression of these proteins in other 
cell types requiring cyclic AMP for growth will induce the same oncogenic 
phenotype.
One important implication from this work is that other mutant G-proteins 
may be responsible for tumour promotion in some cell types. Presumably similar
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mutations in the corresponding Arg and Gin residues conserved within the other G- 
protein a-subunits in the appropriate cell types could also induce uncontrolled 
growth via constitutive activation of signalling pathways
1.11.4 ADRENALECTOMY
Steroid hormones can modulate the abilities of several tissues to respond to 
hormones which regulate adenylate cyclase activity (Davies & Lefkowitz, 1984), 
including liver and adipose tissues (Exton et al., 1972; Allen & Beck, 1972). 
Hence, one might anticipate that adrenalectomy will perturb the permissive 
regulation of adenylate cyclase activity by steroid hormones in their target tissues. 
This is observed in adipocytes where adrenalectomy of rats impairs the 
catecholamine-stimulated lipolytic response in adipocytes (Ros et al., 1989b). 
This study indicated that glucocorticoids regulate cyclic AMP production at the level 
of expression of Gsa  and also the expression of P-subunits, since adrenalectomy 
causes a reduction in the cholera toxin-catalysed labelling of the two forms of Gsa  
and a decrease in the expression of p-subunit mRNA species present in adipocytes 
(Ros et al., 1989b). A similar reduction in hormone-stimulated adenylate cyclase 
activity is also observed in reticulocytes and hepatocytes, although it is not known 
whether a similar mechanism is involved (Stiles et al., 1981).
Consistent with adrenalectomy causing a reduction in expression of Gsa, 
dexamethasone therapy of adrenalectomized animals enhances levels of Gsa  in 
adipocytes and restores the catecholamine-stimulated lipolytic response to some 
extent, although the slightly reduced forskolin-stimulated adenylate cyclase activity 
observed might indicate a lower intrinsic activity of the catalytic unit (Malbon et 
al., 1985). The fact that dexamethasone treatment of growth hormone-secreting 
cells causes increases in both cholera toxin-catalysed labelling of Gga and 
forskolin-stimulated adenylate cyclase activity shows that the effects of steroids on 
the permissive regulation of adenylate cyclase activity are probably tissue-specific
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(Chang & Bourne, 1987). Consistent with this idea is the finding that both GjOC-2 
and Gsa  mRNA levels are regulated by glucocorticoids in brain, unlike adipocytes 
where expression of G^-subunits appears to be unaffected (Saito et al., 1989; 
Ros et al., 1989b)
1.11.5 HEART FAILURE
Cyclic AMP is thought to play an important role in mediating the positive 
inotropic response of cardiac tissue (Bristow & Ginsberg, 1986). Therefore, one 
potential locus for a defect in certain heart diseases could be the adenylate cyclase 
signalling complex. A study by Neumann et al. (1988) demonstrated that heart 
membranes from three patients with idiopathic dilated cardiac myopathy displayed 
an enhanced pertussis toxin-catalysed labelling of GAa  compared with non-failing 
heart membranes. These changes are associated with a reduced response of cardiac 
adenylate cyclase activity to isoproterenol, which may be due in part to an increased 
expression of Gj enhancing the tonic inhibition of adenylate cyclase activity which 
is sufficient to reduce Gs-mediated stimulation (Neumann et al., 1988).
Reduced number and function of p-adrenergic receptors also seems to be an 
important factor in the development of heart failure (Bristow et al., 1985). 
However, as adenylate cyclase is activated by p-adrenergic receptors via a collision 
coupling mechanism which buffers the system against large decreases in receptor 
number (Tolkovsky & Levitzki, 1978), a defect in the coupling between the P- 
adrenergic receptor and Gs may be of greater significance.
1.11.6 DIABETES MELLITUS & INSULIN-RESISTANT STATES
A Type I Diabetes Mellitus (IDDM)
Type I diabetes mellitus (IDDM) arises due to the inability of the p-cells 
within the islets of Langerhans in the pancreas to secrete insulin: the consequences
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of this state for whole body metabolism have been recently reviewed (Taylor & 
Agius, 1988) and are discussed briefly elsewhere in this Introduction.
i Liver Tissue
Evidence suggests that the hyperglucagonaemia associated with IDDM is 
responsible for the increased hepatic glycogenolysis, gluconeogenesis and 
ketogenesis in diabetic patients (Unger & Orci, 1981; Johnson et al., 1982). In 
both genetic (BB/Wor rats) and chemically-induced (streptozotocin [stz] or alloxan) 
rat models of IDDM, these changes are associated with an increase in hepatic cyclic 
AMP concentrations (Pilkis et al., 1974; Appel et al., 1981). Several groups have 
attempted to ascertain whether this increase in cyclic AMP content is attributable to 
defects in the adenylate cyclase signalling complex, with variable results being 
obtained (Allgayer et al., 1982; Dighe et al., 1984; Gawler et al., 1987; Lynch et 
al., 1989).
Most groups have shown there to be an increase in the ability of glucagon to 
stimulate adenylate cyclase in plasma membranes prepared from either whole liver 
(Allgayer et al., 1982; Lynch et al., 1989) or hepatocytes (Gawler et al., 1987). 
However the mechanisms by which this phenomenon occurs are still controversial. 
Lynch et al. (1989) claim that liver plasma membranes prepared from stz-induced 
diabetic animals and BB rats contain increased amounts of Gga-subunits compared 
with normal controls as assessed by immunoblotting and cholera toxin-catalysed 
ADP-ribosylation. This results in an enhanced activation of adenylate cyclase 
activity by cholera toxin, [A1F4]” and GTPyS as well as glucagon (Lynch et al.,
1989). Also, inhibition of adenylate cyclase by angiotensin II in isolated 
membranes and intact hepatocytes was unchanged in stz-induced diabetic animals 
and slightly increased in BB rats compared with normal controls (Lynch et al.,
1989). These results contradict the findings of Gawler et al. (1987) who attributed 
the enhanced activation of adenylate cyclase activity by glucagon in hepatocyte 
plasma membranes to a loss of functional Gj activity relieving a tonic inhibitory
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effect on stimulation, thereby sensitising the response to glucagon. It is thought 
that a 70% reduction in the expression of GjOC-2 and Gjtx-3 associated with a 
phosphorylation of GjOc- 2  in stz-diabetic hepatocytes causes an abolition of the 
ability of Gpp(NH)p to inhibit forskolin-stimulated adenylate cyclase activity 
(Gawler et al., 1987; Bushfield et al., 1990c). However, whilst guanine 
nucleotide-mediated inhibition is abolished, P2y purinergic receptor-mediated 
inhibition of cyclic AMP accumulation in stz-diabetic hepatocytes persists, albeit to 
a lesser extent commensurate with the reduction in expression of G|(X-subunits 
(Bushfield et al., 1990c).
ii Adipose Tissue
The reduction in plasma insulin concentrations associated with IDDM 
results in the mobilization of fatty acids from adipose tissue due to the 
concomitant reduction of insulin's anti-lipolytic effect and the enhanced action of 
lipolytic hormones (Williamson, , 1989). The latter effect presumably 
accounts for the elevated cyclic AMP content of stz-diabetic rat adipocytes (Chiappe 
de Cingolani, 1983). As with hepatocytes, different groups have attempted to 
characterize possible defects in the regulation of adenylate cyclase which could 
explain the observed increase in lipolysis (Kissebah & Fraser, 1972; Zumstein et 
al., 1980; Chiappe de Cingolini, 1986; Strassheim et al., 1990).
Several investigators have noted either an increased sensitivity (La Casa et 
al., 1983) or increased stimulation of adenylate cyclase in response to 
catecholamines (Chiappe de Cingolini, 1986; Strassheim et al., 1990). Whereas 
Chiappe de Cingolini (1986) attributed the enhanced responsiveness to an increase 
in the number of p-adrenergic receptors, Strassheim et al. (1990) demonstrated 
that the tonic inhibitory effect of G  ^is abolished in adipocyte membranes from stz- 
diabetic animals, which in this respect resemble hepatocyte membranes (Gawler et 
al., 1987). Similarly, receptor-mediated inhibition of adenylate cyclase by PIA,
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PGEj and nicotinic acid persists, and is even slightly enhanced in stz-diabetic 
animals (Strassheim et al., 1990). These changes are also accompanied by a 2- 
fold increase in expression of Gja-3, although the authors claim that it is the 
phosphorylation and inactivation of GjOc- 2  which causes the abolition of guanine 
nucleotide-mediated inhibition (Strassheim et al., 1990).
Human studies on IDDM patients failed to show any alteration in their ratios 
of expression of G jx-2 to Gsa  compared with non-diabetic controls as determined 
by Western blotting (Ohisalo et al., 1988) but functional studies have not been 
carried out to ascertain whether there is any alteration in adenylate cyclase 
regulation.
B Type II Diabetes Mellitus (NIDDM)
i Liver Tissue
The main characteristics of hepatic metabolism in the Type II diabetic state 
are increased lipogenesis, leading to triglyceride accumulation, and an enhanced 
hepatic glucose output which contributes to the observed hyperglycaemia 
(DeFronzo, 1988). As for IDDM, several animal models of NIDDM have been 
investigated to determine whether these effects can be explained by alterations in the 
regulation of adenylate cyclase activity. This possibility has been studied in several 
animal models of obesity and NIDDM including the genetically obese (falfa) 
Zucker rat (Houslay et al., 1989), the genetically obese {obiOb') mouse (Begin- 
Heick & Welsh, 1988), and the genetically diabetic (dbldb) mouse (present work).
In hepatocyte membranes prepared from obese Zucker rats, there seem to be 
two defects affecting adenylate cyclase regulation (Houslay et al., 1989). Firstly, 
there is an abolition of the ability of Gpp(NH)p to inhibit forskolin-stimulated 
adenylate cyclase activity in membranes from obese animals, although the amounts 
of G ja - 2  are similar in lean and obese membranes as determined by
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immunoblotting and pertussis toxin-catalysed ADP-ribosylation studies (Houslay 
et al., 1989). As with the stz-diabetic system, P2y purinergic receptor-mediated 
inhibition of cyclic AMP accumulation persists in the obese state (Murphy & 
Houslay, unpublished data). There is also a defect in the ability of glucagon to 
stimulate adenylate cyclase activity, as hepatocyte membranes from obese animals 
exhibit a ten-fold higher EC5 0  value for glucagon activation of adenylate cyclase. 
However, the specific activities produced at maximal glucagon concentrations are 
the same in lean and obese rats (Houslay et al., 1989). The reduced efficacy of 
hormonal activation was attributed to a 50% reduction in expression of the two 
forms of Gsa  expressed in hepatocytes, as determined by cholera toxin-catalysed 
ADP-ribosylation (Houslay et al., 1989).
Another study employing sucrose-purified liver plasma membranes from 
lean and genetically obese (ob/ob) mice gave similar but not identical findings to 
those in obese Zucker rats (Begin-Heick & Welsh, 1988). Gj function was shown 
to be abolished but this was claimed on the basis that a 2-adrenergic receptor- 
mediated inhibition was lost unlike Zucker rat hepatocytes. This was associated 
with an enhanced ability of isoproterenol, but not glucagon, to stimulate adenylate 
cyclase activity in the presence of GTP (Begin-Heick & Welsh, 1988). Whether 
these changes in regulation are related to the reduced cholera toxin-catalysed 
labelling of Gsa  and increased pertussis toxin-catalysed labelling of GjOC observed 
in liver membranes from obese animals compared with leans is unknown (Begin- 
Heick & Welsh, 1988).
ii Adipose Tissue
The most obvious characteristic of severe insulin-resistant states associated 
with NIDDM is obesity, arising from an increased adipocyte volume caused by 
triglyceride accumulation (Taylor & Agius, 1988). Many investigators have 
attempted to determine whether the triglyceride accumulation occurs due to a 
reduced lipolytic capacity of adipocytes in several animal models of obesity and
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insulin resistance, including the Zucker rat (Vannucci et al., 1990), the obese 
(ob/ob) mouse (Begin-Heick & Heick, 1977) and the diabetic (db/db) mouse 
(Kupiecki & Adams, 1974). In these three systems a reduced lipolytic response is 
observed which can be attributed to a reduced ability of stimulatory hormones to 
activate adenylate cyclase activity in adipocyte membranes (Begin-Heick, 1980; 
Vannucci et al., 1990; Begin-Heick & Coleman, 1988).
In adipocyte membranes prepared from obese (ob/ob) mice, stimulation by 
ACTH and the P-adrenergic receptor agonist isoproterenol are severely attenuated 
(Begin-Heick, 1985; Begin-Heick, 1986), even though there are no differences in 
the activity of the catalytic unit or the maximal stimulation by Gpp(NH)p between 
membranes prepared from lean and obese animals (B6 gin-Heick, 1980; B6 gin- 
Heick, 1985). Nevertheless, the BC5 0  value for stimulation of adenylate cyclase by 
Gpp(NH)p is ten-fold higher in membranes from obese animals compared with 
controls, perhaps suggesting an impairment in the GS.C interaction (Begin-Heick, 
1980).
Adipocyte membranes from obese (ob/ob) animals also express a non­
functional Gj activity, as determined by the inability of GTP and Gpp(NH)p to 
inhibit isoproterenol- and forskolin-stimulated adenylate cyclase activity 
respectively (B6 gin-Heick, 1985; Bdgin-Heick & Coleman, 1988). Another group 
demonstrated that receptor-mediated inhibition of adenylate cyclase activity remains 
intact (Greenberg et al., 1987), although this has been disputed (Begin-Heick,
1990). Such defects in the inhibitory regulation of adenylate cyclase activity in 
membranes from obese animals are associated with drastically reduced levels of 
GjCC-1, with slightly reduced expression of the 45 kDa form of Gsa  compared with 
lean controls (Begin-Heick, 1990).
Virtually identical results have been found from studies on adipocyte 
membranes from lean and obese Zucker rats, where a non-functional Gj activity 
was found with respect to tonic inhibition, whilst receptor-dependent inhibition was
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unaltered: such changes were associated with large reductions in the levels of G ^ - l 
and GjOt-3 in membranes from obese rats compared with lean animals (Strassheim 
et al., 1991b). There was also a reduced ability of stimulatory hormones 
(isoproterenol, glucagon, TSH and secretin) to activate adenylate cyclase activity, 
associated with an increase in the EC5 0  value for Gpp(NH)p activation of adenylate 
cyclase activity and a slight reduction in the expression of both forms of Gsa  in 
obese membranes compared with leans (Strassheim et al., 1991b). These results 
differ slightly from a study by Vannucci et al. (1990) who found that only the 
sensitivity of adenylate cyclase to activation by isoproterenol was altered. 
However, whilst their study used young (4 week old) rats, the animals used by 
Strassheim et al. (1991b) were more than 10 weeks old and in the plateau of their 
insulin-resistant phase (Bray, 1977).
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CHAPTER 2 
Materials & Methods
2.1 CHEMICALS
All reagents used were of the highest grade commercially available.
Supplier Chemical/Enzvme
Sigma Chemical Co., BSA
Poole, Dorset, U.K. Cholera Toxin
Theophylline
PIA
Nicotinic Acid 
Prostaglandin Ej 
Isoproterenol 
ATP
Soya Bean Trypsin Inhibitor 
Non-ionic detergent NP 40 
Ortho-dianisidine 
Lubrol-PX 
Secretin (porcine)
Alumina
Dowex 50x4-400 
Mastoparan
Boehringer (U.K.), 
Lewes, East Sussex, U.K.
Creatine Kinase
Creatine Phosphate
Dithiothreitol
Triethanolamine-HCl
Tris
GTP, Gpp(NH)p
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F.S.A. Laboratory Supplies, 
Loughborough, Leics, U.K.
HEPES
May & Baker Ltd., 
Dagenham, Essex, U.K.
Calbiochem,
Cambridge, U.K.
National Diagnostics, 
Aylesbury, Bucks, U.K.
Porton Research Products Ltd. 
Maidenhead, Berks, U.K.
Hydrochloric Acid 
Ammonium Persulphate
Forskolin
"Ecoscint" Scintillation Fluid 
Pertussis Toxin
Whatman Biosystems Ltd., DE-50 Cellulose
Maidstone, Kent.
Worthington Biochemical Corporation, Collagenase
Freehold, New Jersey, U.S.A.
Glucagon (porcine) was donated by Dr. W. W. Brommer, Eli Lilly & Co., IN, 
U.S.A.
ICI 118233 was a gift from I.C.I. Pharmaceuticals Ltd., Alderley Park, 
Macclesfield, Cheshire, U.K.
The following radiochemicals were from Amersham International pic, 
Amersham, Bucks, U.K.:-
[oc-3 2 P] ATP in 50% (w/w) ethanol (Specific Activity 400 Ci/mmol)
[51, 8 -3 H] cyclic AMP in 50% (w/w) ethanol (Specific Activity 40-60 Ci/mmol).
[a- 3 2 P] NAD+ (Specific Activity 800 Ci/mmol) was from New England 
Nuclear.
All other reagents were obtained from B.D.H. Ltd., Poole, Dorset,
U.K.
2.2 ANIMALS
Male C57BL/KsJ heterozygous (db/+ ) lean and homozygous (db/db) 
obese diabetic animals aged between 6  and 15 weeks were obtained from Olac Ltd. 
Oxon., U.K. Male CBA/Ca lean and obese mice aged 16 weeks were obtained 
from the University of Bristol Medical School Breeding Unit, Bristol, U.K.
Animals were allowed ad libitum access to standard laboratory chow and 
water before use.
2.3 PREPARATION OF LIVER PLASMA MEMBRANES
Liver plasma membranes were prepared using a modification (Marchmont 
et al., 1981) of the method of Pilkis et al. (1974) which is derived from the 
original method of Neville (1968).
Between 5 and 10 mice were stunned and killed by cervical dislocation 
before their livers were removed for washing and fine chopping with scissors in 1  
mM potassium bicarbonate, pH 7.2. Using 3 volumes of liver to 1 volume 1 mM 
potassium bicarbonate, pH 7.2, the livers were homogenized with 6  up-and-down 
strokes of a Camlab motor-driven homogenizer at setting 3 with a teflon pestle in a 
50 ml glass Potter-Elvejhem homogenizer. The resulting homogenate was then 
filtered through 2 layers of muslin and diluted to 300 ml with chilled 1 mM 
potassium bicarbonate, pH 7.2, before centrifugation at 2000 gmax for 10 minutes 
at 4°C in the 8x50 fixed angle rotor of a MSE 21 centrifuge. The resulting
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supernatant was discarded and the loose pellets poured onto 72 g of sucrose in a 
plastic beaker before the volume was adjusted to 120 ml using chilled 1 mM 
potassium bicarbonate, pH 7.2, and the mixture stirred gently for 45 minutes to 
form a 60% (w/v) sucrose solution. 2 0  ml portions of the stirred solution were 
then pipetted into 40 ml Beckman Ultra-Clear centrifuge tubes. On top of this 
homogenate was layered 12 ml of ice-cold 48.2% (w/v) sucrose in 3 mM 
imidazole, pH 7.4, followed by 6.5 ml of ice-cold 42.5% (w/v) sucrose in 3 mM 
imidazole, pH 7.4. The gradients were centrifuged at 100,000 gmax for 3 hours at 
4°C on the SW28 rotor of a Beckman L 8  ultracentrifuge: acceleration and 
deceleration settings were slow (setting 7) to minimise disruption of the gradients. 
Plasma membranes were collected at the 48.2-42.5% sucrose interface using a 
Pasteur pipette, diluted 1:1 with chilled 1 mM potassium bicarbonate, pH 7.2, and 
centrifuged at 25,000 gmax at 4°C for 15 minutes in the MSE 21 8x50 rotor. The 
membrane pellet was resuspended in 5 ml of 1 mM potassium bicarbonate, pH 7.2, 
and stored in 100 |il aliquots at -80°C.
2.4 PREPARATION OF ISOLATED ADIPOCYTES
Adipocytes were prepared essentially as described by Rodbell (1964). 
Animals were killed by cervical dislocation before the white epididymal fat pads 
were removed and placed into pre-warmed (37°C) Krebs-Ringer-Henseleit buffer, 
pH 7.4, containing 3% (w/v) BSA (KRH/BSA). The KRH buffer had the 
following composition:- 25 mM HEPES, 1.2 mM M gS04, 1.2 mM KH2 P 0 4, 5 
mM KC1,120 mM NaCl, 2 mM CaCl2  and 20 mM glucose.
After fine chopping with scissors, the pieces of fat tissue were rinsed with 
KRH/BSA and placed into pre-warmed 100 ml glass conical flasks (pre-treated 
with dichlorosilane to prevent cell adhesion) containing 10 ml KRH/BSA 
supplemented with 2 mg/ml collagenase and 0.5 mg/ml soya bean trypsin inhibitor 
and placed in a shaking 37°C waterbath set at 120 cycles per minute. Each flask
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was then sealed with a "Suba-seal" (Gallenkamp & Co., Widnes, Cheshire, U.K.) 
and gassed continuously for between 45 and 60 minutes in an atmosphere of 
0 2 :C0 2  (95%:5%).
After digestion the contents of the flasks were filtered through a plastic 
teastrainer and washed into a pre-warmed glass beaker. The contents of the beaker 
were then poured into prewarmed 50 ml plastic centrifuge tubes and centrifuged at 
600 r.p.m. for 5 seconds in an MSE Centaur 2 bench centrifuge to float the 
adipocytes. Adipocytes were removed from the top of the solution using a plastic 
Pasteur pipette and allowed to settle in a glass tube where the rest of the KRH/BSA 
was removed using a syringe with the attached needle placed below the floating 
cells. The cells were then added to 50 ml centrifuge tubes with 5 volumes of 
KRH/BSA and the procedure repeated twice more. Concentrated adipocytes from 
the last step were used for the subsequent membrane preparation .
2.5 PREPARATION OF A CRUDE MEMBRANE PELLET 
FROM ISOLATED ADIPOCYTES
Membranes were prepared according to the method of Strassheim et al. 
(1990). Cells were added to a pre-warmed (37°C) 50 ml measuring cylinder and 
pre-warmed buffered sucrose (0.25 M sucrose, 50 mM Tris-HCl, 3 mM ATP, pH 
7.4) added such that the volume ratio of cells to buffer was 1:3. This mixture was 
transferred to a 50 ml glass Potter-Elvejhem homogenizer and hand-homogenized at 
room temperature by 6  up-and-down strokes of a teflon pestle. The homogenate 
was then poured into chilled (4°C) 50 ml plastic centrifuge tubes and centrifuged at 
1500 gmax for 15 minutes at 4°C in the 8x50 rotor of a MSE 21 centrifuge. After 
removal of the fat cake from the top of the tube, the supernatant was re-centrifuged 
at 15,000#,^  for 15 minutes in the same centrifuge at the same temperature. The 
resulting pellet was resuspended in chilled buffered sucrose by 5 up-and-down 
strokes of a teflon pestle in a 25 ml glass Potter-Elvejhem homogenizer at 4°C and
re-centrifuged at 15,000gmfl;c at 4°C for 15 minutes. The membrane pellet was 
resuspended in 5 mM Tris-HCl, 1 mM EDTA, pH 7.4, to a concentration of 
between 1 and 2 mg/ml, and 100 p.1 aliquots rapidly frozen for storage at -80°C.
2.6 PREPARATION OF CYCLIC AMP BINDING PROTEIN 
FROM BOVINE HEART
The protocol used was based on that employed by Rubin et al. (1974).
2.6.1 Homogenization
After removal of pericardium and fat tissue, the heart was chopped into 
small (1 inch) cubes and minced using a Moulinex electric blender. The minced 
heart was then mixed with 41 of 40 mM potassium phosphate, pH 6.1, containing 
2 mM p-mercaptoethanol and homogenized in a Waring blender for 1 minute in 
small batches. After centrifugation at 10,000gmfl;c for 10 minutes at 4°C, the 
supernatant was retained and filtered under vacuum through Whatman No. 54 filter 
paper using a Buchner funnel and flask. The remaining pellet from the 
centrifugation step was extracted twice more with 1 1  of the same buffer and the 
filtered supernatants pooled for the next stage.
2.6.2 Ammonium Sulphate Precipitation
The pooled supernatants were made up to 55% saturation by the addition of 
solid ammonium sulphate to a concentration of 320 g/1, the pH being maintained 
between 7 and 8  units by the addition of ammonium hydroxide. Protein 
precipitation was allowed to occur for 3 hours and precipitated material was 
collected by centrifugation at 10,000gmaJC for 10 minutes at 4°C. The pellet was 
then dissolved in 500 ml 50 mM Tris-HCl, pH 7.6, containing 10 mM NaCl and 4 
mM p-mercaptoethanol. This solution was dialysed overnight against 5 1 50 mM 
Tris-HCl, pH 7.6 containing 10 mM NaCl, overnight to remove the remaining 
ammonium sulphate.
97
2.6.3 Pretreatment Of DE-50 Cellulose
50 g DE-50 Cellulose was added to 2 10.5 M HC1 and the mixture stirred 
for 30 minutes. The resin was then washed with distilled water until the pH rose to 
4 units. The resin was stirred for 30 minutes with 2 1 0.5 M sodium hydroxide 
before washing with distilled water as before until the eluate was at neutral pH. 
The acid/alkali washing procedure was repeated once more and the resin finally 
equilibrated with 50 mM Tris-HCl, pH 7.6, containing 10 mM p-mercaptoethanol 
and 10 mM NaCl, such that the final slurry gave a wet settled volume:final volume 
ratio of 2 : 1 .
2.6.4 Absorption Of Cyclic AMP Binding Protein By DE-50 
C ellulose
The dialysed preparation was stirred for 1 hour with 800 ml equilibrated 
DE-50 Cellulose under conditions where cyclic AMP-dependent protein kinase 
activity should be absorbed. After filtration of the resin under vacuum with 
Whatman No. 54 filter paper on a Buchner funnel and flask, the resin was washed 
with 3 1 50 mM Tris-HCl, pH 7.6, containing 10 mM NaCl and 4 mM p- 
mercaptoethanol, for 45 minutes. The resin was collected by filtration and washed 
with the 50 mM Tris-HCl buffer, pH 7.6, containing 10 mM NaCl and 4 mM p- 
mercaptoethanol, using a Buchner flask and funnel.
2.6.5 Isolation Of The Cyclic AMP Binding Protein
The combined filtrates were brought to 35% saturation with 119 g/1 solid 
ammonium sulphate and the pH maintained between 7 and 8  units with ammonium 
hydroxide solution. After stirring for 1 hour, the precipitate was collected by 
centrifugation at 10,000gma;c for 10 minutes at 4°C and the resulting pellet 
discarded. The supernatant was brought to 75% saturation by adding 258 g/1 solid 
ammonium sulphate and after stirring for 1  hour, was collected by centrifugation at
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10,000gmajc as before. The pellet from this step was suspended in a minimal 
volume of 50 mM potassium phosphate buffer containing 4 mM p- 
mercaptoethanol, pH 7.0. This final suspension was dialysed against the same 
buffer overnight at 4°C. The purified protein kinase was stored in 250 jllI aliquots 
at -80°C and under these conditions was stable for between 6  and 9 months. 
Aliquots were never refrozen but could be used for up to 48 hours after thawing if 
stored between 0 and 4°C.
2.7 ASSAY OF ADENYLATE CYCLASE ACTIVITY
This was achieved using either one of 2 methods:-
2.7.1 Determ ination Of Cyclic AMP Form ation Using A 
Binding Protein Assay For Cyclic AMP
This method was based on that described by Heyworth & Houslay (1983). 
The first part of the procedure involves the assaying of cyclic AMP formed by the 
membranes under investigation. Incubations were carried out in a final volume of 
100 ill containing 30 mM Tris-HCl and 0.75 mM EGTA, pH 7.4, with 10 mM 
theophylline (a non-selective cyclic AMP phosphodiesterase inhibitor), 22 mM 
creatine phosphate, 1.0 mM ATP, 2 mM MgS0 4  and 1 mg/ml creatine kinase. In 
experiments using inhibitory ligands in adipocyte membranes, 1 U/ml adenosine 
deaminase was included and theophylline was omitted from the reaction medium 
and replaced with 100 pM ICI 118233, a non-methylxanthine cyclic AMP 
phosphodiesterase inhibitor. These alterations enhance inhibition by reducing the 
effects of adenosine accumulation in the reaction medium. Other components of the 
reaction mixture were added at the final concentrations specified in figure legends 
and tables.
Reactions were initiated by the addition of either 10-15 pg of liver plasma 
membrane protein or 2 - 1 0  pg of adipocyte membrane protein, followed by
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incubation for 15 minutes at 30°C (liver membranes) or 30 minutes at either 24°C or 
30°C (adipocyte membranes) over which time periods cyclic AMP production was 
linear. Adipocyte membranes were subjected to longer incubation times because 
less protein was added per assay than for liver, in order to conserve adipocyte 
membrane samples as much as possible. Hence, in order to produce detectable 
levels of cyclic AMP with reduced amounts of membrane protein, reactions were 
carried out over a longer time period. Experiments involving the use of inhibitory 
ligands in adipocyte membranes were carried out at 24°C instead of 30°C as the 
former temperature allows slightly more potent inhibitory effects to be seen 
(Londos et al., 1978).
Reactions were terminated by incubation in a boiling waterbath for 3 
minutes. Samples were then centrifuged for 5 minutes at 14,000gav in a Hettich 
Micro Rapide centrifuge at 4°C to sediment precipitated denatured protein. Aliquots 
were subsequently taken for assay of cyclic AMP using a competitive binding 
method.
Determination of amounts of cyclic AMP in the samples assayed for 
adenylate cyclase activity was based on the saturation binding assay of Brown et 
al. (1972) as modified by Tovey et al. (1974) and described by Whetton et al. 
(1983). This assay depends upon the specific binding of cyclic AMP to the cyclic 
AMP binding protein purified from bovine heart as described above. Aliquots from 
experimental samples are incubated with [3 H]cyclic AMP and a suitable 
concentration of binding protein until equilibrium has been reached. The labelled 
and unlabelled [3 H]cyclic AMP compete for a finite number of binding sites, thus 
under suitable conditions increased concentrations of unlabelled cyclic AMP will 
lead to reduced binding of the labelled nucleotide. The bound cyclic AMP is then 
separated from unbound cyclic AMP by the addition of a charcoal/BSA slurry, 
which absorbs free nucleotides, and centrifugation, thereby allowing estimation of 
the [3 H]cyclic AMP bound to the protein.
Total cyclic AMP binding to the protein is estimated by incubation of
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[3 H]cyclic AMP in the absence of unlabelled cyclic AMP, while non-specific 
binding is estimated by incubating [3 H]cyclic AMP in the absence of both 
unlabelled cyclic AMP and binding protein. By using unlabelled cyclic AMP over a 
certain range of known concentrations, one can sequentially reduce the proportion 
of [3 H] cyclic AMP bound to the protein, allowing a standard displacement curve to 
be constructed and the estimation of cyclic AMP content.
Aliquots from the sample tubes were made up to a volume of 100 jil with 
binding buffer (50 mM Tris-HCl, 4 mM EDTA, pH 7.4) before 100 jul [3 H]cyclic 
AMP (stock solution of 5', 8  [3 H]cyclic AMP in 50% ethanol diluted in binding 
buffer to give 40-50,000 c.p.m. per 100 jil) and 100 jil of a suitable dilution of 
cyclic AMP binding protein in binding buffer were added. Also included in this 
procedure were duplicate tubes containing known amounts of cyclic AMP (0.0625, 
0.125, 0.25, 0.5, 1, 2, 4, 8  and 16 pmol per tube) with [3 H]cyclic AMP and 
binding protein added to the same concentrations as the sample tubes. After 
incubation for at least 2 hours at 4°C, by which time binding of cyclic AMP to the 
binding protein had reached equilibrium, bound and free nucleotides were separated 
by the addition of 250 |il of a continuously stirred, chilled 2% (w/v) Norit GSX 
charcoal/1 % (w/v) BSA slurry in binding buffer, and centrifugation at 14,000gflV 
at 4°C for 4 minutes. 300 jil of the supernatant was extracted and added to 4 ml 
Ecoscint before scintillation counting. The inclusion of tubes with known amounts 
of cyclic AMP allowed for a standard curve of c.p.m. versus pmol cyclic AMP to 
be derived, from which amounts of cyclic AMP formed in the sample tubes could 
be deduced. The samples were counted in the tritium channel of an LKB Rackbeta 
counter (Model 1219), which had a computer attachment allowing a curve of best- 
fit to be drawn for the standards used in each experiment, and which printed out 
pmol cyclic AMP present in each sample.
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2.7.2 Determination Of Cyclic AMP Formation By Purification 
Using Sequential Column Chromatography With Dowex 
And Alumina
Reaction conditions employed were identical to those above , except that 
[oc-3 2 P]ATP (2xl0 6  c.p.m. per tube) was also present. Reactions were terminated 
by the addition of 100 |il of a "stopping solution" consisting of 1.4 mM cyclic 
AMP, 40 mM ATP and 0.2% (w/v) SDS, pH 7.5. Following the addition of 100 
jil [3 H] cyclic AMP (10xl0 3  c.p.m. per tube) and 750 |il distilled water, 
[32p]cyclic AMP was partially purified by the double column method of Salomon 
et al. (1974). This procedure involves separating cyclic AMP from other 
nucleotides by sequential column chromatography with Dowex and alumina.
Dowex-H+ 50 x 4-400 was mixed with distilled water to form a slurry (1:1 
ratio, v/v). 2  ml of this was then added to each column and the water left to drain 
out: the columns were then ready for use. After each experiment, the Dowex was 
washed with 2 ml 1 M hydrochloric acid until just before the next set of samples 
were applied, when the columns were washed with 1 0  ml distilled water.
The alumina columns were prepared with 0.6 g of neutral alumina per 
column. These were washed with 8  ml 0.1 M imidazole, pH 7.4, before use and 
with 2 ml 0.1 M imidazole, pH 7.4, after each experiment. Before the next set of 
samples were loaded, the columns were washed with another 8  ml 0.1 M 
imidazole, pH 7.4.
Reaction tubes with added distilled water and [3 H]cyclic AMP were applied 
gently down the side of the Dowex columns using a Pasteur pipette. Once the 
columns had run dry, 1  ml distilled water was added slowly and the columns run 
dry once more. Another 1 ml distilled water was then added and the columns 
allowed to run dry again before being placed over the alumina columns. 3 ml 
distilled water were added to elute the Dowex columns and the system run until the 
alumina columns had run dry. Then the alumina columns were placed over
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scintillation vials and eluted with 4 ml 0.1 M imidazole, pH 7.4.
The final eluate from the alumina columns was collected and added to 12 ml 
Ecoscint before counting on a dual label scintillation counting programme which 
automatically accounted for "spillover" from each channel. Recovery of cyclic 
AMP in these experiments was routinely between 70 and 90%. The amount of 
cyclic AMP per sample was calculated by a computer program which converted the 
d.p.m. per sample into pmol cyclic AMP by taking into account the specific activity 
of the [a- 3 2 P] ATP used and the recovery of cyclic AMP from the column steps.
Unless otherwise stated, formation of cyclic AMP was linear over the 
incubation periods and initial rates were taken for subsequent analysis.
2.8 SODIUM DODECYLSULPHATE POLYACRYLAMIDE GEL 
ELECTROPHORESIS (SPS-PAGE1
For these studies, a discontinuous SDS-PAGE system was used as 
originally described by Laemmli (1970), and modified by Milligan & Klee (1985). 
This involved concentrating samples in a 0.3% (w/v) acrylamide/0.08% (w/v) N, 
N'-methylenebisacrylamide stacking gel followed by resolution in a 10% (w/v) 
acrylamide/0.25% (w/v) N, N'-methylenebisacrylamide 12 cm x 14 cm resolving 
gel using a LKB Bromma electrophoresis system.
2.8.1 Stock Solutions (all solutions filtered and stored at 4°C)
a. Buffer 1:-1.5 M Tris, 0.4% (w/v) SDS adjusted to pH 8 . 8  with HC1.
b. Buffer 2:- 0.5 M Tris, 0.4% (w/v) SDS adjusted to pH 6 . 8  with HC1.
c. Acrylamide solution:- 30% (w/v) acrylamide, 0.8% (w/v) N, N'- 
methylenebisacrylamide.
d. 50% (v/v) glycerol solution.
e. N, N, N', N'-Tetramethylenediamine (TEMED).
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2.8.2 Gel P reparation
After assembly of the gel plates, a resolving gel solution was made 
consisting of 8 . 2  ml distilled water, 6  ml buffer 1 , 8  ml acrylamide solution, 1 . 6  ml 
glycerol solution, 20 pi TEMED and 90 pi 10% (w/v) ammonium persulphate 
(prepared fresh). Once poured between the plates, 1 ml distilled water was added 
to cover the top of the solution thereby excluding air and enhancing polymerization. 
When set, the water was poured off and any unpolymerized acrylamide washed 
away with distilled water. A stacking gel mixture was then poured onto the 
resolving gel: this consisted of 9.75 ml distilled water, 3.75 ml buffer 2, 1.5 ml 
acrylamide solution, 20 pi TEMED and 150 pi 10% (w/v) ammonium persulphate. 
A gel comb was then inserted to facilitate loading of samples. Once set, the 
remainder of the kit was assembled and the samples loaded using a Hamilton 
Microsyringe. The anode and cathode were immersed in running buffer (25 mM 
Tris , 200 mM glycine and 0.1% (w/v) SDS) and samples run overnight at 12 mA, 
60V.
2.8.3 Sample Preparation
The required amount of membrane protein (10-300 pg) was sedimented by 
centrifugation at 14,000gflV for 10 minutes at 4°C. After removal of the 
supernatant the membrane pellet was resuspended in 40 pi electrophoresis sample 
buffer (50 mM Tris, 4.5 M urea, 5% (w/v) SDS, 40 mM DTT and a grain of 
bromophenol blue dye). After solubilisation of samples by vortexing and 
incubation in a boiling water bath for 3 minutes, they were ready for 
electrophoresis.
2.8.4 Electrophoretic Separation Of Gj-alpha 1 And 2
Separation of the alpha-subunits of Gjl and Gj2 was achieved by alkylating 
membrane samples before resolution of membrane proteins on a 1 2 % (w/v)
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acrylamide/0.06% (w/v) N, N'-methylenebisacrylamide resolving gel, as described 
by Mitchell et al. (1989).
Before alkylation, the required amount of membrane protein (10-300 jig) 
was sedimented by centrifugation at 14,000g^v at 4°C for 10 minutes. The 
supernatant was discarded and the pellet resuspended in 20 jil 10 mM Tris-HCl, 1 
mM EDTA, pH 7.5. After the addition of 10 pi 5% (w/v) SDS in 50 mM DTT, the 
samples were boiled for 5-10 minutes before cooling on ice for 30 seconds (before 
the SDS precipitated out). 10 pi 100 mM N-ethylmaleimide (NEM) were added 
and the samples left at room temperature for at least 15 minutes to allow the 
alkylation reaction to occur. To stop the reaction, 20 pi electrophoresis sample 
buffer were added and the samples left overnight at 4°C.
The method for electrophoretically separating the alkylated samples is very 
similar to the protocol described in section 2 .8 . 2  using the solutions described in 
section 2 .8 . 1  apart from the following differences:-
a. A Bio-Rad Protean electrophoresis system was used to allow the use of a 
2 0  cm x 2 0  cm resolving gel.
b. For the resolving gel, a different stock acrylamide solution was used, 
consisting of 30% (w/v) acrylamide, 0.15% (w/v) N, N'-methylene­
bisacrylamide.
c. The resolving gel mixture consisted of the following:- 11.6 ml distilled 
water, 12 ml buffer 1, 20 ml acrylamide solution (described above), 4 ml 
glycerol solution, 160 pi 10% (w/v) ammonium persulphate and 40 pi 
TEMED.
d. The stacking gel mixture consisted of the following:- 14.6 ml distilled 
water, 5.6 ml buffer 2, 2.3 ml "normal" acrylamide solution, 225 pi 
ammonium persulphate and 12 pi TEMED.
e. Once loaded, samples were run at 45 mA, 100 V overnight in the
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running buffer previously described.
2.8.5 Molecular Weight Markers
These were obtained from Gibco-BRL Research Products, Uxbridge, 
Middlesex, U.K. The biotinylated pre-stained proteins were myosin H-chain (200 
kDa), phosphorylase b (97.4 kDa), BSA ( 6 8  kDa), ovalbumin (43 kDa), carbonic 
anhydrase (29 kDa), p-lactoglobulin (18.4 kDa), and lysozyme (14.3 kDa).
2.8.6 Staining Of Gels For Protein
After electrophoresis, gels were stained for 1 hour in 200 ml of 0.1% (w/v) 
Coomassie Brilliant Blue R in 40% (v/v) methanol and 10% (v/v) acetic acid. 
Destaining was carried out overnight in the same solution minus the Coomassie 
Brilliant Blue R.
2.9 IMMUNOBLOTTING OF SDS PAGE GELS
2.9.1 Transfer Of Proteins To Nitrocellulose And Detection
This was achieved using a modification of the method of Mitchell et al. 
(1989) which is derived from the original method of Towbin etal. (1979).
After separation of proteins by SDS-PAGE the stacking gel was removed 
and the resolving gel allowed to soak in transfer buffer (25 mM Tris, 200 mM 
glycine in 20 (v/v) methanol) for a few minutes. After soaking, a blotting sandwich 
was constructed which allowed the gel to press tightly against a piece of 
nitrocellulose paper (Schleicher & Schull, 0.45 J i m ) .  These were kept firmly in 
place by pressing a piece of chromatography paper (Whatman) and foam rubber 
either side of this sandwich and keeping them together with plastic holders. This 
sandwich was placed into a LKB Transblot tank and completely immersed in 
transfer buffer. A LKB Transphor powerpack was connected such that the gel side 
of the sandwich was connected to the negative electrode and the proteins transferred
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to the nitrocellulose paper for 2  hours at maximum voltage, producing a direct 
current of 1 A,
After transfer, the blotting sandwich was removed, dismantled and the 
nitrocellulose paper incubated for 3 hours at 30°C in a solution of 5% (w/v) gelatin 
in phosphate-buffered saline (PBS; 136 mM NaCl, 2.7 mM KC1, 80.5 mM 
Na2 H P0 4  and 14.7 mM KH2 P 04) to block non-specific sites on the nitrocellulose 
which the subsequently-used antibodies might bind to. Following blocking, the 
nitrocellulose paper was washed free of excess gelatin with PBS before the primary 
antibody was added as a 1 in 200 dilution in PBS containing 1% (w/v) gelatin, 
0.2% (v/v) non-ionic detergent NP-40 and 0.05% (w/v) ^thimerosal The 
nitrocellulose paper was incubated overnight at 30°C in this solution, by which time 
the binding of antibody had reached equilibrium. The antibody solution was then 
poured off and the nitrocellulose washed with PBS. The paper was then washed 
twice for 10 minutes with shaking in PBS containing 0.2% (w/v) NP-40 before the 
second antibody (horse radish peroxidase-conjugated goat anti-rabbit IgG) was 
added as a 1 in 200 dilution in PBS containing 1% (w/v) gelatin, 0.2% (v/v) non­
ionic detergent NP-40 and 0.05% (w/v)jthimerosal After incubation for 3 hours at 
30°C, the antibody solution was poured off and the washing procedures outlined 
above were repeated. These were followed by a final wash for 10 minutes in PBS 
before this solution was removed and replaced by 40 ml 10 mM Tris-HCl, pH 7.5, 
and 1  ml of a 1 0 % (w/v) orthodianisidine dihydrochloride solution dissolved in 
water. To develop the blot, 10 p,l 30% (w/v) hydrogen peroxide solution were 
added and the mixture swirled over the nitrocellulose paper. Development was 
arrested by pouring off the developing solution and covering the blot with 50 ml 
1 % (w/v) sodium azide: quantification was achieved by scanning blots with an 
Abaton 300 scanner connected to a Macintosh P.C.(C-scan, v.1.0). When stored at 
4°C before and after use, both the primary and secondary antisera could be stored 
as 1 in 200 dilutions in gelatin/PBS/NP-40 and used for up to five times.
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2.9.2 Description Of Antisera
The polyclonal antisera used for these studies were donated by Dr. Graeme 
Milligan, Institute of Biochemistry, University of Glasgow, and have been 
described in several publications (Mitchell et al., 1989; McKenzie & Milligan, 
1990; Milligan & Unson, 1989). Briefly, antisera were raised in New Zealand 
White rabbits against glutaraldehyde conjugates of keyhole-limpet haemocyanin and 
synthetic peptides which represent sections of the deduced amino acid sequences of 
various cloned G-protein subunits (Table 2.1).
Antiserum SGI was raised against the C-terminal decapeptide sequence of 
Gtoc-l. This antiserum recognizes both Gja-1 and G^x-2 as well as Gta-1 and 
Gta-2, but as the expression of the latter two species is restricted to retinal tissue, 
SGI can be used as a specific probe for GjOC-1 and GjCt-2 in other tissues. This 
antiserum does not recognize Gj(X-3 (Mitchell et al., 1989). Antiserum I3B was 
raised against a decapeptide which corresponds to the C-terminal sequence of Gfc- 
3. It does not cross-react with GjOC-1 or G^a-2 but does exhibit weak cross­
reactivity with G0a  (Mitchell et al., 1989). However, the expression of G0a  in 
both liver (Lynch et al., 1989; Huff et al., 1985) and adipocytes (Mitchell et al.,
1989) is below current levels of detection. Antiserum CS1 was generated against a 
decapeptide corresponding to the C-terminal sequence of Gsa  which is present in 
all four of the Gsa  cDNA sequences (Bray et al., 1987). Antiserum BN1 was 
raised against the N-terminal sequence of the P y-subunit, which differs by one 
amino acid substitution from P2  but by three residues from P3  (Levine et al.,
1990). Hence BN1 could be used to probe for both p j and p 2  under suitable 
conditions (Evans et al., 1986), although I was unable to resolve these proteins 
under any of the electrophoretic conditions described in this section.
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Table 2.1:
Description Of Antisera Used For Immunoblotting Analyses
Table shows the antisera used in this thesis, the peptides with which 
they were raised and a list of the G-protein subunits which they recognize. 
For further details see Section 2.9.2.
Antiserum Peptide Used Recognizes:
SGI KENLKDCGLF Gtoc-l, Gta-2,
Gja-1, Gja-2
I3B KNNLKECGLY Gja-3 (G0a  weakly)
CS1 RMHLRQYELL Gsoc
BN1 MSELDQLRQE Pl» P2
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2.10 CHOLERA TOXIN-CATALYSED ADP-RIBOSYLATTON OF
ISOLATED MEMBRANES
The method used was a modification of the protocol described by Heyworth 
et al. (1985) and consisted of 2 distinct stages.
2.10.1 Thiol Pre-activation Of Cholera Toxin
An aliquot of stock cholera toxin (1 mg/ml in 50 mM Tris, 0.2 M sodium 
chloride, 3 mM sodium nitride and 1 mM EDTA) was incubated with 25 mM DTT 
for 20 minutes at 30°C. This reduces disulphide links within the cholera toxin 
complex causing the release of the active Aj subunit (Moss, 1987).
2.10.2 ADP-Ribosylation Of Membranes
Pre-activated cholera toxin was added to a ribosylation cocktail which 
included [a-32P]NAD+ and the necessary factors allowing ribosylation in vitro. 
To start the reaction, 50 p.1 of this cocktail was added to 50 |il of the required 
amount of membrane protein resuspended in 1.0% (v/v) Lubrol-PX such that the 
final reaction mix contained the following components: 20 Jig/ml pre-activated 
cholera toxin, 5 [ id  [a-32P]NAD+ , 10 jiM calcium chloride, 0.5 mM GTP, 15 
mM thymidine, 5 mM DTT, 0.5% (v/v) Lubrol-PX and 5 mM magnesium chloride 
in 0.5 M potassium phosphate buffer, pH 7.0. This mix was incubated for 15 
minutes at 30°C before the reaction was terminated by the addition of 500 |il ice- 
cold 10 mM Tris-HCl, 1 mM EDTA, pH 7.4. Membranes were collected by 
centrifugation at 14,000gflV for 10 minutes at 4°C and the resulting pellet 
resuspended in 30 p.1 electrophoresis sample buffer, boiled for 3 minutes and 
subjected to SDS-PAGE as described in Section 2.8. After electrophoresis, the gel 
was stained with Coomassie Brilliant Blue as previously described, and dried down 
under vacuum at 60°C for 90 minutes. The gel was then subjected to 
autoradiography with pre-flashed Kodak X17R-5 X-ray film and intensifying 
screen for 2-4 days and the film developed with a Kodak Xomat automatic
developer.
Quantitation of the relevant bands on autoradiographs was achieved by
densitometric scanning using a Bio-Rad Video Densitometer connected to an Olivetti
M21 computer driven by the Bio-Rad-ID analysis software package.
2.11 PERTUSSIS TOXIN-CATALYSED ADP-RTBOS YLATION OF 
ISOLATED MEMBRANES
This was carried out using a modification of the method of Hey worth et al.
(1984).
2.11.1 Thiol Pre-Activation Of Pertussis Toxin
An aliquot of stock pertussis toxin (0.2 mg/ml in 50% glycerol-50% 0.05 M 
phosphate buffer, pH 7.2, containing 0.5 M sodium chloride) was incubated with 
25 mM DTT at 30°C for 20 minutes. This activated the toxin in an analogous 
fashion to cholera toxin.
2.11.2 ADP-Ribosylation Of Membranes
The reaction conditions were very similar to those described for cholera 
toxin with the following exceptions
a. Final concentration of pertussis toxin used was 5 |ig/ml.
b. Calcium chloride was not present in the reaction mix for pertussis toxin.
c. ATP was present at a final concentration of 1 mM.
d. The reaction was carried out for 45 minutes at 30°C.
Termination of the reaction, electrophoresis of the ribosylated samples, 
autoradiography and analysis of the results were exactly the same as described for 
cholera toxin.
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2.12 TREATMENT OF ANIMALS WITH PERTUSSIS TOXIN
IN VIVO
Pertussis toxin injection of mice was carried out as described by B6gin- 
Heick (1985) which is a modification of the method of Garcia-Sainz (1981). Stock 
pertussis toxin was diluted in phosphate-buffered saline to a concentration of 10 
jig/ml and each mouse given an i.p.injection of 100 (il using a 25 gauge needle. 
After 3 days, membranes were prepared as described in Section 2.3.
2.13 ESTIMATION OF PROTEIN CONCENTRATION
This was carried out according to the method of Peterson (1977) which is a 
modification of the method of Lowry et al. (1951). This procedure includes an 
initial solubilisation and precipitation step which prevents interference of membrane 
lipids with the reagents involved in the colorimetric step.
2.13.1 Reagents
a. Copper-Tartrate-Carbonate (CTC)-a solution of 20% (w/v) sodium
carbonate added slowly to solution of 0.2% (w/v) copper sulphate in 
0.4% (w/v) potassium tartrate to give final concentrations of 0.1% (w/v) 
copper sulphate, 0.2% (w/v) potassium tartrate and 10% (w/v) sodium 
carbonate.
b. 10% (w/v) SDS.
c. 0.8N sodium hydroxide.
d. 2 N Folin-Ciocalteau’s reagent.
e. 0.15% (w/v) sodium deoxycholate.
f. 72% (w/v) trichloroacetic acid.
g. Reagent A-consists of equal volumes of CTC, sodium hydroxide, SDS
and water: made up fresh before use.
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h. Reagent B -l volume of 2 N Folin-Ciocalteau's reagent mixed with 5 
volumes of distilled water just before use.
2.13.2 Assay Protocol
The samples under investigation and BSA standards of known 
concentration (between 5 and 60 |ig per tube) were brought up to a total volume of 
1 ml with distilled water. Then 0.1 ml 0.15% (w/v) sodium deoxycholate was 
added and the samples left at room temperature for 10 minutes. 0.1 ml 72% (w/v) 
trichloroacetic acid were then added and the samples centrifuged for 30 minutes at 
3000g in a MSE Centaur 2 bench centrifuge. After centrifugation, the supernatants 
were decanted off and the remaining liquid aspirated from the sides of the tubes. 
The remaining pellet was brought up to a volume of 1 ml with distilled water to 
which was added 1 ml reagent A. After standing at room temperature for 10 
minutes to allow solubilisation of the pellet, 0.5 ml reagent B were added and the 
samples vigorously mixed. Absorbances of the solutions were read off within 2 
hours after the addition of reagent B at a wavelength of 750 nm using a LKB 
Spectroplus spectrophotometer. A standard curve was constructed using the 
absorbances of the BSA standard tubes and the equation for a straight line of best- 
fit derived using the Cricketgraph programme of a Macintosh Plus P.C.
2.14 ANALYSIS OF DATA
For all adenylate cyclase assays shown in this thesis, values within a given 
experiment are presented as means ± S.D. of triplicate determinations. For 
immunoblotting and ADP-ribosylation studies, data are expressed as mean band 
intensity ± S.D. compared with control (set at 100%) for at least three experiments. 
When appropriate, statistical significance of data is assessed using Student's t-test 
(paired).
113
CHAPTER 3
The Regulation Of Adenylate Cyclase Activity In Liver Plasma 
Membranes From Lean And Genetically Diabetic (db/db) Mice
3.1 INTRODUCTION
The Type II diabetic state in human beings is associated with several 
alterations in carbohydrate, lipid and protein metabolism. For example, hepatic 
glucose output becomes elevated, contributing to the observed hyperglycaemia, and 
triglyceride accumulates in both liver and fat tissues (DeFronzo, 1988). 
Presumably these changes arise due to perturbed regulation of key enzymes 
involved in glycolysis and gluconeogenesis as well as glycogen and triglyceride 
turnover. As regulation of hepatic metabolism has consequences for whole body 
homeostasis, such key enzymes are regulated in a complex manner by hormones, in 
particular insulin and those hormones modulating levels of cyclic AMP and Ca2+ 
(Pilkis et al.y 1988; Nuttall et al.t 1988). As an example, consider the role of 
cyclic AMP in inhibiting hepatic glycolysis and stimulating gluconeogenesis via the 
activation of cyclic AMP-dependent protein kinase. The nucleotide can act at two 
levels: rapid alteration of the phosphorylation state of rate-limiting enzymes 
(pyruvate kinase and 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase), and 
long-term regulation of gene transcription (phosphoenolpyruvate carboxykinase, 
pyruvate kinase and glucokinase). Insulin opposes the acute effects of cyclic AMP 
on enzyme phosphorylation presumably by activating cyclic AMP 
phosphodiesterases and lowering cyclic AMP levels as well as by altering gene 
expression via an undefined mechanism (Pilkis et al., 1988).
Alterations in the hepatic metabolism of genetically diabetic (db/db) mice 
have been known for several years but the mechanisms by which they occur are 
unknown. Work by Chan et a/.(1975) demonstrated that glucose production was 
elevated, glycogen was turned over more rapidly and that activities of both 
glycolytic and gluconeogenic enzymes were increased in diabetic (db/db) animals 
compared with lean controls. The excessive fat deposition observed in livers from 
diabetic (db/db) animals was associated with increased activities of several 
lipogenic enzymes, although whether this can completely account for the increased
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triglyceride accumulation is uncertain (Coleman & Hummel, 1967).
Considering the alterations observed with respect to the hormonal regulation 
of adenylate cyclase activity in livers from genetically obese (fa/fa) Zucker rats 
(Houslay et al.9 1989) and genetically obese (ob/ob) mice (Begin-Heick & Welsh, 
1988), it was decided to examine the regulation of hepatic adenylate cyclase activity 
in genetically diabetic (db/db) mice. Such investigations were initiated for two 
reasons; firstly, it was important to determine whether any of the alterations 
observed in cyclase regulation in other models of obesity were also present in 
diabetic (db/db) animals. In this respect, it was of particular interest to see if 
inhibitory regulation of adenylate cyclase was intact in the diabetic state as it has 
been suggested that the inability of Gj to tonically inhibit adenylate cyclase activity 
in the presence of guanine nucleotides, but in the absence of inhibitory hormones, 
is characteristic of insulin-resistant states (Bushfield et al., 1990d). Secondly, any 
changes in hormonal regulation of adenylate cyclase activity, in association with an 
insulin-resistant state, may potentially explain some of the long-term alterations in 
liver metabolism observed in diabetic animals.
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Table 3.1:
Adenylate Cyclase Activity In Mouse Liver Plasma Membranes
Sucrose-purified liver plasma membranes prepared from lean and 
diabetic (db/db) animals were assayed for adenylate cyclase activity in the 
absence (basal) and in the presence of the ligands mentioned below for 15 
minutes at 30°C as described in Section 2.7.1. The [22P]cyclic AMP 
formed was measured by the double column method described in Section 
2.7.2. Specific activities are in pmol/min/mg protein and data are expressed 
as MEAN ± S.D. for four experiments using different membrane 
preparations.
(Fold activations above basal activity are given in parentheses).
Ligand Lean Diabetic (db/db)
Basal 5.5 ± 1.8 4.6 ± 1.4
100 jiM Forskolin 131.7 ± 14.1 (23.9) 130.8 ± 17.6 (23.4)
IOOjiMGTP 46.6 ±10.2 (8.5) 41.2 ±12.4  (8.9)
100 pM Gpp(NH)p 48.4 ±8.1 (8.8) 48.3 ± 7.3 (10.5)
10 mM NaF 101.7 ± 11.3 (18.5) 81.0 ± 12.0 (17.6)
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Figure 3.1:
Dose-Response Curves For NaF S tim ulation Of A denylate Cyclase 
A ctivity In  L iver P lasm a M em branes F rom  Lean And D iabetic 
(db/db) Animals
Sucrose-purified liver plasma membranes from lean ( □  ) and diabetic 
(db/db) ( O  ) mice were assayed for adenylate cyclase activity in the presence of 
increasing concentrations of NaF for 15 minutes at 30°C as described in Section 
2.7.1. The [^2P]cyclic AMP formed was measured by the double column method 
described in Section 2.7.2. The figure shows an experiment representative of three 
performed with different membrane preparations which gave quantitatively similar 
results.
Basal activities in this experiment were 6.0 ± 2 .1  (lean) and 5.5 ± 1.8 
(diabetic) pmol/min/mg.
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Figure 3.2:
Dose-Response C urves F or G pp(N H )p S tim ulation O f A denylate 
Cyclase Activity In Liver Plasm a M em branes From  Lean & Diabetic 
(db/db) Animals
Sucrose-purified liver plasma membranes from lean ( □  ) and diabetic 
(db/db) ( O  ) animals were assayed for adenylate cyclase activity in the presence 
of increasing concentrations of Gpp(NH)p for 15 minutes at 30°C as described in 
Section 2.7.1. The [32P]cyclic AMP formed was measured by the double column 
method described in Section 2.7.2. The figure shows an experiment representative 
of three performed on different membrane preparations which gave quantitatively 
similar results.
Basal activities in this experiment were 3.9 ± 1.0 (lean) and 4.8 ± 0.5 
(diabetic) pmol/min/mg.
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Figure 3.3:
Effect Of Pertussis Toxin Treatm ent On The Dose-Response Curve
For Gpp(NH)p Stimulation Of Adenylate Cyclase Activity In Liver
Plasma Membranes From Lean Animals
Sucrose-purified liver plasma membranes from lean ( □  ) and pertussis 
toxin-treated lean ( ■  ) animals were assayed for adenylate cyclase activity with 
increasing concentrations of Gpp(NH)p for 15 minutes at 30°C as described in 
Section 2.7.1. The [32P]cyclic AMP formed was measured by the double column 
method described in Section 2.7.2. The figure shows an experiment representative 
of three performed on different membrane preparations which gave quantitatively 
similar results.
Basal activities in this experiment were 6.4 ± 2.2 (lean) and 5.0 ± 2.0 
(PTx-treated lean) pmol/min/mg..
Sp
ec
ifi
c 
A
ct
iv
ity
 
(p
m
ol
/m
in
/m
g)
200
150-
100 -
50-
No
Ligand 1010 1010
[Gpp(NH)p] (M)
119
Figure 3.4:
Effect Of Pertussis Toxin Treatm ent On The Dose-Response Curve
For Gpp(NH)p Stimulation Of Adenylate Cyclase Activity In Liver
Plasma Membranes From Diabetic (db/db) Animals
Sucrose-purified liver plasma membranes from diabetic (db/db) ( O  ) 
and pertussis toxin-treated diabetic ( •  ) animals were assayed for adenylate
cyclase activity in the presence of increasing concentrations of Gpp(NH)p for 15 
minutes at 30°C as described in Section 2.7.1. The [32P]cyclic AMP formed was 
measured by the double column method described in Section 2.7.2. The figure 
shows an experiment representative of three performed on different membrane 
preparations which gave quantitatively similar results.
Basal activities in this experiment were 5.0 ±1 .5  (diabetic) and 6.2 ± 1.9 
(PTx-treated diabetic) pmol/min/mg.
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Figure 3.5:
D ose-Response C urves F o r G lucagon S tim ulation  O f A denylate 
Cyclase A ctivity In  L iver P lasm a M em branes F rom  Lean And 
Diabetic (db/db) Animals
Sucrose-purified liver plasma membranes from lean ( □  ) and diabetic 
(db/db) ( O  ) animals were assayed for adenylate cyclase activity for 15 minutes 
at 30°C in the presence of 100 |iM GTP and increasing concentrations of glucagon 
as described in Section 2.7.1. The p 2P]cyclic AMP formed was measured by the 
double column method described in Section 2.7.2. The figure shows results 
pooled from four experiments performed on different membrane preparations and 
values are presented as MEAN ± S.D.
The activities obtained with 100 pM GTP alone are given in Table 3.2.
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Figure 3.6:
Effect Of Pertussis Toxin Treatm ent On The Dose-Response Curve
For Glucagon Stimulation Of Adenylate Cyclase Activity In Liver
Plasma Membranes From Lean Animals
Sucrose-purified liver plasma membranes from lean ( □  ) and pertussis 
toxin-treated lean ( ■  ) animals were assayed for adenylate cyclase activity in the 
presence of 100 pM GTP and increasing concentrations of glucagon for 15 minutes 
at 30°C as described in Section 2.7.1. The [^2P]cyclic AMP formed was measured 
by the double column method described in Section 2.7.2. The figure shows results 
pooled from four experiments performed on different membrane preparations and 
values are presented as MEAN ± S.D.
The activities obtained with 100 pM GTP alone are given in Table 3.2.
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Figure 3.7:
Effect Of Pertussis Toxin Treatm ent On The Dose-Response Curve
For Glucagon Stimulation Of Adenylate Cyclase Activity In Liver
Plasma Membranes From Diabetic (db/db) Animals
Sucrose-purified liver plasma membranes prepared from diabetic (db/db)
( O  ) and pertussis toxin-treated ( •  ) animals were assayed for adenylate
cyclase activity for 15 minutes at 30°C in the presence of 100 pM GTP and 
increasing concentrations of glucagon as described in Section 2.7.1. The 
[32p] cyclic AMP formed was measured by the double column method described in 
Section 2.7.2. The figure shows results pooled from four experiments performed 
on different membrane preparations and values are presented as MEAN ± S.D.
The activities obtained with 100 pM GTP alone are given in Table 3.2.
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Figure 3.8:
Dose-Response Curves For Isoproterenol Stim ulation Of Adenylate 
Cyclase A ctivity In  L iver P lasm a M em branes F rom  Lean And 
Diabetic (db/db) Animals
Sucrose-purified liver plasma membranes from lean ( □  ) and diabetic 
(db/db) ( O  ) animals were assayed for adenylate cyclase activity for 15 minutes 
at 30°C in the presence of 100 pM GTP and increasing concentrations of 
isoproterenol as described in Section 2.7.1. The [32P]cyclic AMP formed was 
measured by the double column method described in Section 2.7.2. The figure 
shows results pooled from four experiments performed on different membrane 
preparations and values are presented as MEAN ± S.D.
The activities obtained with 100 pM GTP alone are given in Table 3.2.
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Figure 3.9:
Effect Of Pertussis Toxin On The Dose-Response Curve For
Isoproterenol Stimulation Of Adenylate Cyclase Activity In Liver
Plasma Membranes From Lean Animals
Sucrose-purified liver plasma membranes from lean ( □  ) and pertussis 
toxin-treated lean ( ■  ) animals were assayed for adenylate cyclase activity for 15 
minutes at 30°C with 100 pM GTP and increasing concentrations of isoproterenol 
as described in Section 2.7.1. The [^2P]cyclic AMP formed was measured by the 
double column method described in the Section 2.7.2. The figure shows results 
pooled from four experiments performed on different membrane preparations with 
values presented as MEAN ± S.D.
The activities obtained with 100 jiM GTP alone are given in Table 3.2.
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Figure 3.10:
Effect Of Pertussis Toxin Treatm ent On The Dose-Response Curve
For Isoproterenol Stimulation Of Adenylate Cyclase Activity In Liver
Plasma Membranes From Diabetic {db/db) Animals
Sucrose-purified liver plasma membranes from diabetic {db/db) ( O ) 
and pertussis toxin-treated diabetic ( •  ) animals were assayed for adenylate
cyclase activity for 15 minutes at 30°C in the presence of 100 pM GTP and 
increasing concentrations of isoproterenol as described in Section 2.7.1. The 
[32p] cyclic AMP formed was measured by the double column method described in 
Section 2.7.2. The figure shows results pooled from four experiments performed 
on different membrane preparations and values are presented as MEAN ± S.D.
The activities obtained with 100 pM GTP alone are given in Table 3.2.
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Table 3.2:
Hormonal Stimulation Of Adenylate Cyclase Activity In Mouse 
Liver Plasma Membranes
Sucrose-purified liver plasma membranes from lean, pertussis toxin- 
treated lean, diabetic (db/db) and pertussis toxin-treated diabetic animals were 
assayed for adenylate cyclase activity in the presence of either 100 |iM GTP, or 
100 jiM GTP together with 10 fiM glucagon or with 100 pM isoproterenol as 
described in Section 2.7.1. The [32P]cyclic AMP formed was measured by the 
double column method described in Section 2.7.2. Specific activities are given 
as pmol/min/mg of protein and expressed as MEAN ± S.D. for four 
experiments using different membrane preparations.
(Fold activations above GTP-stimulated activities are in parentheses). 
EC50 is the hormone concentration at which half-maximal activation was 
achieved. 'PTx' denotes the fact that animals were treated with pertussis toxin.
The activities obtained with GTP alone were 43.5 ± 10.6 (lean), 38.2 ± 
9.4 (lean-PTx), 50.5 ± 8.2 (diabetic) and 58.3 ± 15.2 (diabetic-PTx) (MEAN ± 
S.D. from eight experiments).
Table 3.2:
Animal & 
Treatment Glucagon EC50(nM) Isoproterenol EC50 (jiM)
Lean 1081+79 (23.2) 30 ± 7 107 ±9 (2.3) 0.3 ±0.1
Lean-PTx 1420 ± 136 (28.1) 27 ± 3 156 ± 2 0  (3.1) 0.6 ± 0 .4
Diabetic 918 ± 139 (22.3) 25 ± 4 74 ±12  (1.8) 0.6 ± 0.3
Diabetic-PTx 1719 ± 177 (29.5) 22 ± 3 157 ±11 (2.7) 0.9 ± 0.3
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Figure 3.11:
Immunological Detection Of GjOc-2 But Not Gja-1 In Liver Plasma
Membranes From Lean And Diabetic (db/db) Animals
Sucrose-purified liver plasma membranes were prepared and subjected to 
SDS-PAGE under conditions allowing the resolution of G ^ - l  and G ^-2  before 
transfer to nitrocellulose paper and immunoblotting with antiserum SGI, which 
recognizes G ^ - l  and G ^-2 , as described in Sections 2.8.4 and 2.9. The tracks 
contain the following:- lane 1, 400 jig liver plasma membrane protein from lean 
animals; lane 2, 400 |ig liver plasma membrane protein from diabetic (db/db) 
animals; lane 3, 60 jig adipocyte membrane protein from lean animals. This 
immunoblot is one of two such experiments performed with different membrane 
preparations from lean and diabetic (db/db) animals which yielded identical results.
41 KDa G j a - 1
G j a - 2
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Figure 3.12:
Immunoblotting Of GjOc-2 In Liver Plasma Membranes From Lean
And Diabetic (db/db) Animals
Sucrose-purified liver plasma membranes were prepared and subjected 
to SDS-PAGE under 'normal' conditions before transfer to nitrocellulose paper 
and immunoblotting using antiserum SGI as the primary antiserum as described 
in Sections 2.8 and 2.9. The tracks contain the following:- lane 1, 50 p,g 
membrane protein from lean animals; lane 2, 100 p.g membrane protein from 
lean animals; lane 3, 200 jig membrane protein from lean animals; lane 4, 300 
|ig membrane protein from lean animals; lane 5, 50 |ig membrane protein from 
diabetic (db/db) animals; lane 6, 100 }ig membrane protein from diabetic 
(db/db) animals; lane 7, 200 |ig membrane protein from diabetic (db/db) 
animals; lane 8, 300 |ig membrane protein from diabetic (db/db) animals. The 
immunoblot shown is representative of four performed with different membrane 
preparations from lean and diabetic animals.
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Figure 3.13:
Immunoblotting Of GjOc-3 In Liver Plasma Membranes From Lean
And Diabetic (db/db) Animals
Sucrose-purified liver plasma membranes were prepared and subjected 
to SDS-PAGE under 'normal' conditions before transfer to nitrocellulose paper 
and immunoblotting using antiserum I3B as the primary antiserum as described 
in Sections 2.8 and 2.9. The tracks contain the following:- lane 1, 50 pg 
membrane protein from lean animals; lane 2, 100 pg membrane protein from 
lean animals; lane 3, 200 pg membrane protein from lean animals; lane 4, 300 
pg membrane protein from lean animals; lane 5, 50 pg membrane protein from 
diabetic (db/db) animals; lane 6, 100 pg membrane protein from diabetic 
(dbldb): animals; lane 7, 200 pg membrane protein from diabetic (db/db) 
animals; lane 8, 300 pg membrane protein from diabetic (db/db) animals. The 
immunoblot shown is representative of four performed with different membrane 
preparations from lean and diabetic animals.
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Figure 3.14:
Im munoblotting Of p-Subunits In Liver Plasma Membranes From
Lean And Diabetic (db/db) Animals
Sucrose-purified liver plasma membranes were prepared and subjected to 
SDS-PAGE under 'normal' conditions before transfer to nitrocellulose paper and 
immunoblotting using antiserum BN1 as the primary antiserum as described in 
Sections 2.8 and 2.9. The tracks in the immunoblot shown in panel a contain the 
following:- lane 1, 50 pg membrane protein from lean animals; lane 2, 100 pg 
membrane protein from lean animals; lane 3, 200 pg membrane protein from lean 
animals; lane 4, 300 pg membrane protein from lean animals; lane 5, 50 pg 
membrane protein from diabetic (db/db) animals; lane 6,100 pg membrane protein 
from diabetic (db/db) animals; lane 7, 200 pg membrane protein from diabetic 
(db/db) animals; lane 8, 300 pg membrane protein from diabetic (db/db) animals. 
The immunoblot shown is representative of four performed with different 
membrane preparations from lean and diabetic animals. Panel b shows a plot of 
band intensity versus amount of protein loaded for membranes from lean and 
diabetic animals in the blot shown in panel a.
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Figure 3.15:
Im m unoblotting Of Gsa  In Liver Plasm a M embranes From  Lean And 
Diabetic (db/db) Animals
Sucrose-purified liver plasma membranes were prepared and subjected to 
SDS-PAGE under 'normal' conditions before transfer to nitrocellulose paper and 
immunoblotting using antiserum CS1 as the primary antiserum as described in 
Sections 2.8 and 2.9. The tracks contain the following:- lane 1, 25 jig membrane 
protein from lean animals; lane 2,50 jig membrane protein from lean animals; lane 
3, 75 jig membrane protein from lean animals; lane 4, 25 jig membrane protein 
from diabetic (db/db) animals; lane 5, 50 jig membrane protein from diabetic 
(db/db) animals; lane 6, 75 jig membrane protein from diabetic (db/db) animals. 
The immunoblot shown is representative of four performed with different 
membrane preparations from lean and diabetic animals.
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Table 3.3:
Com parative Levels Of G-Protein Subunits In Liver Plasm a M em branes 
From  Lean And Diabetic (db/db) Animals
Sucrose-purified liver plasma membranes from lean and diabetic (db/db) 
animals were prepared and subjected to SDS-PAGE before transfer to nitrocellulose 
and immunoblotting with the primary antisera described in the appropriate figure 
legends and in. Sections 2.8 and 2.9. Data express levels of G-protein components in 
diabetic (db/db) animals as a percentage of those found in lean animals. In each case, 
a range of amounts of membrane protein from lean and diabetic (db/db) animals was 
loaded on a single gel and comparisons made over conditions where linear increases in 
absorption were noted for increasing amounts of membrane protein applied when the 
blots were densitometrically' scanned after visualisation with a peroxidase-conjugated 
second antibody. For each G-protein subunit, data are expressed as MEAN ± S.D. for 
four immunoblots performed with different membrane preparations. * denotes a 
significant difference between lean and diabetic animals, i.e. p<0.005.
G-Protein Subunit
Level As A Percentage Of That In Lean 
Animals (100%)
GjOc-2 30 ±10*
GAa-3 53 ± 6*
p-subunit 33 ± 8*
Gsa(42kD a) 102 ± 8
Gscc (45 kDa) 95 ± 10
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Figure 3.16:
Effect Of Pertussis Toxin Treatment On The Immunodetection Of 
Gi(x-2 And GjOC-3 In Liver Plasma Membranes From Lean And 
Diabetic (db /db) Animals
200 |ig sucrose-purified liver plasma membranes from lean (lanes 1 & 
2) and diabetic animals (lanes 3 & 4) that either had (lanes 1 & 3) or had not 
(lanes 2 & 4) been treated with pertussis toxin in vivo were prepared and 
subjected to SDS-PAGE, transferred to nitrocellulose and immunoblotted using 
SGI and I3B as primary antisera as described in Sections 2.8 and 2.9. These 
antisera allow the detection of GjOC-2 and GjOc-3 respectively. The immunoblots 
shown are representative of two experiments performed with different 
membrane preparations.
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Figure 3.17:
Effect O f Pertussis Toxin T reatm ent On The Im m unodetection Of 
G sa -  And p-Subunits In  L iver Plasm a M em branes From  Lean And 
Diabetic (db/db) Animals
Sucrose-purified liver plasma membranes prepared from lean (lanes 1 & 3) 
and diabetic (db/db) (lanes 2 & 4) animals which either had (lanes 3 & 4) or had 
not (lanes 1 & 2) been treated with pertussis toxin in vivo were prepared and 
subjected to SDS-PAGE, transferred to nitrocellulose and immunoblotted using 
antisera CS1 and BN1 as primary antisera as described in Sections 2.8 and 2.9. 
These antisera allow the detection of Gga- and p-subunits respectively. When 
immunoblotting with antiserum CS1, 40 jig of membrane protein were loaded per 
lane. 200 gig of membrane protein were used when immunoblotting with antiserum 
BN1. The immunoblots shown are representative of two experiments performed 
with different membrane preparations.
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Figure 3.18:
Tim e-Course Of Pertussis Toxin-Catalysed ADP-Ribosylation Of
Liver Plasma Membranes From Lean Animals
Pertussis toxin-catalysed ADP-ribosylation of 100 pg of sucrose-purified 
liver plasma membranes from lean animals was carried out in vitro with thiol- 
preactivated toxin and [a-32P]NAD+ at 30°C for various times before the reaction 
was stopped. The samples were then prepared for and subjected to SDS-PAGE 
before drying down of the gel for autoradiography as described in Section 2.11.
The tracks contain samples ribosylated for the following times:- lane 1, 0 
minutes; lane 2, 15 minutes; lane 3, 30 minutes; lane 4, 45 minutes; lane 5, 60 
minutes; lane 6,75 minutes; lane 7, 90 minutes. The autoradiograph shown is a 2 
day exposure of an experiment which is representative of three performed on 
different membrane preparations which gave essentially identical results.
The graph overleaf shows a plot of band intensity versus incubation j  
time for the autoradiograph.
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Figure 3.19:
Time-Course Of Pertussis Toxin-Catalysed ADP-Ribosylation Of
Liver Plasma Membranes From Diabetic (db/db) Animals
Pertussis toxin-catalysed ADP-ribosylation of 100 fig of sucrose- 
purified liver plasma membranes from diabetic (db/db) animals was carried out 
in vitro with thiol-preactivated toxin and [a-32P] NAD+ at 30°C for various 
times before the reaction was stopped. The samples were then prepared for and 
subjected to SDS-PAGE before drying down of the gel for autoradiography as 
described in Section 2.11.
The tracks contain samples ribosylated for the following times:- lane 1, 
0 minutes; lane 2,15 minutes; lane 3,30 minutes; lane 4,45 minutes; lane 5, 60 
minutes; lane 6, 90 minutes. The autoradiograph shown represents a 5 day 
exposure of an experiment which is representative of three performed on 
different membrane preparations which gave essentially identical results.
The graph overleaf shows a plot of band intensity versus incubation 
time for the autoradiograph.
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Figure 3.20:
Pertussis Toxin-Catalysed ADP-Ribosylation Of Mouse Liver Plasma
Membranes
Pertussis toxin-catalysed ADP-ribosylation of 100 \ig of sucrose-purified 
liver plasma membranes from lean and diabetic (db/db) animals which either had or 
had not been treated with pertussis toxin was carried out in vitro with thiol- 
preactivated toxin and [a-32P] NAD+ at 30°C for 45 minutes before the reaction 
was stopped. The samples were then prepared for and subjected to SDS-PAGE 
before drying down of the gel for autoradiography as described in Section 2.11.
The tracks in panel a contain the following:- lane 1, 100 pig liver plasma 
membranes from lean animals; lane 2,100 |ig liver plasma membranes from diabetic 
(db/db) animals; lane 3,100 p.g liver plasma membranes from lean animals treated 
with pertussis toxin; lane 4, 100 p.g liver plasma membranes from diabetic (db/db) 
animals treated with pertussis toxin. The autoradiograph shown is a 2 day exposure 
of an experiment which is representative of four performed on different membrane 
preparations which gave essentially identical results. Panel b shows the gel from 
panel a after staining for protein using Coomassie Brilliant Blue R. This shows 
that equal amounts of membrane protein were added in each lane, and that neither 
the diabetic state nor pertussis toxin treatment in vivo had any gross effect on the 
electrophoretic profile of the liver plasma membrane preparations.
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Figure 3.21:
Time-Course Of Cholera Toxin-Catalysed ADP-Ribosylation Of
Liver Plasma Membranes From Lean Animals
Cholera toxin-catalysed ADP-ribosylation of 100 jig of sucrose-purified 
liver plasma membranes from lean animals was carried out in vitro with thiol- 
preactivated toxin and [a -32P]NAD+ at 30°C for various times before the 
reaction was stopped. The samples were then prepared for and subjected to 
SDS-PAGE before drying down of the gel for autoradiography as described in 
Section 2.10.
The tracks contain samples ribosylated for the following times:- lane 1,
0 minutes; lane 2, 5 minutes; lane 3, 10 minutes; lane 4, 15 minutes; lane 5, 20 
minutes; lane 6, 25 minutes; lane 7, 30 minutes; lane 8, 40 minutes. The 
autoradiograph shown is a 2 day exposure of an experiment which is 
representative of three performed on different membrane preparations which 
gave essentially identical results.
The graph overleaf shows plots of band intensity versus incubation time 
for the two forms of Gsa  in the autoradiograph.
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Figure 3.22:
Tim e-C ourse Of C holera Toxin-C atalysed ADP-Ribosylation Of
Liver Plasm a M embranes From  Diabetic (dbldb) Animals
Cholera toxin-catalysed ADP-ribosylation of 100 |ig of sucrose-purified 
liver plasma membranes from diabetic {dbldb) animals was carried out in vitro 
with thiol-preactivated toxin and [a-32P]NAD+ at 30°C for various times before 
the reaction was stopped. The samples were then prepared for and subjected to 
SDS-PAGE before drying down of the gel for autoradiography as described in 
Section 2.10.
The tracks contain samples ribosylated for the following times:- lane 1,
0 minutes; lane 2, 5 minutes; lane 3, 10 minutes; lane 4,15 minutes; lane 5,20 
minutes; lane 6, 25 minutes; lane 7, 30 minutes; lane 8, 40 minutes. The 
autoradiograph shown represents a 2 day exposure of an experiment which is 
representative of three performed on different membrane preparations which 
gave essentially identical results.
The graph overleaf shows plots of band intensity versus incubation time I 
for the two forms of Gsa  in the autoradiograph.
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Figure 3.23:
Cholera Toxin-Catalysed ADP-Ribosylation Of Mouse Liver Plasma 
Membranes
Cholera toxin-catalysed ADP-ribosylation of 100 [ig of sucrose-purified 
liver plasma membranes from lean and diabetic (dbldb) animals was carried out in 
vitro with thiol-preactivated toxin and [a-32P]NAD+ at 30°C for 15 minutes before 
the reaction was stopped. The samples were then prepared for and subjected to 
SDS-PAGE before drying down of the gel for autoradiography as described in 
Section 2.10.
The tracks contain the following samples:- lane 1,100 jig liver membranes 
from lean animals incubated without cholera toxin; lane 2, 100 (ig liver membranes 
from diabetic animals; lane 3, 100 p.g liver membranes from lean animals. The 
autoradiograph shown is a 2 day exposure of an experiment which is representative 
of four performed on different membrane preparations which gave essentially 
identical results.
Cholera to x in -c a ta ly se d  ADP-ribosylation  
o f  con tro l and db/db l iv e r  plasma membranes
IV (KDa)
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143
Table 3.4:
Bacterial Toxin-Catalysed ADP-Ribosylation Of Mouse Liver Plasma
Membranes
Sucrose-purified liver plasma membranes from lean and diabetic (dbldb) 
animals were subjected to ADP-ribosylation by cholera and pertussis toxins as 
described in Sections 2.10 and 2.11 and the legends to Figures 3.20 and 3.23. Non­
saturating autoradiographs were densiometrically scanned as described in Section 2.10. 
Data are expressed as %-absorption of the relevant G-protein subunit in the diabetic 
samples compared with lean membranes (100%) and are presented as MEAN ± S.D. of 
four experiments performed with different membrane preparations from lean and 
diabetic (dbldb) animals .* denotes a significant difference between lean and diabetic 
animals, i.e.pcO.001.
G-Protein Subunit
Level As a Percentage (%) Of That Found 
In Lean Animals (100%)
G{a  (41 kDa) 14 + 5*
Gsa  (42 kDa) 364 ± 57*
Gsoc (45 kDa) 393 ±80*
1 4 4
Figure 3.24:
Dose-Response Curves For Gpp(NH)p Stimulation Of Adenylate 
Cyclase Activity In The Presence Of 1 pM Glucagon In Liver Plasma 
Membranes From Lean And Diabetic (dbldb) Animals
Sucrose-purified liver plasma membranes from lean ( □  ) and diabetic 
(dbldb) ( O ) animals were assayed for adenylate cyclase activity for 15 minutes 
at 30°C in the presence of 1 pM glucagon and increasing concentrations of 
Gpp(NH)p as described in Section 2.7.1. The [32P]cyclic AMP formed was 
measured by the double column method described in Section 2.7.2. The figure 
shows an experiment representative of three performed on different membrane 
preparations which gave quantitatively similar results.
In this experiment, the specific activities obtained in the presence of 1 pM 
glucagon alone were 111.9 ± 9.0 (lean) and 141.5 ±2.1 (diabetic) pmol/min/mg.
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Figure 3.25:
Dose-Response Curves For Angiotensin II- And N oradrenaline-
M ediated Inhibition Of Adenylate Cyclase Activity In Liver Plasma
Membranes From Lean And Diabetic (dbldb) Animals
Sucrose-purified liver plasma membranes from lean ( □  ) and diabetic 
(idbldb) ( O  ) animals were assayed for adenylate cyclase activity for 15 minutes 
at 30° C in the presence of 100 pM GTP and increasing concentrations of 
angiotensin II (panel a) or noradrenaline (panel b) as described in Section 2.7.1. 
The [32P]cyclic AMP formed was measured by the double column method 
described in Section 2.7.2.
For experiments using angiotensin II as an inhibitory ligand, membranes 
were resuspended in 10 mM Tris-HCl, 5 mM EDTA and 0.05% (v/v) p- 
mercaptoethanol to a concentration of 1.5 mg/ml. The membranes were then 
assayed for adenylate cyclase activity as described in Sections 2.7.1 and 2.7.2 with 
the inclusion of 200 mM lithium chloride in the incubation medium. These 
conditions have been shown by others to maximize angiotensin Il-mediated 
inhibition of adenylate cyclase activity in liver membranes (Pobiner et al., 1985; 
Lynch et al., 1989).
The figure shows experiments representative of three performed for each 
inhibitory ligand on different membrane preparations which gave quantitatively 
similar results.
In the presence of 100 |iM GTP alone, the specific activities obtained in the 
experiment in panel a were 13.7 ± 0.6 (lean) and 16.7 ± 2 .1  (diabetic) 
pmol/min/mg. For the experiment shown in panel b , the specific activities 
obtained in the presence of 100 pM GTP were 48.0 ± 4.6 (lean) and 52.0 ± 2.0 
(diabetic) pmol/min/mg.
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Figure 3.26:
Dose-Response Curves For Gpp(NH)p Stimulation Of Adenylate 
Cyclase Activity In The Presence Of 100 pM Forskolin And 11% 
(v/v) Ethanol In Liver Plasma Membranes From Lean And Diabetic 
{dbldb)  Animals
Sucrose-purified liver plasma membranes from lean ( □  ) and diabetic 
{dbldb) ( O  ) animals were assayed for adenylate cyclase activity for 15 minutes 
at 30°C in the presence of 100 pM forskolin, 11% (w/v) ethanol and increasing 
concentrations of Gpp(NH)p as described in Section 2.7.1. The [32P]cyclic AMP 
formed was measured by the double column method described in Section 2.7.2. 
The figure shows results pooled from three experiments performed on different 
membrane preparations and values are presented as MEAN ± S.D.
Under these conditions, basal activities were 28.3 ± 6.0 (lean) and 34.5 ±
7.2 (diabetic) pmol/min/mg, whilst forskolin-stimulated activities were 91.3 ± 4.2 
(lean) and 128.7 ± 6.7 (diabetic) pmol/min/mg.
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Figure 3.27:
Dose-Response Curves For Gpp(NH)p Inhibition Of Adenylate 
Cyclase Activity In The Presence Of 100 pM Forskolin And 1%  (v/v) 
Ethanol In Liver Plasma Membranes From Lean And Diabetic 
Cd b ld b ) Animals
Sucrose-purified liver plasma membranes from lean ( □  ) and diabetic 
(dbldb) ( O ) animals were assayed for adenylate cyclase activity for 5 minutes 
at 30°C in the presence of 100 pM forskolin, 1% (w/v) ethanol and increasing 
concentrations of Gpp(NH)p as described in Section 2.7.1. The [32P]cyclic AMP 
formed was measured by the double column method described in Section 2.7.2. 
The figure shows an experiment representative of three performed on different 
membrane preparations which gave quantitatively similar results.
Basal activities in this experiment were 5.5 ± 2.1 (lean) and 5.9 ± 3.0 
(diabetic) pmol/min/mg. Forskolin-stimulated activities were 150.9 ± 10.2 (lean) 
and 149.0 ± 15.0 (diabetic) pmol/min/mg.
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Figure 3.28:
Effect Of Pertussis Toxin Treatment On The Dose-Response Curve 
For Gpp(NH)p Inhibition Of Adenylate Cyclase Activity In The 
Presence Of 100 pM Forskolin And 1% (v/v) Ethanol In Liver 
Plasma Membranes From Lean Animals
Sucrose-purified liver plasma membranes from lean ( □  ) and pertussis 
toxin-treated lean ( ■  ) animals were assayed for adenylate cyclase activity for 5 
minutes at 30°C in the presence of 100 jiM forskolin, 1% (w/v) ethanol and 
increasing concentrations of Gpp(NH)p as described in Section 2.7.1. The 
[32P] cyclic AMP formed was measured by the double column method described in 
Section 2.7.2. The figure shows an experiment representative of three performed 
on different membrane preparations which gave quantitatively similar results.
Basal activities in this experiment were 4.9 ± 2.2 (lean) and 5.0 ± 1.0 
(pertussis toxin-treated lean) pmol/min/mg. Forskolin-stimulated activities were
157.2 ± 13.0 (lean) and 149.3 ± 10.0 (pertussis toxin-treated lean) pmol/min/mg.
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Figure 3.29:
Effect Of Pertussis Toxin Treatment On The Dose-Response Curve 
For Gpp(NH)p Inhibition Of Adenylate Cyclase Activity In The 
Presence Of 100 fiM Forskolin And 1% (v/v) Ethanol In Liver 
Plasma Membranes From Diabetic {dbldb) Animals
Sucrose-purified liver plasma membranes from diabetic {dbldb) ( O ) 
and pertussis toxin-treated diabetic ( •  ) animals were assayed for adenylate
cyclase activity for 5 minutes at 30°C in the presence of 100 pM forskolin, 1% 
(w/v) ethanol and increasing concentrations of Gpp(NH)p as described in Section 
2.7.1. The [32P]cyclic AMP formed was measured by the double column method 
described in Section 2.7.2. The figure shows an experiment representative of three 
performed on different membrane preparations which gave quantitatively similar 
results.
Basal activities in this experiment were 5.9 ± 3.0 (diabetic) and 4.2 ±1.2  
(pertussis toxin-treated diabetic) pmol/min/mg. Forskolin-stimulated activities were 
149.0 ± 15.0 (diabetic) and 141.5 ± 9.8 (pertussis toxin-treated diabetic) 
pmol/min/mg.
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Figure 3.30:
Time Courses For The Effects Of Gpp(NH)p On Forskolin- 
Stimulated Adenylate Cyclase Activity
Time courses were performed in a final reaction volume of 1.25 ml in a 6 ml 
plastic scintillation vial stirred continuously in a 30°C water bath by means of an 
underwater stirrer (Cambridge Instruments). The reaction mixture contained the 
components described in Section 2.7.1 with the addition of [<x-32P]ATP at a final 
concentration of 2jiCi/50 pi. This mixture was stirred for 5 minutes at the desired 
temperature before the addition of membranes to initiate the reaction. At 30 or 60 
second intervals, 50 pi aliquots were withdrawn and added to 100 pi aliquots of the 
"stopping solution" described in Section 2.7.2 before the addition of 800 pi 
distilled water and purification of the [32P] cyclic AMP formed by sequential column 
chromatography (Section 2.7.2). ^
Panel a and panel b show the inhibitory effect of the addition of 100 pM 
Gpp(NH)p (closed symbols) on 100 pM forskolin-stimulated activity (open 
symbols). The experiment in panel a employed membranes from lean animals (□, 
■  ), while panel b used membranes from diabetic {dbldb) animals (O , • ) .  
Panel c demonstrates the effect of the addition of 100 pM Gpp(NH)p on 100 pM 
forskolin-stimulated activity in membranes from lean animals which had been 
treated with pertussis toxin in vivo (A,A).
These experiments were performed on the same day using the same batches 
of reagents, and are representative of two such groups of experiments performed 
with different membrane preparations which gave quantitatively similar results.
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Figure 3.31:
Effect Of Increasing Ethanol Concentrations On Forskolin-Stimulated 
Adenylate Cyclase Activity In Liver Plasma Membranes From Lean 
Animals
Sucrose-purified liver plasma membranes from lean animals ( □  ) were 
assayed for adenylate cyclase activity for 15 minutes at 30°C in the presence of 100 
|iM forskolin and increasing concentrations of absolute ethanol as described in 
Section 2.7.1. The [22P]cyclic AMP formed was measured by the double column 
method described in Section 2.7.2. The figure shows an experiment representative 
of three performed on different membrane preparations which gave quantitatively 
similar results.
In this experiment, basal and forskolin-stimulated activities in the presence 
of a minimal concentration of ethanol were 4.0 ± 1.1 and 120.5 ± 11.9 
pmol/min/mg respectively.
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Figure 3.32:
Effect Of Increasing Ethanol Concentrations On 'Forskolin + 
Gpp(NH)p'-Stimulated Adenylate Cyclase Activity In Liver Plasma 
Membranes From Lean Animals
Sucrose-purified liver plasma membranes from lean animals ( □  ) were 
assayed for adenylate cyclase activity for 15 minutes at 30°C in the presence of 100 
jiM forskolin, 100 jiM Gpp(NH)p and increasing concentrations of absolute 
ethanol as described in Section 2.7.1. The [32P]cyclic AMP formed was measured 
by the double column method described in Section 2.7.2. The figure shows an 
experiment representative of three performed on different membrane preparations 
which gave quantitatively similar results.
In this experiment, basal and 'forskolin + Gpp(NH)p'-stimulated activities 
in the presence of a minimal concentration of ethanol were 4.0 ± 2.2 and 86.5 ± 4.3 
pmol/min/mg respectively.
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3.2 RESULTS & DISCUSSION
Initially it was decided to test for any potential defects in adenylate cyclase 
regulation by activating the adenylate cyclase system of membranes from lean and 
diabetic animals with maximal doses of a range of ligands capable of activating the 
system at various loci (Table 3.1). Basal activities were the same in both lean and 
diabetic animals (Table 3.1). Furthermore, the addition of a saturating dose of 
forskolin, a diterpene capable of binding to and activating the catalytic unit of 
adenylate cyclase directly (Seamon & Daly, 1981), resulted in the same fold 
activation of adenylate cyclase activity over basal in membranes from both lean and 
diabetic animals (Table 3.1). This data implied that the functioning of the adenylate 
cyclase catalytic unit was unaltered by the diabetic state. Similarly, the fold 
activations of adenylate cyclase activity above basal after stimulation with 
maximally effective concentrations of GTP, Gpp(NH)p and NaF, which act on the 
system at the level of G-protein-mediated activation of the catalytic unit, were also 
the same for membranes from lean and diabetic animals (Table 3.1).
To characterise the responses to Gpp(NH)p and NaF further, dose-response 
curves were performed for each of these ligands (Figures 3.1 and 3.2). Whereas 
the dose-response curves for NaF stimulation of adenylate cyclase were identical 
for membranes from lean and diabetic animals (EC50=1.5 ± 0.5 mM for lean 
animals, 2.0 ± 0.4 mM for diabetic animals: data expressed as MEAN ± S.D. for 
three experiments on different membrane preparations) (Figure 3.1 and Table 3.1), 
the dose-response curves for Gpp(NH)p activation of cyclase activity were quite 
different (Figure 3.2). Although Gpp(NH)p was capable of stimulating adenylate 
cyclase activity to the same extent in membranes from lean and diabetic animals 
(Table 3.1), the EC^q value for stimulation was lower in membranes from diabetic 
animals (60 ± 8 nM for diabetic animals compared with 158 ± 10 nM for lean 
animals: data expressed as MEAN ± S.D for three separate experiments on different 
membrane preparations).
Considering the fact that both Gpp(NH)p and NaF are supposed to act at the
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level of G-protein activation, it is difficult to resolve the altered kinetics of cyclase 
activation by Gpp(NH)p but not NaF in liver membranes from diabetic animals 
compared with those from lean animals. It is possible that the differences observed 
are related to the different mechanisms by which NaF and Gpp(NH)p activate G- 
protein a-subunits. From studies on the retinal-specific G-protein transducin, it 
has been proposed that NaF forms a [A1F4]" complex which binds to the guanine 
nucleotide binding site of GDP-bound holomeric a-subunits and mimics the 
terminal y-phosphate group of GTP, thereby inducing activation (Bigay et al., 
1985). However, this model has been contested for NaF-mediated regulation of 
adenylate cyclase activity in platelet membranes due to the inability of NaF, but not 
Gpp(NH)p, to cause a reduction in the agonist binding affinity of a 2-adrenergic 
receptors (Stadel & Crooke, 1988). From these observations it was suggested that 
Gpp(NH)p and NaF mediate G-protein activation by distinct routes (Stadel & 
Crooke, 1988). Gpp(NH)p activation of a G-protein necessarily requires the 
release of GDP from the guanine nucleotide binding site before a molecule of 
Gpp(NH)p can bind. Such distinct modes of activation are presumably reflected in 
the markedly different maximal activities with which Gpp(NH)p and NaF can 
stimulate adenylate cyclase (Table 3.1). These, in turn, may reflect different 
conformations of Gpp(NH)p- and NaF-activated Gsa-subunits which may be 
differentially susceptible to altered regulatory conditions in liver membranes from 
diabetic animals compared with controls. In support of this idea is the observation 
made by Lynch et al. (1989) that guanine nucleotide-stimulated, but not NaF- 
stimulated, adenylate cyclase activity was enhanced in liver plasma membranes 
prepared from rats that had been pretreated with pertussis toxin (to inactivate Gj) 
compared with the activity seen with membranes from sham-injected controls. 
However, a reduction in a tonic inhibitory effect of Gj in liver plasma membranes 
from diabetic animals was not responsible for the altered response to Gpp(NH)p 
observed here as membranes from pertussis toxin-treated diabetic mice retained
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their greater sensitivity to activation by Gpp(NH)p compared to membranes from 
pertussis toxin-treated lean mice (Figures 3.3 and 3.4).(EC50=100 ± 9 nM for 
PTx-treated diabetic animals compared with 355 ± 45 nM for PTx-treated lean 
animals: data are presented for three experiments performed on different membrane 
preparations). Nevertheless, when such experiments were performed in the 
presence of 1 pM glucagon, no such difference in sensitivity was observed (250 ± 
15 nM for lean animals, 220 ± 10 nM for diabetic animals: data presented for three 
experiments performed on different membrane preparations) and the maximal 
stimulations elicited were similar between membranes from lean and diabetic 
animals (870 ± 50 pmol/min/mg for lean animals, 922 ± 33 pmol/min/mg for 
diabetic animals: data presented for three experiments performed on different 
membrane preparations) (Figure 3.24).
There are several potential explanations for the enhanced sensitivity of liver 
membranes from diabetic animals to activation by Gpp(NH)p in the absence of 
stimulatory receptor activation. Altered expression of G-protein subunits could 
potentially affect Gs dissociation in several ways. For example, an altered ratio of 
expression of Gsa-subunits compared with p-subunits might alter the ability of 
holomeric Gs to dissociate into its constituent subunits. Indeed, a decreased 
activation of Gs in the presence of increasing concentrations of Py-subunits has 
been noted by others (Gilman, 1987; Katada et al., 1984c). However, in 
comparative immunoblotting studies of Gsa-subunits using antiserum CS1 there 
was no alteration in the expression of the two forms of Gsa  present between liver 
membranes from lean and diabetic animals (Table 3.3 and Figure 3.15). In 
contrast, there was a 70% reduction in the expression of P-subunits present in 
diabetic samples compared with leans (Table 3.3 and Figure 3.14). This could 
potentially provide an explanation for the observed difference in the response to 
Gpp(NH)p observed in diabetic membranes compared with controls by the 
following j argument. As detailed above, this effect cannot have been due to an
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altered tonic inhibitory effect of Gj in membranes from diabetic animals as the 
enhanced sensitivity of membranes from diabetic animals to stimulation by 
Gpp(NH)p was retained after pertussis toxin treatment in vivo (Figures 3.3 and 
3.4), which abolished Gj function (Figures 3.28 and 3.29). Therefore the 
enhanced sensitivity of adenylate cyclase to stimulation by Gpp(NH)p is likely to be 
due to an alteration in Gs activation. Gpp(NH)p activates Gs by binding to the 
guanine nucleotide binding site such that a conformational change is induced which 
yields the free activated Gpp(NH)p-bound a-subunit (Bimbaumer et al., 1985b). 
This activation of Gs can be attenuated by the addition of py-subunit complexes 
(Bimbaumer et al., 1985b), and so the observation that membranes from diabetic 
animals were more sensitive to activation by Gpp(NH)p may be a reflection of the 
reduction in expression of p-subunits, and the concomitant reduction in levels of 
py-subunits. That such a sensitizing effect was not observed for NaF-mediated 
stimulation of adenylate cyclase might reflect the different conformations which 
Gpp(NH)p and NaF induce, with Gpp(NH)p-bound Gs being more susceptible to 
the reduction in concentration of Py-subunits in membranes from diabetic animals.
The validity of such an argument rests on an appreciation of the relative 
expressions of other G-protein subunits capable of complexing with py-subunits. 
To address this question, at least in part, comparative immunoblotting analyses 
were performed with antisera SGI and I3B to compare the relative expressions of 
different G^-subunits expressed in liver plasma membranes. As discussed in 
Section 2.9, in non-retinal tissues SGI is capable of recognising the a-subunits of 
G jl and G{2 which can only be resolved under the specific electrophoretic 
conditions described in Section 2.8. Figure 3.11 shows that whereas both Gjtx-1 
and Gxol-2 were expressed in membranes prepared from mouse white adipose 
tissue, only one band corresponding to G^ol-2 was expressed in liver membranes 
from both lean and diabetic animals. This is consistent with studies on the 
expression of various G-protein components in rat liver, where neither mRNA or 
protein corresponding to Gja-1 was detected (Suki et al., 1987; Bushfield et al.,
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1990c). Hence SGI could be used as a specific probe for Gxoc-2 in liver plasma 
membranes from both lean and diabetic animals. Comparative immunoblotting 
studies with SGI demonstrated that the expression of Gja-2 was decreased by 
approximately 70% in membranes from diabetic animals compared with leans 
(Figure 3.12 and Table 3.3). Using antiserum I3B in similar immunoblotting 
experiments demonstrated that the expression of GjOC-3 was also reduced in liver 
plasma membranes from diabetic animals compared with leans, but not to the same 
extent as GfL-2 (Figure 3.13 and Table 3.3).
Considering the concomitant reductions in expression of G^a-2 and GjOt-3 
with p-subunits, it was necessary to prove whether such alterations in expression 
could alter the equilibria between holomeric and activated G-protein subunits in the 
presence of guanine nucleotides. This question was addressed by using the abilities 
of cholera and pertussis toxins to catalyse the NAD+-dependent ADP-ribosylation 
of Gs and Gj respectively. Cholera toxin can catalyse the ADP-ribosylation of 
either holomeric or activated Gga-subunits, but the latter are the preferred substrates 
(Ribeiro-Neto et al., 1987). In contrast, pertussis toxin can only catalyse the 
ADP-ribosylation of holomeric GDP-bound G ^-subunits (Tsai et al., 1984). 
Pertussis toxin-catalysed ADP-ribosylation of 100 jig of membranes from lean and 
diabetic animals in the presence of [a- 3 2 P]NAD+ resulted in the labelling of three 
bands (Figure 3.20). However, only labelling of the band with a molecular weight 
of 41 kDa was absolutely dependent on the presence of pertussis toxin, and 
presumably this represented a mixture of Gj(x-2 and GjCX-3 previously identified by 
immunoblotting (Figures 3.12 and 3.13). The labelling of this band was reduced 
by some 8 6 % in membranes from diabetic animals compared with controls (Figure
3.20 and Table 3.4) and presumably this reflects the reductions in levels of GjCX-2 
and Gja-3 observed by immunoblotting (Table 3.3). Comparing Figures 3.18 and 
3.19, it can be seen that the rates at which the ribosylation reaction reached 
equilibrium were similar, with equilibrium being attained after 4 5  minutes for
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membranes from both lean and diabetic animals (Figure 3.14, Table 3.3). 
Therefore, the incubation time chosen for the comparative labelling experiments 
(Figure 3.20) was such that the labelling of Gja-subunits had reached their 
maximum in membranes from both lean and diabetic animals, i.e. after 45 minutes 
(Figure 3.18 and 3.19).
When analogous experiments were performed using cholera toxin and [3 2 P] 
NAD+, five bands were labelled of which two (42 and 45 kDa bands) were labelled 
in a toxin-dependent manner in membranes from both lean and diabetic animals 
(Figure 3.23). Presumably these cholera toxin substrates correspond to the two 
forms of Gsa-subunits recognised previously by immunoblotting (Figure 3.15). 
However in contrast to the results obtained in the comparative immunoblotting 
experiments, when no difference in expression between control and diabetic 
samples was noted (Figure 3.15 and Table 3.3), the labelling of the two forms of 
Gsa  was enhanced by some 3.5- to 4-fold in diabetic samples (Figure 3.23 and 
Table 3.4). The time courses of the ADP-ribosylation reactions in liver membranes 
from lean and diabetic animals showed that ribosylation was maximal for both sets 
of membranes under the conditions in which comparative labelling was measured 
(Figures 3.21 and 3.22). In contrast to the pertussis toxin-catalysed ADP- 
ribosylation experiments, membranes from diabetic animals reached equilibrium 
more rapidly in the cholera toxin-catalysed ADP-ribosylation compared with 
membranes from lean animals. This is particularly marked for the 45 kDa form of 
Gsa ,  which takes approximately 15 minutes longer to reach equilibrium in 
membranes from lean animals compared with those from diabetic animals (Figure
3.21 compared with Figure 3.22). Two obvious potential explanations for these 
effects are (i) liver membranes from diabetic animlals contained relatively more 
active ADP-ribosylation factor (ARF), the low molecular weight GTP-binding 
protein whose presence is essential for cholera toxin to catalyse the ADP- 
ribosylation of its substrates (Kahn & Gilman, 1984) and, since there was no
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means available by which to measure ARF activity, this possibility cannot be 
excluded; (ii) alternatively, the observed reduction in expression of p-subunits in 
liver membranes from diabetic animals compared with lean animals may also effect 
the ADP-ribosylation reaction by increasing the concentration of dissociated Gsa- 
subunits. In the ribosylation mixture, GTP was present at a concentration of 500 
jiM, i.e. Gs was saturated with GTP as it would be under physiological conditions 
(Bimbaumer et al., 1985). Now, it has been noted for Gi and G0  that G-proteins 
are capable of traversing through their regulatory cycle in the presence of GTP but 
in the absence of agonist-bound receptor (Costa & Herz, 1989). In the case of Gs, 
this dissociation would be promoted by the reduction in concentration of Py- 
subunits in diabetic samples, thereby causing an increase in the proportion of free 
GTP-bound Gsa-subunits. As these free subunits are the preferred substrates for 
cholera toxin-catalysed modification compared with the holomeric form (Ribeiro- 
Neto et al., 1987), this situation would lead to the enhanced rate and extent of 
cholera toxin-catalysed ADP-ribosylation of Gsa  in the absence of any change in 
expression of Gsa . In order to test this hypothesis thoroughly, it would be 
necessary to test whether the addition of increasing concentrations of py-subunits 
caused a reduction in the cholera toxin-catalysed labelling of Gsa  in diabetic 
samples. However, no purified P-subunits were available to me during the course 
of these studies.
Despite the observed reductions in expression of various G-protein 
subunits, and the possible alterations in equlilibria between holomeric and 
dissociated G-protein subunits, there was no effect of these changes on either the 
sensitivity or responsiveness of adenylate cyclase to stimulation by glucagon 
(Figure 3.5, Table 3.2). The reasons for this are unclear as one might have 
expected an enhanced sensitivity to stimulation by glucagon in membranes from 
| diabetic animals for the same reasons that account for the increased sensitivity such
membranes exhibit to Gpp(NH)p (Figure 3.2). However, it is possible that there 
was another modification in the adenylate cyclase system from diabetic animals
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which counteracted the affect of the reduced concentrations of py-subunits. In this 
respect it is worth noting that genetically diabetic (db /db ) animals are 
hyperglucagonaemic (Laube et al., 1973). Hence it is likely that the number of 
glucagon receptors present in liver plasma membranes from diabetic animals was 
reduced compared with lean animals due to the persistent hyperglucagonaemia 
causing receptor down-regulation. With regard to this point, other workers have 
shown that the hyperglucagonaemia caused by the induction of Type I diabetes 
leads to a reduction in the number of glucagon receptors present in liver plasma 
membranes from these animals compared with non-diabetic controls (Dighe et al., 
1984; Bhathena et al., 1978). A reduced receptor number would tend to reduce the 
sensitivity of the system to activation by glucagon without necessarily affecting 
maximal stimulation until very high losses are elicited (Houslay et al., 1980),thus 
tending to counteract the effect of reduced levels of py-subunits.
The response of adenylate cyclase to stimulation by isoproterenol was 
slightly reduced in membranes from diabetic animals compared with leans (Figure 
3.8, Table 3.2). As has been postulated above, a reduction in P-adrenergic receptor 
number could explain why no enhanced sensitivity to isoproterenol was observed 
in membranes from diabetic animals compared with leans, but may not account for 
the reduction in maximal stimulation (Figure 3.8, Table 3.2). Hence the 
functioning of the receptor may have been altered such that its ability to couple to 
Gs was impaired in membranes from diabetic animals. Comprehensive receptor 
binding studies could address these points, as one could assess the degree of 
coupling between the p-adrenergic receptor and Gs by measuring the ability of non- 
hydrolysable GTP analogues to reduce agonist affinity for the receptor.
Studies on the effects of the reductions in expression of GjOC-2, GjOC-3 and 
p-subunits on the inhibitory regulation of adenylate cyclase activity proved difficult. 
Other workers have been able to measure pertussis toxin-sensitive inhibition of 
GTP-stimulated adenylate cyclase activity in liver plasma membranes using either
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angiotensin II (Pobiner et al., 1985; Lynch et al., 1989) or a 2-adrenergic agonists 
(Begin-Heick & Welsh, 1988). However, I was unable to observe any inhibitory 
effects of these ligands on adenylate cyclase activity stimulated with 100 pM GTP 
in either lean or diabetic samples (Figure 3.25) despite incorporating modifications 
to the reaction medium described by Pobiner et al. (1985) which have been 
suggested to enhance the inhibitory effect of angiotensin II (see legend to Figure 
3.25 for details).
The ability of GTP and Gpp(NH)p to inhibit forskolin-stimulated adenylate 
cyclase activity in membranes prepared from either whole liver or hepatocytes has 
been reported in several publications (Gawler et al., 1987; Itoh et al., 1985). 
Since Gpp(NH)p exhibits a higher affinity for Gj than Gs, low concentrations of 
Gpp(NH)p can selectively activate GA resulting in the inhibition of adenylate cyclase 
activity (Hildebrandt et al., 1982; Hudson & Fain, 1982). As the concentration of 
the nucleotide increases, Gs becomes activated such that the final maximal specific 
activity obtained reflects the situation when both Gs and Gj are fully activated 
(Gawler, 1987). However, these experiments were performed in the presence of 
1 0 % (v/v) absolute ethanol, the solvent used to dilute the forskolin from its stock 
solution (10 mM) before addition to the assay (Gawler, 1987). Under these 
conditions, I was unable to detect any inhibitory phase to the Gpp(NH)p dose- 
response curve in the presence of 100 pM forskolin (Figure 3.26). At maximally 
effective concentrations of Gpp(NH)p, lean and diabetic animals produced similar 
fold stimulations above basal activity (10.0 ± 0.4 for lean animals, 10.1 ±0.1 for 
diabetic animals; data are presented as MEAN ± S.D. for three experiments 
performed on different membrane preparations) with similar EC5 0  values (105 ± 63 
nM for lean animals, 80 ± 28 nM for diabetic animals; data are presented as MEAN 
± S.D. for three experiments performed on different membrane preparations). 
However, dilution of the stock forskolin solution with distilled water such that the 
final carry-over concentration of ethanol into the assay is 1 % (v/v) produced a
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completely different response (Figures 3.27, 3.28 and 3.29). In membranes from 
both lean and diabetic animals, increasing concentrations of Gpp(NH)p produced a 
dose-dependent inhibition of forskolin-stimulated adenylate cyclase activity: 
presumably these inhibitory effects reflected Gj functioning as they were completely 
abolished by pretreatment of either lean (Figure 3.28) or diabetic (Figure 3.29) 
animals with 1 |ig of pertussis toxin for 3 days in vivo. The concentrations of 
Gpp(NH)p resulting in half-maximal inhibition of adenylate cyclase activity were 
similar for lean and diabetic preparations (10 + 5 pM for lean animals, 5 + 3 |iM for 
diabetic animals; data presented as MEAN + S.D for three experiments performed 
on different membrane preparations) although the maximal inhibition achieved was 
slightly greater in membranes prepared from lean animals (55 ± 6 % for lean animals 
compared with 37 ± 3% for diabetic animals; data presented as MEAN ± S.D. for 
three experiments performed on different membrane preparations).
Because the inclusion of ethanol produced drastic changes in the nature of 
the responses of liver membranes to Gpp(NH)p in the presence of 100 jiM 
forskolin, it was decided to determine the effects of increasing concentrations of 
ethanol on forskolin-stimulated activity and 'forskolin + Gpp(NH)p'-stimulated 
activity. Figure 3.31 shows that increasing ethanol concentrations caused a 
successive reduction in forskolin-stimulated adenylate cyclase activity until at an 
ethanol concentration of 2.5 M, only 5% of the activity attained at 0.2 M was 
detectable. In contrast, increasing concentrations of ethanol within the same range 
as used for the experiment in Figure 3.31 enhanced the specific activity obtained by 
forskolin and Gpp(NH)p (Figure 3.32). The mechanism by which ethanol exerted 
these effects is unknown, but presumably the alcohol must act at more than one 
point in the hormone-sensitive adenylate cyclase system to cause opposite effects on 
forskolin-stimulated activity depending on the presence of a guanine nucleotide.
As these inhibitory effects of Gpp(NH)p observed were distinct from those 
reported by others (Gawler et al., 1987; Hudson & Fain, 1982), it was decided to 
characterise the effect in lean and diabetic preparations (Figure 3.30). For control
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membrane preparations, the addition of 100 }iM forskolin produced a stimulation of 
adenylate cyclase activity which was linear over the time-course of the incubation 
(Figure 3.30, panel a). On the inclusion of 100 fiM Gpp(NH)p to this mixture, a 
'lag phase' was induced over the first 5 minutes before a final steady-state velocity 
was attained which is lesser in magnitude than the reaction rate observed with 
forskolin alone (Figure 3.30, panel a). In membranes from diabetic animals, 
distinct kinetic characteristics were observed; the inclusion of Gpp(NH)p did not 
induce a 'lag phase' but a linear steady-state velocity which was less than the rate 
obtained with forskolin alone was attained (Figure 3.30, panel b). However, in 
samples from diabetic animals, this final steady-state rate was not as reduced 
compared with the forskolin-stimulated activity as was observed for membranes 
from lean animals (Figure 3.30, panel b). Both the 'lag phase' and the reduced 
steady-state velocity seen in the presence of 100 |iM Gpp(NH)p were abolished by 
pertussis toxin pretreatment (Figure 330, panel c).
Three studies have implied that liver membranes contain "spare" Gj 
(Pobiner et al., 1985; Lynch et al., 1989; Bushfield et al., 1990c). Pobiner et 
al. (1985) noted that more than 80% of the 41 kDa pertussis toxin substrate in 
hepatocytes had to be modified before there was any effect on angiotensin II- 
mediated inhibition of adenylate cyclase activity. Also, Bushfield et al. (1990c) 
noted that despite 60% reductions in expression of GjOC-2 and Gj(X-3 compared 
with non-diabetic controls, there was only a small effect on the ability of P2y- 
purinergic receptor agonists to inhibit cyclic AMP accumulation in streptozotocin- 
induced diabetic rat hepatocytes. In a similar study, Lynch et al. (1989) observed 
that a 50% reduction in the expression of GjOC-2 had no effect on the ability of 
angiotensin II to inhibit adenylate cyclase activity in liver membranes from BB/Wor 
Type I diabetic rats compared with non-diabetic controls. It is not yet clear which 
of the pertussis toxin substrates in liver is responsible for the inhibition of adenylate 
cyclase activity, although indirect evidence has suggested that G ja - 2  may be
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responsible (Bushfield et al., 1990a). However, the concept of a "spare" 
inhibitory capacity in liver plasma membranes is consistent with the observations 
here of a 70% reduction in levels of GjOC-2 and a 50% reduction in GjOC-3 causing 
less than a 40% reduction in the maximal inhibitory capacity in membranes from 
diabetic samples compared with leans.
The lack of any gross affects of reduced expressions of GjOc-2 and GjOC-3 
on tonic inhibitory regulation of adenylate cyclase in liver membranes is further 
demonstrated in Figures 3.3, 3.4, 3.6, 3.7, 3.9 and 3.10. Each of these figures 
demonstrate that membranes from both lean and diabetic animals pretreated with 
pertussis toxin, resulting in the ADP-ribosylation and inactivation of Gj in vivo, 
exhibited enhanced maximal responses to Gpp(NH)p, glucagon and isoproterenol 
but similar EC 5 0  values compared with non-treated animals (Table 3.2, Figures 
3.3, 3.4, 3.6, 3.7, 3.9 and 3.10). Therefore, these results appear to be consistent 
with the presence of a tonic GTP-dependent inhibitory effect of Gj on stimulation of 
adenylate cyclase activity in lean and diabetic samples which is abolished by 
treatment with pertussis toxin. However, since the animals were treated for 3 days 
it was important to ascertain whether this treatment caused any alterations in 
expression of G-protein subunits which could otherwise explain the enhanced 
hormone- and guanine nucleotide-mediated stimulations of adenylate cyclase. 
Indeed, an altered expression of p-subunits in adipocyte membranes prepared from 
PTx-treated rats compared with untreated rats has been noted by others (Watkins et 
al., 1989). Therefore comparative immunblotting experiments were performed on 
liver membranes prepared from toxin-treated and untreated animals (Figures 3.16 
and 3.17). Immunoblotting with antisera SGI and I3B, to identify GjOC-2 and 
GjOC-3 respectively, demonstrated that the immunoreactivity of both these proteins 
was enhanced and their mobility on SDS-PAGE gels was reduced (G^a-2 signal 
increased by 3.8±0.6-fold in lean animals, and by 4.1±0.5-fold in diabetic animals 
after PTx treatment; GjOc-3 signal increased by 6.9±0.7-fold in lean animals, and by
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7.8±0.9-fold in diabetic animals after PTx treatment: data presented as MEAN ± 
S.D for two experiments performed on different membrane preparations). The 
reduction in mobility observed for both GjOC-2 and G ^ -3  in membranes from 
pertussis toxin-treated lean and diabetic animals is consistent with their ADP- 
ribosylation (Goldsmith et al., 1987). This observation is particularly important 
with regard to determining the extent of ADP-ribosylation of Gj proteins in liver 
membranes from diabetic animals in vivo as it was impossible to ascertain whether 
these proteins had been fully ribosylated in vivo using thiol-preactivated toxin and 
[32p]NAD+ because the labelling obtained with untreated diabetic animals was 
already small (Figure 3.20). Hence any reduction in labelling in membranes from 
toxin-treated diabetic animals was difficult to estimate. However, the fact that all 
the immunoreactivity corresponding to GjOc- 2  and GjCC-3 exhibited a reduced 
mobility demonstrated that a 3 day treatment of diabetic animals with pertussis toxin 
was sufficient to cause the complete ribosylation of Gj proteins in vivo whereas a 
60 minute in vitro treatment of membranes with preactivated toxin was not (Figure 
3.20).
The reason for the enhanced immunoreactivity of GjOC-subunits in 
membranes from pertussis toxin-treated animals is not clear. Ribeiro-Neto & 
Rodbell (1989) demonstrated that treatment of membranes from rat brain cortex 
with pertussis toxin caused both a reduced mobility of GjOC-1 and GjOC-2 and 
increased the immunoreactivity of these proteins to polyclonal antisera raised 
against their C-terminal decapeptide sequences. Of course, it was also possible that 
pertussis toxin-mediated inactivation of Gja-subunits in vivo increased 
intracellular levels of cyclic AMP in liver such that expression of these proteins was 
increased: isolation of the Gj<x-2 gene has shown there to be a positive cyclic AMP- 
responsive element upstream of the promoter sequence (Brann et al., 1987). 
However, any increase in expression did not correlate with the presence of a 
functional Gj activity in liver membranes from pertussis toxin-treated animals 
(Figures 3.29 and 3.30) or a reduced stimulation of adenylate cyclase activity by
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various ligands (Figures 3.3, 3.4, 3.6, 3.7, 3.8 and 3.9).
Pertussis toxin-treatment of diabetic animals resulted in other changes which 
were not observed for membranes from pertussis toxin-treated lean animals. The 
expression of both forms of Gga-subunits and p-subunits were altered in toxin- 
treated animals compared with untreated animals (Figure 3.17). In membranes 
from PTx-treated lean animals the expression of both forms of Gsa-subunits were 
elevated (2.5±0.5-fold for the 45 kDa form, and 2.9±0.6-fold for the 42 kDa form; 
data presented as MEAN ± S.D. for two experiments performed on different 
membrane preparations). In contrast, levels of these Gsa-subunits were decreased 
in membranes from diabetic animals which had been treated with PTx in vivo 
(20±6% reduction for the 45 kDa form, and 15±5% reduction for the 42 kDa form; 
data presented as MEAN ± S.D. for two experiments performed on different 
membrane preparations). Treatment of both lean and diabetic animals with PTx in 
vivo led to a small reduction in the expression of p-subunits ( 1 1 + 6 % for lean 
animals, 28+6% reduction for diabetic animals; data presented as MEAN ± S.D. for 
two experiments performed on different membrane preparations). The mechanisms 
by which these changes in expression occur are unknown. However, the similarity 
between membranes from toxin-treated lean and toxin-treated diabetic animals with 
respect to the kinetics of hormone- (Figures 3.6, 3.7, 3.9 and 3.10) and guanine 
nucleotide-dependent (Figures 3.3 and 3.4) stimulation of adenylate cyclase activity 
implies that pertussis toxin treatment in vivo causes alterations in the adenylate 
cyclase system which extended beyond the simple modification of GjOC-subunits 
and which together result in a net increase in adenylate cyclase activity.
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3.3 CONCLUSIONS
Several groups have shown that insulin resistance in rodents is associated 
with tissue-specific alterations in the expression and functioning of various 
components of the hormone-sensitive adenylate cyclase system. These changes 
may be partly responsible for the metabolic perturbations associated with diabetic 
syndromes.
A common feature of the regulation of adenylate cyclase activity in liver 
membranes prepared from insulin-resistant Type I and Type II diabetic animals is 
an impaired functioning of this has been noted for the genetically obese Zucker 
rat (Houslay et al., 1989), the genetically obese mouse (B6 gin-Heick & Coleman, 
1988) and the stz-induced Type I diabetic rat (Gawler et al., 1987; Bushfield et 
al., 1990c). This defect is restricted to the abolition of guanine nucleotide- but not 
receptor-dependent inhibition of adenylate cyclase activity (Houslay, 1989), as 
assessed by measuring the ability of the non-hydrolysable GTP analogue 
Gpp(NH)p to inhibit forskolin-stimulated adenylate cyclase activity: whilst a 30- 
40% maximal inhibitory effect was observed for membranes from non-diabetic 
controls, membranes from stz-diabetic and genetically obese rats did not display 
any inhibition (Gawler et al., 1987; Bushfield et al., 1990c). In both these 
systems, this attenuated functioning was attributed to a constitutively elevated PKC 
activity which resulted in the phosphorylation and inactivation of G-va-2 (Bushfield 
et al., 1990b and c).
In contrast to these findings, a pertussis toxin-sensitive tonic inhibitory 
effect of Gj was found to be present in liver plasma membranes prepared from both 
lean and genetically diabetic (db/db) animals. The magnitude of this inhibition was 
slightly reduced in diabetic animals compared with leans, probably as a result of the 
large reductions in expression of the three species capable of mediating inhibitory 
effects, i.e. GjOC-2 , Gja-3 and P-subunits, in membranes from diabetic animals. 
Consistent with the presence of a tonic inhibitory effect of Gj in diabetic samples
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was the enhanced stimulation of adenylate cyclase by Gpp(NH)p, isoproterenol and 
glucagon after preparation of membranes from lean and diabetic animals which had 
been treated with pertussis toxin in vivo to inactivate However, pertussis toxin 
treatment resulted in alterations in G-protein subunit expression in liver membranes 
from both lean and diabetic animals, and it may have produced other changes in the 
adenylate cyclase system which could also explain the enhanced maximal activities 
attained after such treatment.
One interesting observation from this work was the inability to observe 
Gpp(NH)p-dependent inhibition of forskolin-stimulated adenylate cyclase activity 
under conditions which have been reported to give reproducible inhibitory effects 
(Gawler, 1987). By reducing the ethanol concentration to a minimum, potent 
pertussis toxin-sensitive inhibition of forskolin-stimulated activity was observed, 
but only at Gpp(NH)p concentrations which were 2 log orders of magnitude greater 
than those previously reported. Time-course experiments showed that Gpp(NH)p 
inhibition of forskolin-stimulated adenylate cyclase activity in membranes from lean 
animals, but not diabetics, proceeded with a 'lag phase' of approximately 5 minutes 
before a steady-state rate was attained which was lesser in magnitude than that 
attained by forskolin alone. In membranes prepared from pertussis toxin-treated 
animals, Gpp(NH)p did not induce a lag phase and the steady state reaction velocity 
attained was similar in magnitude to that attained with forskolin alone.
Increasing the ethanol concentration present in the reaction mixture reduced 
the forskolin-stimulated activity, yet potentiated the activity observed with forskolin 
and 100 |iM Gpp(NH)p. The mechanisms by which these effects of ethanol occur 
are unknown, but presumably it acts on more than one locus to produce such 
effects on cyclase stimulation.
One might expect that such gross alterations in G-protein subunit expression 
might have profound affects on the regulation of adenylate cyclase activity in 
membranes from diabetic animals compared with their lean littermates. Indeed, the
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observed reduction in expression of p-subunits, and the subsequent reduction in 
levels of Py-subunits that would occur, was expected to alter the equilibria between 
holomeric and dissociated G-protein a-subunits. As Gsa-subunits are supposed to 
be less abundant than G^-subunits in most membranes (Gilman, 1987), one might 
have expected a particularly large effect of the reduced expression of p-subunits on 
the equilibrium between holomeric and dissociated Gsa-subunits. One line of 
evidence supporting this hypothesis was the enhanced cholera toxin-catalysed 
incorporation of [3 2 P]ADP-ribose into the two forms of Gsa-subunits present in 
liver plasma membranes from diabetic animals compared with leans. A similar 
explanation may have contributed to the small reduction in rate and large reduction 
in the extent of pertussis toxin-catalysed ADP-ribosylation of Gja-subunits in 
membranes from diabetic animals compared with leans, although these factors were 
difficult to assess due to the contribution of the reductions in expression of G ja - 2  
and Gja-3 to the reduction in labelling.
Despite these alterations in expression of G-protein subunits and possible 
changes in the ratio of holomeric to dissociated subunits, there were only two 
alterations in the kinetics of adenylate cyclase stimulation in diabetic samples 
compared with leans: an enhanced sensitivity to stimulation by Gpp(NH)p and a 
reduced response to isoproterenol. A similarly reduced response to isoproterenol 
has been noted in adipocyte membranes prepared from genetically diabetic animals, 
although the mechanisms by which this occurs is unknown (Begin-Heick & 
Coleman, 1988; see Chapter 4). The reduced ability of the p-adrenergic agonist 
isoproterenol to activate adenylate cyclase in membranes from diabetic animals 
would suggest that this defect is not restricted to white adipose tissue. However, 
since the stimulation of adenylate cyclase by isoproterenol was only 2- to 2.5-fold 
in membranes from lean animals, p-adrenergic receptor-mediated stimulation of 
cyclic AMP production is unlikely to have any effect on the stimulation of 
gluconeogenesis and glycogenolysis, as the activation of cyclic AMP-dependent 
protein kinase required for these processes necessitates large increases in levels of
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intracellular cyclic AMP, i.e. those cyclic AMP levels attained by stimulation with 
nanomolar concentrations of glucagon. As stimulation of adenylate cyclase by 
glucagon was unaffected by the diabetic state, there were two possibilities which 
could explain the observed reduction in isoproterenol-stimulated adenylate cyclase 
activity in diabetic samples: firstly, the defect was specific to the p-adrenergic 
receptor and may either have been the result of a large reduction in receptor number 
or a defect in the receptor's ability to couple to Gs. Secondly, there could have 
been a G-protein defect, manifested in the altered response to Gpp(NH)p, which 
caused the reduced stimulation by isoproterenol but did not affect the response to 
glucagon because the interaction of the glucagon receptor with Gs was also altered 
in such a manner that it counteracted any G-protein defect, for example there could 
have been a reduced glucagon receptor in liver membranes from diabetic animals. 
However, since the G-protein defect merely involved an enhanced sensitivity to 
guanine nucleotides in the absence of hormones, and GTP is present in vast excess 
of the concentrations required for G-protein activation (Bimbaumer et al., 1985b), 
it is most likely that the reduced p-adrenergic receptor-mediated activation of 
adenylate cyclase was a receptor-specific defect.
Considering the aims of undertaking work on this system as they were 
stated in the introduction to this chapter, the results obtained have produced two 
conclusions. Firstly, the alterations in hepatic carbohydrate and lipid metabolism 
seen in genetically diabetic mice are not simply explicable by any alteration in the 
regulation of hormone-stimulated adenylate j cyclase activity in liver membranes from 
diabetic animals compared with lean controls. Secondly, unlike the genetically 
obese mouse and obese rat systems previously studied, liver membranes from 
diabetic mice exhibit a functional Gj activity, albeit slightly reduced. Therefore a 
non-functional hepatic Gj activity, with respect to the guanine nucleotide-dependent 
tonic inhibitory functioning of this protein(s), is not a universal characteristic of 
severe insulin-resistant and obese states.
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CHAPTER 4
Further Studies On The Regulation Of Adenylate Cyclase Activity In 
Adipocyte Membranes From  Lean And Diabetic (db/db) Mice
4.1 INTRODUCTION
The most obvious characteristic of severe insulin-resistant states associated 
with Type II diabetes mellitus is obesity. This arises due to an increase in adipocyte 
volume caused by triglyceride accumulation. Such a scenario could arise due to 
altered regulation of any of the several steps involved in the control of triglyceride 
metabolism: examples include a reduced synthesis or increased degradation of 
cyclic AMP, a reduced activity of cyclic AMP-dependent protein kinase (PKA), a 
reduced phosphorylation and activation of hormone-sensitive lipase, increased 
lipogenesis, etc.
Several animal models of obesity and insulin resistance have been studied 
with respect to hormone-regulated lipolysis and lipogenesis. The most 
comprehensive studies have been performed on the genetically obese 
hyperglycaemic (oblob) mouse. In adipocytes prepared from these animals, there 
is a drastically reduced ability of catecholamines to stimulate lipolysis (Begin-Heick 
& Heick, 1977; Shepherd et al., 1977). This is not associated with any reduced 
ability of non-metabolisable cyclic AMP analogues to activate lipolysis via 
stimulation of PKA and the subsequent activation of hormone-sensitive lipase 
(Herberg et al., 1970). Hence the defect must reside upstream of PKA activation. 
Consistent with this hypothesis is the reduced ability of catecholamines to elevate 
intracellular cyclic AMP levels (Begin-Heick & Heick, 1977). Although adipocytes 
from obese animals possess a greater cyclic AMP phosphodiesterase activity 
compared with lean animals, hormone-stimulated lipolysis remains lower in 
adipocytes from obese animals in the presence of PDE inhibitors (Shepherd et al., 
1977). Hence, the defect must reside in a reduced ability of catecholamines to 
stimulate cyclic AMP synthesis. This has been confirmed by several groups who 
have noted a reduced stimulation of adenylate cyclase activity in isolated adipocyte 
membranes from obese animals compared with lean animals (Dehaye e ta l., 1978).
Detailed studies on the kinetics of adenylate cyclase regulation have been
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performed for the genetically obese mouse adipocyte system by B6 gin-Heick and 
co-workers and have been described in several publications (Begin-Heick, 1985; 
Bdgin-Heick, 1986; Bdgin-Heick & Coleman, 1988). As well as a reduced steady- 
state stimulation of adenylate cyclase by catecholamines, there is a noticeable 'lag 
phase', or hysteresis, before steady-state activation is reached on stimulation with 
GTP and p-adrenergic agonists in membranes from obese animals but not leans 
(Begin-Heick, 1986). These defects are also associated with the absence of a GTP- 
dependent tonic inhibitory effect of Gj in adipocyte membranes from obese animals 
compared with leans (Begin-Heick, 1985). However, receptor-dependent 
inhibition by the classical anti-lipolytic agents PIA, PGEj and nicotinic acid persists 
in membranes from obese animals (Greenberg et al., 1987).
Relatively few studies have attempted to explain the reduced catecholamine- 
dependent stimulation of lipolysis and adenylate cyclase observed in adipocytes 
from genetically diabetic (db/db) mice (Kupiechi & Adams, 1974; Levilliers et al., 
1978; Begin-Heick & Coleman, 1988). One study performed with adipocyte 
membranes from genetically diabetic animals showed that Gj functioning was intact 
with respect to GTP-dependent 'tonic' inhibitory effects, unlike genetically obese 
(ob/ob) animals, but this was not a detailed study (Begin-Heick & Coleman, 
1988). A more detailed examination of the regulation of adenylate cyclase activity 
in adipocytes from genetically diabetic mice was undertaken for several reasons. 
Firstly, it might have provided some insight into potential mechanisms by which the 
reduced stimulation of adenylate cyclase activity by p-adrenergic receptor agonists 
occurred. Secondly, it might have revealed other signalling defects which could 
exacerbate the reductions in catecholamine-stimulated cyclic AMP levels observed 
in diabetic mouse adipocytes. Finally, it was important to compare any altered 
regulation of adenylate cyclase activity with defects observed in other obesity model 
systems, such as the obese (ob/ob) mouse and the obese (fa/fa) Zucker rat. This 
was undertaken in order to determine whether the obese state is characterised by a
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common set of defects which may help to explain the abnormal accumulation of 
triglyceride.
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Figure 4.1:
D ose-R esponse  C urves F o r Iso p ro te re n o l S tim u la tio n  In  
Adipocyte M embranes From  Lean And Diabetic (db/db) Animals
Adipocyte membranes from lean ( □  ) and diabetic (db/db) ( O  ) 
animals were assayed for adenylate cyclase activity for 30 minutes at 30°C in 
the presence of 100 |iM GTP and increasing concentrations of isoproterenol as 
described in Section 2.7.1. The [3 2 P]cyclic AMP formed was measured by the 
double column method described in Section 2.7.2. The figure shows results 
pooled from three experiments performed on different membrane preparations 
and values are presented as MEAN ± S.D.
Specific activities obtained in the presence of 100 pM GTP alone were
6.3 ± 2 . 1  (lean) and 5.6 ± 2.2 (diabetic) pmol/min/mg (data presented as 
MEAN ± S.D.).
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Table 4.1:
Adenylate Cyclase Activity In Adipocyte Membranes From Lean
And Diabetic (db/db) Animals
Adipocyte membranes prepared from lean and diabetic (db/db) animals 
were assayed for adenylate cyclase activity in the absence (basal) and in the 
presence of the ligands mentioned below for 15 minutes at 30°C as described in 
Section 2.7.1. The [32 P]cyclic AMP formed was measured by the double 
column method described in Section 2.7.2. For experiments employing 
mastoparan, isoproterenol, glucagon, TSH and secretin, GTP was also present 
at a final concentration of 100 |iM. Specific activities are in pmol/min/mg 
protein and data are expressed as MEAN ± S.D. for three experiments using 
different membrane preparations. * denotes a significant difference between 
lean and diabetic animals, z\e.p<0 .0 0 1 .
n.a.=not applicable. n.d.=not determined.
i
As stated in the Acknowledgements, his study was performed in j 
collaboration with Derek Strassheim, Molecular Pharmacology Group, 
Institute of Biochemistry, University of Glasgow. Therefore the kinetic 
parameters obtained with glucagon, secretin, TSH and NaF were obtained 
from his experiments.
Table 4.1:
Stimulating
Lean Diabetic (db/db)
Ligand Spec. Ac. EC5 0  (pM) Spec. Ac. EC5 0 (pM)
Basal 6.5±1.3 n.a. 6.7+1.4 n.a.
100 pM Forskolin 180+14 n.d. 175±12 n.d.
20 mM NaF 55±3 n.d. 51±5 n.d.
100 pM GTP + ! 60 pM Mastoparan 36.4+3.2 n.d. 40.2+5.3 n.d.
100 pM GTP + 1100 pM Isoproterenol 302±10
i
0.36±0.04 160±11* 2 .2 ± 0 .2 *
100 pM GTP + 10 pM Glucagon 33 ± 4 0.16+0.02 16±2* 0.09±0.01
100 pM GTP + 2 pM TSH 18.6±0.9 0.079±0.008 19.0±2.1 0.081±0.009
100pM GTP + 10 pM Secretin 23.8±1.1 0.71±0.08 13.6+0.9* 0.42±0.05
178
Figure 4.2:
Effect Of Increasing Protein Concentration On The Detection Of 
Gsa-Subunits In Adipocyte Membranes From Lean Animals
Increasing amounts of adipocyte membrane protein prepared from lean 
animals were subjected to SDS-PAGE before transfer to nitrocellulose and 
immunoblotting with antiserum CS1 as described in Sections 2.8 and 2.9. The 
amounts loaded are 10 pg (lane 1), 20 pg (lane 2), 30 pg (lane 3), 40 pg (lane 
4), 50 pg (lane 5) and 60 pg (lane 6 ). The blot shown in panel a is 
representative of three performed with different membrane preparations which 
produced identical results. Panel b shows the corresponding graph of band 
intensity versus amount of protein loaded for the 45kDa ( □  ) and 42 kDa 
( O  ) forms of Gga .
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Figure 4.3:
Effect Of Increasing Protein Concentration On The Detection Of
GjCX-1 And G-a-2 In Adipocyte Membranes From Lean Animals
Increasing amounts of adipocyte membrane protein prepared from lean 
animals were subjected to SDS-PAGE under the electrophoretic conditions 
described in Section 2.8.4 before transfer to nitrocellulose and immunoblotting 
with antiserum SGI as described in Section 2.9. The amounts loaded are 10 pg 
(lane 1), 20 pg (lane 2), 30 pg (lane 3), 40 pg (lane 4), and 60 pg (lane 5). 
The blot shown in panel a is representative of three performed with different 
membrane preparations which produced identical results. Panel b shows the 
corresponding graph of band intensity versus amount of protein loaded for both 
Gja-1 and Gja-2.
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Figure 4.4:
Effect Of Increasing Protein Concentration On The Detection Of 
Gjtx-3 In Adipocyte Membranes From Lean Animals
Increasing amounts of adipocyte membrane protein prepared from lean 
animals were subjected to SDS-PAGE before transfer to nitrocellulose and 
immunoblotting with antiserum I3B as described in Sections 2.8 and 2.9. The 
amounts loaded are 50 pg (lane 1), 100 pg (lane 2), 150 pg (lane 3), 200 pg 
(lane 4) and 300 pg (lane 5). The blot shown in panel a is representative of 
three performed with different membrane preparations which produced identical 
results. Panel b shows the corresponding graph of band intensity versus 
amount of protein loaded.
Panel a
A
bs
or
ba
nc
e 
(A
rb
itr
ar
y 
U
ni
ts
)
350
Panel b
300"
250-
200 -
150-
100-
50"
0 50  100 150 200  250  300  350
Protein (jig)
1 8 4
Figure 4.5:
Effect Of Increasing Protein Concentration On The Detection Of 
(3-Subunits In Adipocyte Membranes From Lean Animals
Increasing amounts of adipocyte membrane protein prepared from lean 
animals were subjected to SDS-PAGE before transfer to nitrocellulose and 
immunoblotting with antiserum BN1 as described in Sections 2.8 and 2.9. The 
amounts loaded are 20 pg (lane 1), 40 pg (lane 2), 80 pg (lane 3), 120 pg (lane 
4), 160 pg (lane 5) and 200 pg (lane 6). The blot shown in panel a is 
representative of three performed with different membrane preparations which 
produced identical results. Panel b shows the corresponding graph of band 
intensity versus amount of protein loaded.
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Figure 4.6:
Immunoblotting Of Gsa  In Adipocyte Membranes From Lean And
Diabetic (db/db) Animals
40 jig of adipocyte membrane protein from lean (lane 1) and diabetic 
(db/db) (lane 2) animals were prepared and subjected to SDS-PAGE under 
'normal1 conditions before transfer to nitrocellulose paper and immunoblotting 
using antiserum CS1 as the primary antiserum as described in Sections 2.8 and
2.9. The immunoblot shown is representative of three performed with different 
membrane preparations from lean and diabetic (db/db) animals.
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Figure 4.7:
Im m unoblotting Of GjOC-1 A nd G ja-2  In Adipocyte M embranes
From Lean And Diabetic (dbldb) Animals
70 jig of adipocyte membrane protein from lean (lane 1) and diabetic 
(dbldb) (lane 2) animals were prepared and subjected to SDS PAGE under 
conditions allowing resolution of GjOC-1 and GjOC-2 before transfer to 
nitrocellulose paper and immunoblotting using antiserum SGI as the primary 
antiserum as described in Sections 2.8.4 and 2.9. The immunoblot shown is 
representative of three performed with different membrane preparations from 
lean and diabetic (dbldb) animals. ;
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Figure 4.8:
Im munoblotting Of GjOC-3 In Adipocyte Membranes From Lean
And Diabetic {dbldb) Animals
100 |ig of adipocyte membrane protein from lean (lane 1) and diabetic 
{dbldb) (lane 2) animals were prepared and subjected to SDS-PAGE under 
'normal’ conditions before transfer to nitrocellulose paper and immunoblotting 
using antiserum I3B as the primary antiserum as described in Sections 2.8 and
2.9. The immunoblot shown is representative of three performed with different 
membrane preparations from lean and diabetic {dbldb) animals.
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Figure 4.9:
Im munoblotting Of p-Subunits In Adipocyte M embranes From
Lean And Diabetic {dbldb) Animals
80 pg of adipocyte membrane protein from lean (lane 1) and diabetic 
{dbldb) (lane 2) animals were prepared and subjected to SDS-PAGE under 
'normal' conditions before transfer to nitrocellulose paper and immunoblotting 
using antiserum BN1 as the primary antiserum as described in Sections 2.8 and
2.9. The immunoblot shown is representative of three performed with different 
membrane preparations from lean and diabetic {dbldb) animals.
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Table 4.2:
C om parative Levels O f G -Protein  Subunits In  Adipocyte
Membranes From Lean And Diabetic (db/db) Animals
Adipocyte membranes from lean and diabetic (db/db) animals were 
prepared and subjected to SDS-PAGE before transfer to nitrocellulose and 
immunoblotting with the primary antisera described in Section 2.9.2 by the 
method outlined in Sections 2.8 and 2.9.1. Data express levels of G-protein 
components in diabetic (db/db) animals as a percentage of those found in lean 
animals. For each antiserum, a range of amounts of membrane protein from 
lean and diabetic (db/db) animals was loaded on a single gel to determine 
protein loadings which produced linear increases in absorption with increasing 
amounts of membrane protein applied when the blots were densiometrically 
scanned after visualisation with a peroxidase-conjugated second antibody. 
Subsequent comparative blots employed protein concentrations within these 
parameters.
For each G-protein subunit, data are expressed as MEAN ± S.D. for 
three immunoblots performed with different membrane preparations.
* denotes a significant difference between lean and diabetic animals, 
i.e. pcO.OOl.
Table 4.2:
G-Protein Subunit
Level As A Percentage Of That In Lean 
Membranes (100%)
G ^ - l 192+8*
Gjtx-2 115 ± 12
GjCX-3 115 ± 10
p-subunit 105 ± 2
Gsa  (42 kDa) 111 ± 7
Gsa  (45 kDa) 108 + 7
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Figure 4.10:
Dose-Response Curves For PIA Inhibition Of Isoproterenol-
Stim ulated Adenylate Cyclase Activity In Adipocyte Membranes
From Lean And Diabetic (db/db) Animals
Adipocyte membranes from lean ( Q ) and diabetic (db/db) ( O  ) 
animals were assayed for adenylate cyclase activity for 30 minutes at 23°C in the 
presence of 100 pM GTP, 100 pM isoproterenol and increasing concentrations 
of PIA as described in Section 2.7.1. The cyclic AMP formed was measured by 
the competitive binding method also described in Section 2.7.1. The figure 
shows results pooled from three experiments performed on different membrane 
preparations and values are presented as MEAN ± S.D.
The activities obtained with isoproterenol and GTP alone are given in
Table 4.3.
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Figure 4.11:
Dose-Response Curves For P rostag landin  E j Inhibition Of
Isoproterenol-Stimulated Adenylate Cyclase Activity In Adipocyte
Membranes From Lean And Diabetic (db/db) Animals
Adipocyte membranes from lean ( □  ) and diabetic (db/db) ( O  ) 
animals were assayed for adenylate cyclase activity for 30 minutes at 23°C in 
the presence of 100 pM GTP, 100 pM isoproterenol and increasing 
concentrations of prostaglandin Ej as described in Section 2.7.1. The cyclic 
AMP formed was measured by the competitive binding method also described 
in Section 2.7.1. The figure shows results pooled from three experiments 
performed on different membrane preparations and values are presented as 
MEAN ± S.D.
The activities obtained with isoproterenol and GTP alone are given in
Table 4.3.
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Figure 4.12:
Dose-Response C urves For N icotinic Acid Inh ib ition  Of
Isoproterenol-Stimulated Adenylate Cyclase Activity In Adipocyte
Membranes From Lean And Diabetic (db/db) Animals
Adipocyte membranes from lean ( □  ) and diabetic (db/db) ( O ) 
animals were assayed for adenylate cyclase activity for 30 minutes at 23°C in 
the presence of 100 pM GTP, 100 pM isoproterenol and increasing 
concentrations of nicotinic acid as described in Section 2.7.1. The cyclic AMP 
formed was measured by the competitive binding method also described in 
Section 2.7.1. The figure shows results pooled from three experiments 
performed on different membrane preparations and values are presented as 
MEAN ± S.D.
The activities obtained with isoproterenol and GTP alone are given in
Table 4.3.
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Table 4.3:
Receptor-M ediated Inhibition Of Adenylate Cyclase Activity In
Adipocyte Membranes From Lean And Diabetic (db/db) Animals
Adipocyte membranes from lean and diabetic (db/db) animals were 
assayed for adenylate cyclase activity for 30 minutes at 23°C in the presence of 
100 pM GTP, 100 pM isoproterenol and either 10 pM PIA, 10 pM 
prostaglandin Ej or 100 pM nicotinic acid as described in Section 2.7.1. Data 
are expressed as %-inhibition of the activity observed in the absence of an 
inhibitory ligand but with 100 pM isoproterenol and 100 |iM GTP present. For 
each ligand, results were pooled from three experiments performed on different 
membrane preparations and values are presented as MEAN ± S.D. IC50 is the 
ligand concentration at which half-maximal inhibition was achieved.
Specific activities obtained in the presence of 100 pM isoproterenol and 
100 pM GTP were 275 ± 31 and 97 ± 12 pmol/min/mg protein for lean and 
diabetic animals respectively (MEAN ± S.D. for nine experiments).
* denotes a significant difference between lean and diabetic animals, i.e 
p<0.005.
Table 4.3:
Lean Diabetic (dbldb)
Ligand Inhibition (%) ICjq OiM) Inhibition (%) IC50 (nM)
PIA 60 ± 3 46 ± 5 83 ±9* 25 ± 7
Prostaglandin Ej 66 ± 5 16 ± 3 65 ± 1 18 ± 3
Nicotinic Acid 74 ± 9 400 ± 90 69 ± 3 950 ±120*
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Figure 4.13:
Effect Of Replacing GTP W ith Gpp(NH)p On Isoproterenol
S tim ulation  Of A denylate Cyclase A ctivity In  Adipocyte
Membranes From Lean And Diabetic (db/db) Animals
Adipocyte membranes from lean (□, ■ ) and diabetic (db/db) (O, • )  
animals were assayed for adenylate cyclase activity for 30 minutes at 30°C as 
described in Section 2.7.1.with increasing concentrations of isoproterenol in the 
presence of either 100 |iM GTP (open symbols) or 100 jiM Gpp(NH)p (closed 
symbols). The cyclic AMP formed was measured by the competitive binding 
method also described in Section 2.7.1.
The experiments show the effects of the different nucleotides on the 
responses to isoproterenol in membranes from lean (panel a) and diabetic 
(panel b) animals.
The dose-response curves are shown for an experiment representative of 
three performed with different membrane preparations from lean and diabetic 
(db/db) animals which gave essentially identical results. In this experiment, 
the activities obtained in the presence of 100 pM GTP were 10.0 ± 0.3 (lean) 
and 7.2 ±1.1 (diabetic) pmol/min/mg. In the presence of 100 pM Gpp(NH)p, 
the specific activities obtained were 30.8 ± 2.2 (lean) and 45.5 ±1.0  (diabetic) 
pmol/min/mg.
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4.2 RESULTS & DISCUSSION
As previously discussed, an impairment in the responsiveness of adenylate 
cyclase to stimulation by catecholamines is a characteristic property of adipocyte 
membranes prepared from genetically diabetic (db/db) mice (Levilliers et al., 
1978; B6gin-Heick & Coleman, 1988). This was shown to be true for adipocyte 
membranes prepared from the diabetic animals used in these studies (Figure 4.1 and 
Table 4.1). However, one important difference from the findings of other groups 
was the observed reduction in sensitivity of adenylate cyclase to stimulation by 
isoproterenol in membranes from diabetic animals (Figure 4.1 and Table 4.1). 
When similar dose-response curves were performed using other lipolytic 
hormones, it was found that the maximal stimulation elicited by either glucagon or 
secretin was also reduced by some 50% in membranes from diabetic animals 
compared with leans, although membranes from diabetic animals were slightly 
more sensitive to activation by these ligands (Table 4.1). In contrast, neither 
maximal stimulation of adenylate cyclase by TSH nor the EC50 value for 
stimulation were markedly different in membranes from diabetic animals compared 
with those from lean animals (Table 4.1).
There were several potential explanations for the observed reduction in 
hormone-stimulated adenylate cyclase activity observed in membranes from diabetic 
animals. For example, a reduced activity of the common catalytic unit to which the 
receptors are coupled could account for the reduced response in diabetic animals. 
However, both basal and forskolin-stimulated activities were similar in membranes 
from lean and diabetic samples (Table 4.1). Coupling of the catalytic unit with Gs 
was also unaffected by the diabetic state as NaF-stimulated activities were the same 
in membranes from lean and diabetic animals (Table 4.1).
Altered expression or functioning of any of the G-protein subunits 
controlling adenylate cyclase activity could have potentially accounted for the 
observed reduction in responsiveness. Therefore, comparative immunoblotting
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experiments were performed. Preliminary experiments performed for each 
antiserum determined which range of protein loadings produced directly 
proportional increases in absorption of the second antibody-substrate complex as 
measured by densiometric scanning (Figures 4.2, 4.3, 4.4 and 4.5). Subsequent 
comparisons employed protein concentrations which produced a signal within this 
linear range. Comparative immunoblotting of Gsa-subunits using antiserum CS1 
showed there to be no alterations in the expression of either the 42 kDa or 45 kDa 
forms of the protein expressed in membranes from lean and diabetic animals 
(Figure 4.6 and Table 4.2), confirming the lack of any defect in GS.C coupling as 
implied by the similar responses of membranes from lean and diabetic animals to 
NaF (Table 4.1). Using electrophoretic conditions which allowed the resolution of 
G ja-l and GjCX-2 before detection with antiserum SGI, a two-fold increase in the 
relative expression of Gj(X-l was observed in the absence of any significant change 
in the expression of GjCX-2 between membranes from lean and diabetic animals 
(Figure 4.7 and Table 4.2). Similarly, GjOC-3 was expressed at similar levels in 
membranes from both lean and diabetic animals as assessed using antiserum I3B 
(Figure 4.8 and Table 4.2). Unlike the situation for liver plasma membranes from 
diabetic (db/db) animals, there was no alteration in expression of P-subunits 
between adipocyte membranes from lean and diabetic animals (Figure 4.9 and Table 
4.2). However, since the BN1 antiserum recognizes Pj- and p2-subunits, which 
are both expressed in adipocytes (Rapiejko et al., 1989), the possibility that there 
were alterations in the ratio of expression of both these forms without any change in 
the total complement of P-subunits cannot be discounted.
As discussed in Section 1.9.3, the mechanisms by which Gj inhibits 
adenylate cyclase activity have not yet been proven unequivocally. In adipocytes, 
the identity of the major inhibitory species has yet to be determined. Thus it was 
not initially possible to discount the presence of an enhanced tonic inhibitory effect 
of Gj in diabetic animals, due to the elevated expression of GjOC-1 (Figure 4.7 and
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Table 4.2), resulting in the observed attenuation of hormone-stimulated adenylate 
cyclase activity (Figure 4.1 and Table 4.1). However, studies carried out by 
B6 gin-Heick & Coleman (1988) suggested that the tonic inhibitory effect of GTP 
on forskolin-stimulated adenylate cyclase activity in adipocyte membranes from 
diabetic animals was of a similar magnitude to that found in membranes from lean 
animals. Nevertheless it was also important to determine whether the increased 
expression of GjOC- 1  had any affect on receptor-dependent inhibitory phenomena. 
This was tested using the classical adipocyte anti-lipolytic agents PIA,(the A l 
adenosine receptor agonist) prostaglandin Ej and nicotinic acid, which inhibit 
adenylate cyclase activity via activation of GA (Londos et al., 1978). Maximal 
inhibition of 100 pM isoproterenol-stimulated adenylate cyclase activity by PIA was 
slightly enhanced in membranes from diabetic animals, and diabetic animals were 
also slightly more sensitive to inhibition by this ligand (Figure 4.10 and Table 4.3). 
In contrast, the maximal inhibition elicited by either PGEj or nicotinic acid was 
similar between membranes from lean and diabetic animals, although membranes 
from diabetic animals were slightly less sensitive to inhibition by nicotinic acid 
(Figures 4.11, 4.12 and Table 4.3). The fact that the maximal inhibitions elicited 
by PGEj and nicotinic acid were unaffected by the diabetic state demonstrated that 
the increased expression of G ^ - l  in adipocyte membranes from diabetic animals 
had little affect on inhibitory processes, as any potentiation of inhibition might be 
expected to alter each inhibitory process to some degree. That PIA-mediated 
inhibition was slightly enhanced might have reflected an increased abundance or 
activity of the adenosine Aj receptor: binding studies with [3 H]PIA would have 
tested these proposals. However we cannot discount the possibility that the Aj 
adenosine receptor was preferentially affected by the increase in G |a - 1  relative to 
the other two inhibitory receptors. In either case, enhanced adenosine receptor- 
mediated inhibition might be expected to exacerbate the reductions in cyclic AMP 
levels and lipolysis caused by the defect in hormone-stimulated adenylate cyclase 
activity (Figure 4.1 and Table 4.1) although the latter defect would be expected to
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make a greater contribution to the observed triglyceride accumulation.
A basic preliminary study was undertaken to determine whether the 
coupling between the P-adrenergic receptor and Gs was defective. This was 
achieved by carrying out isoproterenol dose-response experiments using saturating 
concentrations of either GTP or GTPyS as the guanine nucleotide, and comparing 
the nature of the altered kinetics when GTPyS replaces GTP in the dose-response 
curves to isoproterenol for membranes from lean and diabetic animals. In adipocyte 
membranes from lean and obese Zucker rats, the responses to isoproterenol, when 
GTP was replaced with GTPyS, were markedly different (Strassheim et al., 
1991b). In the presence of GTP, there was a marked reduction in the maximal 
specific activity (Vmax) attained by obese animals compared with leans with no 
difference in the EC5 0  value with which isoproterenol could stimulate adenylate 
cyclase. When GTPyS replaced GTP in the assays, the Vmax values obtained with 
lean and obese animals were similar but membranes from obese animals became 
less sensitive to stimulation by isoproterenol. Hence the inclusion of GTPyS 
caused a greater increase in sensitivity to isoproterenol in membranes from lean 
animals than obese animals. In contrast to those results, a similar increase in 
sensitivity to isoproterenol was noted in membranes from lean and diabetic animals 
when GTPyS replaced GTP in the isoproterenol dose-response experiments (Figure 
4.13). Therefore any defect in coupling between the P-adrenergic receptor and Gs 
in adipocyte membranes from diabetic (db/db) animals was distinct from that 
observed in membranes from obese Zucker rats (Strassheim et al. 1991b). Of 
course, it is possible that that the reduced stimulation of adenylate cyclase activity 
by isoproterenol was due to the 70% reduction in the number of p-adrenergic 
receptor binding sites in membranes from diabetic animals compared with lean 
animals, as determined by receptor binding experiments using the p-adrenergic 
receptor antagonist [ 1 2 5 I]iodocyanopindolol (Strassheim et al., 1991a). However, 
work carried out by Tolkovsky & Levitzki (1978) on the p-adrenergic receptor
mediated-stimulation of turkey erythrocyte membrane adenylate cyclase activity has 
suggested that a successive reduction in receptor number may only reduce the rate at 
which Vmax is attained without affecting its magnitude. Hence, if this is correct, 
the observed reduction in receptor number in membranes from diabetic animals 
would merely account for the reduced sensitivity to stimulation by isoproterenol 
without accounting for the reduced Vmax. This might be taken to imply the 
existence of a separate defect(s) in hormone-stimulated adenylate cyclase activity. 
One might expect that any potential defect is at the level of receptor modification 
since the response to TSH in membranes from diabetic animals was identical to that 
in membranes from lean animals (Table 4.1). In support of this idea was the 
finding that stimulation of adenylate cyclase activity by a saturating concentration of 
the wasp venom mastoparan, which is thought to activate G-proteins by a similar 
mechanism to that employed by G-protein-linked receptors (Hagashijima et al., 
1988), was similar in membranes from lean and diabetic animals (Table 4.1). 
Nevertheless the possibility that a defect at the level of Gs may exist which results 
in less efficient coupling between some, but not all, Rs receptors and Gs cannot be 
discounted. For instance, the TSH receptor may already have been poorly coupled 
to Gs in control membranes under the assay conditions employed such that any 
abblated coupling in membranes from diabetic animals was not detectable.
4.3 CONCLUSIONS
Several rodent model systems of diabetes mellitus and obesity are associated 
with a reduced ability of lipolytic hormones to mobilise triglyceride stores present in 
adipose tissue. These include the Zucker rat, obese (<ob/ob) mouse, the NZO 
mouse and the high fat diet-fed rat. In all of these systems an impaired lipolytic 
response is associated with a reduced ability of catecholamines to stimulate 
adenylate cyclase activity in isolated adipocyte membranes. Such characteristics are 
also found in the genetically diabetic (db/db) mouse (see Section 1.11).
201
As well as exhibiting a reduced responsiveness and sensitivity to stimulation 
by isoproterenol, a reduced responsiveness was also observed for adenylate cyclase 
stimulation by two other lipolytic hormones (glucagon and secretin) in adipocyte 
membranes from diabetic animals. However, stimulation by TSH was unaffected 
by the diabetic state. This contrasts with the kinetics of adenylate cyclase 
stimulation in adipocyte membranes prepared from obese Zucker rats, where 
stimulation by all Gs-linked hormones was severely attenuated (Strassheim et a l,  
1991b). Like the diabetic mouse, adipocyte membranes from the genetically obese 
mouse also exhibit a drastically reduced response to stimulation of adenylate cyclase 
by isoproterenol but the responsiveness to other Gs-linked receptors has not been 
tested. However, one important difference observed for the diabetic (dbldb) mice, 
compared to both the obese mouse and Zucker rat systems, was the presence of a 
functional GA activity in diabetic mouse adipocyte membranes, both with respect to 
GTP-dependent and receptor-dependent inhibition of isoproterenol-stimulated 
adenylate cyclase activity. In this respect, adipose tissue from diabetic animals 
resembles the situation in liver membranes which also exhibit guanine nucleotide- 
dependent inhibitory effects, albeit slightly reduced, in contrast to hepatocyte 
membranes from the obese Zucker rat and the Type I diabetic rat, where 'tonic' 
inhibitory functioning of Gj is abolished (Houslay et al., 1989; Bushfield et al., 
1990c).
An important finding in the course of these studies on insulin-resistant 
animals has been the altered expression of specific G-protein subunits. Adipose 
tissue from the genetically diabetic mouse contained elevated levels of GjOC- 1  
subunits compared with lean controls, but this had very little effect on inhibitoiy 
phenomena. In adipocyte membranes prepared from the obese Zucker rat, there 
were large reductions in expression of both Gja - 1  and GjOC-3 with no alteration in 
levels of Gja-2: as with the diabetic mouse system, receptor-dependent inhibition 
of adenylate cyclase activity was largely unaffected by these changes. Also, the 
lack of any change in expression of G ^ -2 ,  GjOC-3 or P-subunits, unlike liver
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membranes prepared from the same animals (see Chapter 3), indicates that 
alterations in the regulation of G-protein subunit expression caused by the diabetes 
(db) gene are tissue-specific.
The mechanisms by which the reductions in reponsiveness to isoproterenol, 
glucagon and secretin arose are unknown. The large reduction in p-adrenergic 
receptor number could potentially account for the reduction in responsiveness and 
sensitivity observed for isoproterenol-stimulated adenylate cyclase activity. 
However, the assumption of a Collision Coupling model of adenylate cyclase 
activation by receptors would suggest the existence of a separate defect to account 
for the reduced activity. Nevertheless, preliminary studies on the effect of replacing 
GTP with a non-hydolysable GTP analogue Gpp(NH)p, when performing 
isoproterenol dose-resonse experiments, indicated that if there was a defect in the 
coupling between the p-adrenergic receptor and Gs, it was distinct from that 
observed in membranes from obese Zucker rats and the obese mouse (Strassheim 
et al., 1991b; Bdgin-Heick, 1980). Comprehensive binding studies are therefore 
necessary to determine whether the observed 70% reduction in p-adrenergic 
receptor number is sufficient to cause the drastic reduction in maximal stimulation 
by isoproterenol, or whether another defect is responsible. This could be achieved 
by measuring the effect of successively reducing receptor number, either by using 
irreversible antagonists or trypsin-treating intact adipocytes, on adenylate cyclase 
activity in normal adipocyte membranes and correlating changes with reductions in 
receptor number. If inactivation of 70% of the total number of P-adrenergic 
receptors produced the same response as that observed in membranes from diabetic 
animals, then the reduction in receptor number found in membranes from diabetic 
animals would presumably account for the attenuated response to p-adrenergic 
receptor agonists. However, if a different response was obtained to that observed 
in membranes from diabetic animals, then a separate defect would be implicated.
One would also need to determine whether the pharmacological properties
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of p-adrenergic receptor-mediated stimulation of adenylate cyclase were the same 
between membranes from lean and diabetic animals. It is theoretically possible that 
another p-adrenergic receptor subtype expressed in adipocytes becomes coupled to 
adenylate cyclase in diabetic animals due to a loss in p j receptors (mainly 
responsible for catecholamine stimulation of adenylate cyclase in fat, as recently 
confirmed by Bahouth & Malbon (1988)), and that these subtypes do not couple to 
Gs as efficiently as Pj. Thorough pharmacological studies would be necessary to 
test this hypothesis.
Finally, it can be concluded that the gross effects of the diabetic (db/db) 
syndrome on reducing the stimulation of adenylate cyclase activity in adipocyte 
membranes probably contribute greatly to the attenuated lipolytic response and the 
• concomitant accumulation of triglyceride. This state would be compounded by 
the slightly enhanced adenosine receptor-mediated inhibition of cyclic AMP 
production and the enhanced lipogenic effect of insulin in adipose tissue from 
genetically diabetic animals (Kupiecki & Adams, 1974). However the mechanisms 
by which these changes arise, and whether they are a cause or a consequence of the 
development of obesity, remain unclear.
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CHAPTER 5
The Regulation Of Adenylate Cyclase Activity In Adipocyte Membranes 
From Lean And Obese CB A/Ca Mice
5.1 INTRODUCTION
As with all the genetic models of Type II diabetes mellitus, the CBA/Ca 
mouse is characterised by severe obesity. However, to our knowledge, no studies 
have been carried out to determine whether any defect in hormone-stimulated 
lipolysis could be explained by perturbed regulation of adenylate cyclase activity in 
adipocyte membranes prepared from these obese animals. Considering the nature 
of the alterations in the regulation of adenylate cyclase activity seen in adipocyte 
membranes from other obese rodents, as discussed earlier, it was considered 
important to determine whether similar defects were observed in the CBA/Ca 
mouse. In particular, I was particularly interested in finding out whether a reduced 
stimulation of adenylate cyclase activity occurred via any of the classical lipolytic 
hormone receptors, as has been conclusively shown for adipocyte membranes from 
the obese (fa/fa) Zucker rat, the obese (ob/ob) mouse and the diabetic (db/db) 
mouse. In these three models of obesity, a resistance to the action of Gs-linked 
hormones appears to be a major factor contributing to the abnormal triglyceride 
< accumulation i (see Section 1.11). It was also necessary to examine the inhibitory 
regulation of adenylate cyclase activity, as one could envisage a scenario whereby 
enhanced inhibition of adenylate cyclase activity, and the ensuing reduction in cyclic 
AMP i accumulation i, could lead to reduced rates of lipolysis and a net 
accumulation of triglyceride. With regard to this point, altered receptor-dependent 
and -independent inhibitory phenomena have been noted in other models of diabetes 
mellitus as well as hypothyroid states (see Section 1.11).
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Figure 5.1:
D ose-R esponse Curves For Isoproterenol Stim ulation Of 
Adenylate Cyclase Activity In Adipocyte Membranes From Lean 
And Obese CBA/Ca Animals
Adipocyte membranes from lean ( □  ) and obese ( O  ) CBA/Ca 
animals were assayed for adenylate cyclase activity for 30 minutes at 30°C in 
the presence of 100 |iM GTP and increasing concentrations of isoproterenol as 
described in Section 2.7.1. The [3 2 P]cyclic AMP formed was measured by the 
double column method described in Section 2.7.2. The figure shows results 
pooled from three experiments performed on different membrane preparations 
and values are presented as MEAN ± S.D.
The specific activities obtained in the presence of 100 jiM GTP alone are
given in Table 5.2.
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Figure 5.2:
Dose-Response Curves For Glucagon Stimulation Of Adenylate
Cyclase Activity In Adipocyte Membranes From Lean And Obese
CBA/Ca Animals
Adipocyte membranes from lean ( □  ) and obese ( O  ) CBA/Ca 
animals were assayed for adenylate cyclase activity for 30 minutes at 30°C in 
the presence of 100 jxM GTP and increasing concentrations of glucagon as 
described in Section 2.7.1. The [3 2 P]cyclic AMP formed was measured by the 
double column method described in Section 2.7.2. The figure shows results 
pooled from three experiments performed on different membrane preparations 
and values are presented as MEAN ± S.D.
The specific activities obtained in the presence of 100 pM GTP alone are
given in Table 5.2.
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Figure 5.3:
Dose-Response Curves For Secretin Stimulation Of Adenylate
Cyclase Activity In Adipocyte Membranes From Lean And Obese
CBA/Ca Animals
Adipocyte membranes from lean ( □  ) and obese ( O  ) CBA/Ca 
animals were assayed for adenylate cyclase activity for 30 minutes at 30° C in 
the presence of 100 |iM  GTP and increasing concentrations of secretin as 
described in Section 2.7.1. The [ 2^ P]cyclic AMP formed was measured by the 
double column method described in Section 2.7.2. The figure shows results 
pooled from three experiments performed on different membrane preparations 
and values are presented as MEAN ± S.D.
The specific activities obtained in the presence of 100 pM GTP alone are
given in Table 5.2.
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Table 5.1:
Hormonal Stimulation Of Adenylate Cyclase Activity In Adipocyte 
Membranes From Lean And Obese CBA/Ca Mice
Adipocyte membranes from lean and obese CBA/Ca animals were assayed 
for adenylate cyclase activity for 30 minutes at 30°C in the presence of either 100 
joM GTP alone or with 10 pM glucagon, 100 pM isoproterenol or 2.5 pM secretin 
as described in Section 2.7.1. The [3 2 P] cyclic AMP formed was measured by the 
double column method described in Section 2.7.2. Specific activities are given as 
pmol/min/mg of protein and expressed as MEAN ± S.D. for three experiments 
using different membrane preparations.
EC5q is the hormone concentration at which half-maximal activation was
%achieved. n.a.=not applicable, denotes significant differences between samples 
from lean and obese animals i.e. p<0.005.
Table 5.1:
Lean Obese
Ligand Spec. Ac. EC5 0  (pM) Spec. Ac. EC5 0  (pM)
100 pM GTP 24.7+2.1 n.a. 28.3±1.9 n.a.
100 pM GTP + Isoproterenol 414.3±27.6 0.9±0.2 930.3±30.0* 2.5+0.3
100 pM GTP + Glucagon 335.7±13.5 0.095±0.012 24.7 ± 5.0* n.a.*
100 pM GTP + Secretin 140.4± 5.6 0.011±0.05 151.1±6.0 0.009±0
9HQ
Table 5.2:
Non-Hormonal Stimulation Of Adenylate Cyclase Activity In
Adipocyte Membranes From Lean And Obese CBA/Ca Mice
Adipocyte membranes prepared from lean and obese CBA/Ca 
animals were assayed for adenylate cyclase activity in the absence (basal) 
and in the presence of the ligands mentioned below for 30 minutes at 
30°C as described in Sections 2.7.1. The [3 2 P] cyclic AMP formed was 
measured by the double column method described in Section 2.7.2. 
Specific activities are in pmol/min/mg protein and data are expressed as 
MEAN ± S.D. for three experiments using different membrane 
preparations, denotes significant differences between samples from lean 
and obese animals i.e. p <0.005.
(Fold activations above basal activity are given in parentheses).
Ligand Lean Obese
Basal 17.6 ± 5 .3  20.3 ± 3.2
100 pM GTP 24.7 ± 2.1 28.3 ±  1.9
lOmMNaF 237 ±20  (13.5) 284 ± 15  (14.0)
5 mM MnCl2  215 ± 13 (12.2) 364 ± 21 (17.9)*
100 pM Forskolin 1381 ± 110 (78.5) 2600 ± 115 (128.1)*
Figure 5.4:
Dose-Response C urves F or PIA Inh ib ition  O f Forskolin-
Stimulated Adenylate Cyclase Activity In Adipocyte Membranes
From Lean And Obese CBA/Ca Animals
Adipocyte membranes from lean ( □  ) and obese ( O  ) CBA/Ca 
animals were assayed for adenylate cyclase activity for 30 minutes at 23°C in 
the presence of 100 pM GTP, 100 pM forskolin and increasing concentrations 
of PIA as described in Section 2.7.1. The cyclic AMP formed was measured 
by the competitive binding method also described in Section 2.7.1. The figure 
shows results pooled from three experiments performed on different membrane 
preparations and values are presented as MEAN ± S.D.
The specific activities obtained with 100 pM forskolin and 100 pM GTP
are given in Table 5.3.
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Figure 5.5:
Dose-Response Curves For P rostag landin  E j Inhibition Of
Forskolin-Stim ulated Adenylate Cyclase Activity In Adipocyte
Membranes From Lean And Obese CBA/Ca Animals
Adipocyte membranes from lean ( □  ) and obese ( O  ) CBA/Ca 
animals were assayed for adenylate cyclase activity for 30 minutes at 23°C in 
the presence of 100 |iM GTP, 100 |iM forskolin and increasing concentrations 
of prostaglandin Ej as described in Section 2.7.1. The cyclic AMP formed was 
measured by the competitive binding method also described in Section 2.7.1. 
The figure shows results pooled from three experiments performed on different 
membrane preparations and values are presented as MEAN ± S.D.
The specific activities obtained with 100 |iM forskolin and 100 |iM GTP
are given in Table 5.3.
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Figure 5.6:
Dose-Response C urves For N icotinic Acid Inh ib ition  Of
Forskolin-Stim ulated Adenylate Cyclase Activity In Adipocyte
Membranes From Lean And Obese CBA/Ca Animals
Adipocyte membranes from lean ( □  ) and obese ( O  ) CBA/Ca 
animals were assayed for adenylate cyclase activity for 30 minutes at 23°C in 
the presence of 100 pM GTP, 100 jiM forskolin and increasing concentrations 
of nicotinic acid as described in Section 2.7.1. The cyclic AMP formed was 
measured by the competitive binding method also described in Section 2.7.1. 
The figure shows results pooled from three experiments performed on different 
membrane preparations and values are presented as MEAN ± S.D.
The specific activities obtained with 100 pM forskolin and 100 pM GTP
are given in Table 5.3.
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Table 5.3:
Receptor-M ediated Inhibition Of Adenylate Cyclase Activity In 
Adipocyte Membranes From Lean And Obese CBA/Ca Animals
Adipocyte membranes from lean and obese CBA/Ca animals were assayed 
for adenylate cyclase activity for 30 minutes at 23°C in the presence of 100 pM 
GTP, 100 pM forskolin and either 10 pM PIA, 10 pM prostaglandin Ej or 100 pM 
nicotinic acid as described in Section 2.7.1 and the legends to Figures 5.4,5.5 and 
5.6. Data are expressed as %-inhibition of the activity observed in the absence of 
an inhibitory ligand but with 100 pM forskolin and 100 pM GTP present. For each 
ligand, results are pooled from three experiments performed on different membrane 
preparations and values are presented as MEAN ± S.D. IC^q is the ligand 
concentration at which half-maximal inhibition was achieved.
Specific activities obtained in the presence of 100 pM forskolin and 100 pM 
GTP were 952.2 ±81.3 and 2177 ± 226.6 pmol/min/mg protein for samples from 
lean and obese animals respectively (MEAN ± S.D. for nine experiments).
♦denotes a significant difference between lean and obese animals, i.e. 
p<0.005.
Table 5.3:
Ligand
Lean Obese
Inhibition (%) IC5 0 (nM) Inhibition (%) IC5 0  (nM)
PIA 62 ± 8 30 ± 4 81 ± 6 * 40 ± 5
Prostaglandin Ej 61 ± 7 15 ± 9 72 ± 5 10 ± 5
Nicotinic Acid 65 ± 8 450 ± 60 69 ± 6 150 + 70*
91 c;
Figure 5.7:
Dose-Response Curves For Gpp(NH)p Inhibition Of Forskolin-
Stim ulated Adenylate Cyclase Activity In Adipocyte Membranes
From Lean And Obese CBA/Ca Animals
Adipocyte membranes from lean ( □  ) and obese ( O  ) CBA/Ca 
animals were assayed for adenylate cyclase activity for 30 minutes at 23°C in the 
presence of 100 fiM forskolin and increasing concentrations of Gpp(NH)p as 
described in Section 2.7.1. The cyclic AMP formed was measured by the 
competitive binding method also described in Section 2.7.1. The figure shows 
results pooled from three experiments performed on different membrane 
preparations and values are presented as MEAN ± S.D. Basal activities were
10.1 ± 2.2 (lean animals) and 9.0 ± 18 (obese animals) pmol/min/mg. The 
specific activities obtained in the presence of 100 fiM forskolin alone were 981 ± 
32 (lean animals) and 2251 ± 53 (obese animals) pmol/min/mg.
%
-A
ct
iv
at
io
n 
Co
m
pa
re
d 
W
ith
 
10
0 
ji
M
 F
or
sk
ol
in
110
100
9 0 -
8 0 -
7 0 -
5 0 -
I i  i n n i |  i  i  i n i i j  i  i  m m  1
No 1 0 ' 1 1 1 0 ' 1 O 1 0 1010101 0 ' °  10
G pp(N H )p
[Gpp(NH)p] (M)
01 c
Figure 5.8:
Dose-Response C urves For G TP-D ependent Inh ib ition  Of
Isoproterenol-Stimulated Adenylate Cyclase Activity In Adipocyte
Membranes From Lean And Obese CBA/Ca Animals
Adipocyte membranes from lean (panel a, □ ) and obese (panel b , 0 )  
CBA/Ca animals were assayed for adenylate cyclase activity for 30 minutes at 
23°C in the presence of 100 |iM isoproterenol and increasing concentrations of 
GTP as described in Section 2.7.1. The cyclic AMP formed was measured by 
the competitive binding method also described in Section 2.7.1. The figure 
shows results from one experiment representative of three performed on 
different membrane preparations.
For this experiment, the specific activities obtained with 100 |iM 
isoproterenol alone were 342.2 ± 8.4 (lean) and 453.2 ± 40.0 (obese) 
pmol/min/mg.
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Figure 5.9:
Im m unoblotting Of GjOt-1 A nd GjOc-2 In Adipocyte M embranes
From Lean And Obese CBA/Ca Animals
30 |ig of adipocyte membrane protein from lean (lane 1) and obese (lane 
2) CBA/Ca animals were prepared and subjected to SDS-PAGE under conditions 
allowing the resolution of G ^ - l  and GjOC-2 before transfer to nitrocellulose 
paper and immunoblotting using antiserum SGI as the primary antiserum as 
described in the Sections 2.8.4 and 2.9. The immunoblot shown is 
representative of three performed with different membrane preparations from lean 
and obese CBA/Ca animals.

Figure 5.10:
Immunoblotting Of GjOc-3 In Adipocyte Membranes From Lean And
Obese CBA/Ca Animals
100 fig of adipocyte membrane protein from lean (lane 1) and obese (lane 
2) CBA/Ca animals were prepared and subjected to SDS-PAGE under 'normal' 
conditions before transfer to nitrocellulose paper and immunoblotting using 
antiserum I3B as the primary antiserum as described in Sections 2.8 and 2.9. 
The immunoblot shown is representative of three performed with different 
membrane preparations from lean and obese CBA/Ca animals.

Figure 5.11:
Immunoblotting Of Gsa  In Adipocyte Membranes From Lean And
Obese CBA/Ca Animals
40 jig of adipocyte membrane protein from lean (lane 1) and obese (lane 
2) CBA/Ca animals were prepared and subjected to SDS-PAGE under 'normal' 
conditions before transfer to nitrocellulose paper and immunoblotting using 
antiserum CS1 as the primary antiserum as described in Sections 2.8 and 2.9. 
The immunoblot shown is representative of three performed with different 
membrane preparations from lean and obese CBA/Ca animals.
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Figure 5.12:
Im munoblotting Of P-Subunits In Adipocyte M embranes From
Lean And Obese CBA/Ca Animals
70 fig of adipocyte membrane protein from lean (lane 1) and obese (lane 
2) CBA/Ca animals were prepared and subjected to SDS-PAGE under ‘normal’ 
conditions before transfer to nitrocellulose paper and immunoblotting using 
antiserum BN1 as the primary antiserum as described in Sections 2.8 and 2.9. 
The immunoblot shown is representative of three performed with different 
membrane preparations from lean and obese CBA/Ca animals.
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Table 5.4:
C om parative Levels Of G -Protein  Subunits In  Adipocyte
Membranes From Lean And Obese CBA/Ca Animals
Adipocyte membranes from lean and obese CBA/Ca animals were 
prepared and subjected to SDS-PAGE before transfer to nitrocellulose and 
immunoblotting with the primary antisera described in Section 2.9.2 by the 
method outlined in Sections 2.8 and 2.9.1. Data express levels of G-protein 
components in membranes from obese animals as a percentage of those found in 
membranes from lean animals. For each antiserum, a range of amounts of 
adipocyte membrane protein from lean and obese animals was loaded on a single 
gel to determine protein loadings which produced linear increases in absorption 
with increasing amounts of membrane protein applied when the blots were 
densiometrically scanned after visualisation with a peroxidase-conjugated second 
antibody. Subsequent comparative blots employed protein concentrations within 
these parameters.
For each G-protein subunit, data are expressed as MEAN ± S.D. for three 
immunoblots performed with different membrane preparations.
* denotes a significant difference between lean and diabetic animals, i.e. 
p<0.005.
Table 5.4:
G-Protein Subunit
Level As A Percentage Of That In Lean 
Animals (100%)
GjOC-1 49 ±10*
Gja-2 76 ±8*
G|0c-3 54 ± 9*
(3-subunit 111 ± 9
Gsa  (42 kDa) 107 ±12
Gsoc (45 kDa) 115 ± 13
9 9 9
5.2 RESULTS & DISCUSSION
Since a marked attenuation in hormone-stimulated adenylate cyclase activity 
is a characteristic feature of adipocytes from several models of obesity associated 
with insulin resistance, the responses to three Gs-linked hormones were examined 
in adipocyte membranes prepared from lean and obese CBA/Ca mice. In the 
presence of 100 |iM GTP, the stimulation of adenylate cyclase activity elicited by 
increasing concentrations of secretin was similar in membranes from lean and obese 
animals (Figure 5.3, Table 5.1) as were the EC50 values for stimulation by this 
ligand (Figure 5.3, Table 5.1). In contrast, the maximal stimulatory response to the 
P-adrenergic receptor agonist isoproterenol was markedly greater in membranes 
from obese animals compared with lean animals, although the EC50 values obtained 
for stimulation were similar (Figure 5.1, Table 5.1). In this respect, the regulation 
of adenylate cyclase activity in adipocyte membranes from obese CBA/Ca animals 
was distinct from that of other rodent models of obesity in which the stimulatory 
responses to p-adrenergic receptor agonists have been shown to be severely 
attenuated. However, under conditions where membranes from lean CBA/Ca mice 
responded potently to increasing concentrations of glucagon in the presence of 100 
|iM GTP, no stimulation above basal activity was observed for membranes from 
obese animals (Figure 5.2, Table 5.1). Considering the heterogenous nature of the 
changes in responsiveness found in membranes from obese animals it seemed most 
likely that these changes arose from changes in either receptor number or 
functioning as opposed to a G-protein defect, as the latter might be expected to 
affect all stimulatory processes to the same extent. Nevertheless, it is possible that 
post-receptor defects could either exacerbate or counteract any affect of altered 
receptor functioning. Hence it was decided to assess any potential contribution of 
the functioning of the catalytic unit of adenylate cyclase and of Gs to the observed 
alterations in the responses to Gs-linked hormones in obese animals (Table 5.2). 
Although basal adenylate cyclase activity, i.e. the activity observed in the absence
of any ligand, was the same in membranes from lean and obese animals, direct 
stimulation of the catalytic unit, achieved using either 100 |iM forskolin or 5 mM 
MnCl2, resulted in a greater stimulation of activity in membranes from obese 
animals compared with lean animals (Table 5.2). If adenylate cyclase activity 
assayed in the presence of either of these two ligands is taken as an index of the 
functioning of the catalytic unit of adenylate cyclase itself, then there there is clearly 
a discrepancy between these observations and those showing that basal activities are 
similar between membranes from lean and obese animals. Potential explanations 
for this discrepancy could relate to the mechanisms by which MnCl2 and forskolin 
activate adenylate cyclase. These are likely to involve interactions and unmask 
differences other than those resulting from a 'pure' interaction with the catalytic unit 
alone. Some of these, of course, are not relevant in vivo where C would not 
encounter these ligands. Thus, Mn2+ ions have two effects on the adenylate 
cyclase system; firstly, they uncouple the catalytic unit from G-protein control, 
thereby removing input to the system from both Gs and Gj, and, secondly, they 
stimulate the catalytic unit by binding to its allosteric Mg2+-binding site (Limbird et 
al., 1979). Forskolin also binds directly to the catalytic unit, although some 
studies have suggested that it also affects regulation of C by Gs (Seamon & Daly, 
1981). The stimulation of adenylate cyclase activity by 10 mM NaF was similar in 
membranes from obese animals compared with lean animals, as was the specific 
activity attained with 100 |iM GTP (Table 5.2). Therefore, the observation that the 
coupling between the catalytic unit of adenylate cyclase and Gs appeared to be 
unaltered in membranes from obese animals compared with those from lean animals 
seemed to confirm the hypothesis that the heterogeneous changes in hormonal 
stimulation of adenylate cyclase observed in membranes from obese animals 
compared with lean animals were due to specific lesions at the level of individual 
receptor number and functioning. However, although the coupling between Gs and 
the catalytic unit of adenylate cyclase was unaffected, it was theoretically possible 
that a reduced functioning of Gj could account for the enhanced stimulation of
n o r
adenylate cyclase activity seen in response to increasing concentrations of 
isoproterenol in membranes from obese animals.
Therefore, studies on the inhibitory regulation of adenylate cyclase activity 
in membranes from lean and obese CBA/Ca mice were undertaken for two reasons; 
firstly, it was possible that enhanced inhibition of adenylate cyclase activity could 
lower intracellular cyclic AMP levels, resulting in a reduced rate of lipolysis and a 
net increase in triglyceride synthesis. Secondly, as discussed in Section 1.11 and 
Chapter 4, altered inhibitory regulation of adenylate cyclase activity is a common 
feature of several rodent models of insulin resistance. Therefore it was important to 
ascertain whether similar aberrations in Gj function were present in this system as it 
has been proposed that altered functioning of this protein is a characteristic feature 
of insulin-resistant states (Bushfield et al., 1990d): as stated above, such an 
attenuated functioning of Gj could potentially have accounted for the enhanced P- 
adrenergic receptor-mediated stimulation of adenylate cyclase activity observed in 
adipocyte membranes from obese animals compared with those from lean animals.
The ability of the non-hydrolysable GTP analogue Gpp(NH)p to inhibit 
forskolin-stimulated adenylate cyclase activity has been used by several groups 
investigating liver (Gawler et al., 1987) and adipocyte (Strassheim et al., 1990; 
Begin-Heick, 1985) membranes to assess G| functioning in the absence of 
inhibitory receptor agonists. Potent inhibitory effects of increasing concentrations 
of Gpp(NH)p were observed for adipocyte membranes from both lean and obese 
animals (Figure 5.7) with both sets of membranes producing similar maximal 
inhibitions of 52.1 ± 3.4% (lean animals) and 45.0 ± 3.4% (obese animals) (data 
presented as MEAN ± S.D. for three separate experiments performed on different 
membrane preparations) at a Gpp(NH)p concentration of 1 |iM. The presence of a 
'tonic' inhibitory effect of Gj in adipocyte membranes from lean and obese animals 
was also tested by using the ability of high concentrations of GTP to inhibit 
isoproterenol-stimulated adenylate cyclase activity (Cooper et al., 1978; Murayama
& Ui, 1983). Membranes from lean and obese animals both exhibited classical 
biphasic responses to increasing concentrations of GTP, with Gs being 
preferentially activated at low GTP concentrations before Gi became activated at 
higher concentrations (Figure 5.8, panels a and b). Other groups have shown 
that the inhibitory phase of this response represents Gj functioning as it can be 
abolished by pertussis toxin treatment to produce a simple monophasic stimulatory 
response to GTP (Murayama & Ui, 1983). Nevertheless, whereas in lean animals 
a maximally effective low concentration of GTP (1 fiM) produced a 76 ± 20% 
increase in adenylate cyclase activity over the control value (Figure 5.8, panel a) an 
increase of 338 ± 5% over control was observed in membranes from obese animals 
(Figure 5.8, panel b). Also, a GTP concentration of 100 |iM produced an 80% 
inhibition of the activity seen at 1 JJ.M in membranes from lean animals; this 
contrasts with the response observed for membranes from obese animals, where 
only a 30% inhibitory effect was observed comparing the activities at the same GTP 
concentrations (Figure 5.8, panels a and b). These differences are unlikely to have 
been due to any enhanced functioning of Gs as GTP- and NaF-stimulated adenylate 
cyclase activities were similar between membranes from lean and obese animals 
(Table 5.2). Also, there was no alteration in the expression of the two Gga-subunit 
isoforms present in adipocyte membranes from lean and obese animals (Figure 5.11 
and Table 5.4). However, it is possible that the greater stimulation of adenylate 
cyclase activity observed at low concentrations of GTP in membranes from obese 
animals compared with lean animals merely reflects the enhanced stimulatory 
response to isoproterenol (Figure 5.1 and Table 5.1). Nevertheless, the simplest 
conclusion from these experiments is that the 'tonic' GTP-dependent inhibitory 
functioning of Gj is severely attenuated in membranes from obese animals, 
resulting in a potentiation of the stimulation elicited at low GTP concentrations and 
a dimunition of the inhibition caused at higher GTP concentrations.
Receptor-dependent inhibition of forskolin-stimulated adenylate cyclase
activity was also measured for membranes from lean and obese animals. Whereas 
the maximal inhibition of adenylate cyclase activity elicited by either PGEj or 
nicotinic acid was similar in membranes prepared from both lean and obese animals 
(Figures 5.5 and 5.6; Table 5.3), the maximal inhibitory effect of the non- 
metabolisable Aj adenosine receptor agonist PIA was approximately 20% greater in 
membranes from obese animals (Figure 5.4, Table 5.3). Membranes from lean and 
obese animals exhibited very similar IC50 values for inhibition by PIA and PGEj, 
although membranes from obese animals were slightly more sensitive to inhibition 
by nicotinic acid (Figures 5.4, 5.5 and 5.6; Table 5.3). The enhanced maximal 
inhibition attained by PIA may have been due to altered Aj adenosine receptor 
functioning or expression since the maximal inhibition achieved by PGEj and 
nicotinic acid were similar between lean and obese animals (Table 5.3). Also, if 
enhanced inhibition was due to a more efficient functioning of the common step in 
the inhibitory process, i.e. Gj, one might have expected a greater tonic inhibitory 
effect of G| to have been present in membranes from obese animals compared with 
lean animals, but this was obviously not the case as determined by both 
Gpp(NH)p-dependent and GTP-dependent inhibitory experiments (Figures 5.7 and 
5.8). However, the possibility that the Aj adenosine receptor was preferentially 
affected by an alteration in Gj function, compared with the other two G--linked 
hormones, cannot be discounted.
Adipocyte membranes from rodent models of pathological states associated 
with obesity, including hypothyroidism (Milligan & Saggerson, 1990) and diabetes 
mellitus (Btigin-Heick, 1990), are associated with changes in the expression of 
various G-protein subunits (see Section 1.11). Hence comparative immunoblotting 
studies were performed to assess the relative expression of various G-protein 
subunits in adipocyte membranes prepared from lean and obese CBA/Ca mice. 
Since the identity of the Gj protein which mediates the inhibition of adipocyte 
adenylate cyclase activity is unknown, comparative immunoblotting studies were 
performed to measure the relative levels of each of the three G^a-subunits
expressed in adipocyte membranes (Mitchell et al., 1989). SDS-PAGE of 
adipocyte membranes under conditions which allow the resolution of GjCc-1 and 
GjOC-2 followed by immunoblotting with antiserum SGI identifies two bands which 
correspond to each of these proteins (Mitchell et al., 1989). Similar experiments 
performed with adipocyte membranes prepared from lean and obese CBA/Ca mice 
demonstrated that the levels of expression of GjOc-1 and Gxa-2 in membranes from 
obese animals were reduced by approximately 50% and 30% respectively compared 
with membranes from lean animals (Figure 5.9 and Table 5.4). The expression of 
GjOt-3 was also reduced by some 50% in membranes from obese animals compared 
with lean animals, as determined using antiserum I3B (Figure 5.10 and Table 5.4). 
In contrast, the levels of the two forms of Gsa-subunit recognised by antiserum 
CS1 were unaffected by the obese state (Figure 5.11 and Table 5.4), as was the 
level of the total pool of p-subunits present in adipocyte membranes, assessed 
using antiserum BN1 (Figure 5.12 and Table 5.4). However, since the single band 
recognised by antiserum BN1 represents a mixture of Pj- and p2-subunits, the 
possibility that an increase in one form was associated with a decrease in the other 
such that the total amount of p-subunits remained unaltered cannot be discounted.
5.3 CONCLUSIONS
The elevation of intracellular cyclic AMP concentrations stimulates lipolysis 
in adipocytes via activation of cyclic AMP-dependent protein kinase and the 
subsequent phosphorylation and activation of hormone-sensitive lipase (Allen et 
al., 1986). Therefore this process is intimately associated with changes in 
adenylate cyclase activity. In several rodent models of obesity, profound alterations 
in lipolytic hormone-stimulated adenylate cyclase activity have been observed, 
including the high-fat diet-fed rat (Gorman et al., 1973), the genetically diabetic 
(db/db) mouse (Bdgin-Heick & Coleman, 1988), the obese (ob/ob) mouse 
(Begin-Heick, 1985) and the genetically obese (falfa) rat (Vannucci et al., 1990).
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Since defects in the regulation of adipocyte adenylate cyclase activity seem to 
characterise obese states, and may contribute to the abnormal accummulation of 
triglyceride, the regulation of adenylate cyclase activity in adipocyte membranes 
prepared from genetically obese CBA/Ca mice was studied to determine whether 
similar changes occurred to those observed in the other models of obesity 
mentioned above.
Isoproterenol and glucagon were potent stimulators of adenylate cyclase 
activity in adipocyte membranes from lean mice. Adipocyte membranes from 
genetically obese (fa!fa) Zucker rats (Strassheim et al., 1991b), genetically 
diabetic (dbfdb) mice (Chapter 4) and high fat diet-fed rats (Gorman et al., 1973) 
exhibit severely attenuated responses to maximally effective concentrations of both 
these ligands compared with membranes from lean animals. Indeed, a reduced 
catecholamine-stimulated lipolytic response is a universal feature of rodent models 
of obesity associated with either hypothyroidism (Debons & Schwartz, 1961) or 
Type II diabetes mellitus (Begin-Heick & Heick, 1977; Levilliers et al., 1978; 
Vannucci et al., 1990). However, membranes from genetically obese CBA/Ca 
mice actually exhibited an enhanced maximal response to isoproterenol stimulation, 
whilst the response to glucagon was completely abolished in membranes from 
obese animals. The responses of both sets of membranes to increasing 
concentrations of secretin were similar, indicating that the alterations in the 
responses to isoproterenol and glucagon may have been receptor-specific.
Another possible explanation for the enhanced response to isoproterenol in 
membranes from obese animals could have been the increase in the activity of the 
catalytic unit (C), which was determined by measuring the stimulations elicited by 
maximally effective concentrations of forskolin and MnCl2. However basal, GTP- 
and NaF-stimulated adenylate cyclase activities were similar between samples from 
lean and diabetic animals. There are two potential explanations for this discrepancy; 
firstly, both forskolin and MnCl2 are potent stimulators of C which are not
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encountered by the protein in vivo. Hence, any conformational change and 
concomitant increase in the activity of C which these ligands might unmask may 
not occur normally, i.e. under basal conditions or when C is activated by Gs, and 
this may explain why basal and Gs-stimulated activities are unaltered. 
Alternatively, it is possible that whilst maximally effective concentrations of MnCl2 
and forskolin bind to and activate the total complement of C present in adipocyte 
membranes, GTP and NaF are only capable of activating that proportion of C 
which is coupled to Gs, thus accounting for the lack of any affect of the increased 
activity of C on Gs-stimulated activity.
Since GTP- and NaF-stimulated activities were similar between membranes 
from lean and obese animals, the activation of C elicited by GS.C coupling appeared 
to be normal. This was consistent with the lack of any change in expression of the 
two forms of Gsa-subunits between adipocyte membranes from lean and obese 
animals. Hence the alterations in hormonal stimulation observed may have resulted 
from either altered receptor numbers or inefficient coupling between receptors and 
Gs. Glucagon receptor binding studies are necessary to address the reason for the 
abolition of a glucagon response in membranes from obese animals. A large 
reduction in the number of glucagon receptors may have accounted for the 
reduction, but as explained in Chapters 1 and 4, activated receptors behave 
kinetically as catalysts, being capable of activating several Gs molecules in their 
lifespan. One consequence of this mechanism is that large reductions in receptor 
number may merely reduce the rate at which the steady-state velocity is attained 
without affecting its final value: this has been shown for P-adrenergic receptors in 
turkey erythrocytes (Tolkovsky & Levitzki, 1978) as well as glucagon receptors in 
rat hepatocytes (Houslay et al., 1980). Hence a reduction in the number of 
glucagon receptors should only reduce the sensitivity with which glucagon is 
capable of stimulating adenylate cyclase activity without affecting the final maximal 
specific activity attained. Hence it is most likely that the major defect accounting for 
the abolition of glucagon-stimulated adenylate cyclase activity in membranes from
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obese animals is a gross perturbation of the interaction between the glucagon 
receptor and Gs. The nature of this lesion is unknown but considering the receptor- 
specific nature of the alterations in hormone-stimulated adenylate cyclase activity 
that were seen, the defect probably resulted from a non-functional glucagon 
receptor in membranes from obese animals, possibly as a result of a regulatory 
covalent modification. An increase in p-adrenergic receptor number could explain 
the enhanced maximal response to isoproterenol, but comprehensive binding 
studies would be necessary to address this question. However, the possibility that 
the P-adrenergic receptor was preferentially affected by a G-protein defect, such as 
a reduced 'tonic'GTP-dependent inhibitory effect on stimulation, is also likely.
To determine whether adipocyte membranes from the obese CBA/Ca mouse 
exhibited alterations in inhibitory regulation, both guanine nucleotide-mediated and 
receptor-dependent inhibitory phenomena were examined. The abolition of the 
'tonic1 inhibitory effect of Gj has been observed in adipose tissue from the Type I 
diabetic rat (Strassheim et al., 1990), the obese (ob/ob) mouse (B6gin-Heick, 
1985) and the obese (fa/fa) Zucker rat (Strassheim et al., 1991b). This effect was 
monitored either by measuring Gpp(NH)p-dependent inhibition of forskolin- 
stimulated adenylate cyclase activity, or by measuring the ability of GTP to inhibit 
isoproterenol-stimulated activity. Gpp(NH)p was capable of eliciting a similar 
maximal inhibition of forskolin-stimulated adenylate cyclase activity in membranes 
from either lean or obese CBA/Ca animals. In contrast, whilst GTP was also 
capable of causing inhibition of isoproterenol-stimulated activity in membranes 
from lean and obese animals, the inhibition elicited in membranes from lean animals 
was much greater. Hence, in this respect adipocyte membranes from genetically 
obese CBA/Ca mice are similar to those from genetically obese (ob/ob) mice and 
obese Zucker rats, which do not exhibit a functional Gj activity with respect to 
GTP-dependent inhibitory effects (Begin-Heick & Coleman, 1988; Strassheim et 
al.t 1991b). However, adipocyte membranes from obese (ob/ob) mice and
2 3 2
Zucker rats also displayed similarly attenuated Gpp(NH)p-dependent inhibitory 
effects, unlike the CBA/Ca mouse. This may imply the existence of a defect in Gi 
functioning which is distinct from that previously described for adipocytes from 
obese animals. It is possible that the aspect of GA function measured by the ability 
Of Gpp(NH)p to inhibit forskolin-stimulated adenylate cyclase activity activity is 
distinct from that measured by GTP-dependent inhibition of hormone-stimulated 
activity. With regard to this point, it has been suggested that inhibition of basal and 
forskolin-stimulated activities reflects the ability of py-subunits to inhibit adenylate 
cylase activity, whereas inhibition of hormone-stimulated activity represents mainly 
the functioning of G^a-subunits (Hildebrandt & Kohnken, 1990). Hence, the 
reduced ability of GTP to inhibit hormone-stimulated adenylate cyclase activity may 
reflect an attenuated functioning of GjOC-subunits, which does not affect the ability 
of py-subunits to inhibit adenylate cyclase activity. However, it would be 
necessary to determine the effects of pretreating adipocytes with pertussis toxin to 
determine unequivocally that the altered response to GTP in the presence of 
isoproterenol represents a reduced 'tonic' inhibitory functioning of GA. Given that 
inhibition of adenylate cyclase appears to be mediated by GjOC-2 in several systems, 
including platelets (Simmonds et al., 1989a) and possibly hepatocytes (Bushfield 
et al., 1990a), it is possible that this protein has been modified such that it cannot 
function in the absence of an agonist-occupied inhibitory receptor. Such a 
phenomenon has been noted from adipocytes (Strassheim et al., 1990) and 
hepatocytes (Bushfield et al., 1990c) from streptozotocin-induced Type I diabetic 
rats, as well as adipocytes from the genetically obese (ob/ob) mouse (Begin-Heick, 
1985; Greenberg et al., 1987) and the obese Zucker rat (Strassheim et al., 
1991b). Work on the streptozotocin-diabetic rat hepatocyte system suggests that 
the attenuation in inhibitory regulation is due to the phosphorylation and inactivation 
of G ft-2  (Bushfield et al., 1990c).
Receptor-dependent inhibition of forskolin-stimulated adenylate cyclase
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activity was monitored using the anti-lipolytic agents PIA, nicotinic acid and 
prostaglandin Ej. Whereas the maximal inhibitory effects of PGEj and nicotinic 
acid were unaltered in membranes from obese animals, the maximal inhibition 
achieved by PIA was slightly enhanced in membranes from obese animals. 
Therefore the attenuation in the GTP-dependent 'tonic' inhibitory functioning of Gi 
does not produce any gross alteration in receptor-dependent inhibitory phenomena. 
The slightly enhanced Aj adenosine receptor-mediated inhibition of adenylate 
cyclase may reflect either an increased number or functioning of the Aj adenosine 
receptor, although it may be a consequence of the possible loss of a 'tonic' 
inhibitory functioning of Gj in membranes from obese animals. The enhanced 
PIA-mediated inhibition could not be explained by any increased expression of any 
of the Gja-subunits or the total complement of P-subunits; indeed, levels of GjOC-1, 
G^a-2 and GjOc-3 were reduced by between 30 and 50% in membranes from obese 
animals. This situation bears some similarity to adipocyte membranes prepared 
from obese (fa/fa) Zucker rats, in which large reductions in the expression of Gj(X- 
1 and GjOC-3 are not accompanied by any change in receptor-dependent inhibitory 
regulation, although 'tonic' inhibitory effects are abolished (Strassheim et al., 
1991b). A similar increase in Aj adenosine receptor-mediated inhibition of 
adenylate cyclase has also been found in adipocyte membranes from the diabetic 
(dbldb) mouse (Chapter 4) and has also been observed in adipocyte membranes 
from obese aged rats (Green & Johnson, 1989; Guidicelli & Pecquery, 1978).
Considering the heterogeneous nature of the changes in the regulation of 
adenylate cyclase activity in adipocyte membranes from genetically obese CBA/Ca 
mice, it is difficult to assess these changes with respect to their potential relevance 
in the development of obesity in this system. The effect of the enhanced p- 
adrenergic receptor-mediated activation of adenylate cyclase on increasing lipolytic 
rates would be offset by the abolition of a glucagon-stimulated activity. Thus the 
consequences of these changes on lipolytic rates in vivo would depend on the 
particular combination of stimulatory hormones that the adipocytes would be
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exposed to at a given time. Therefore adipocytes from the CBA/Ca mouse are 
distinct from the Zucker rat and the genetically diabetic (db/db) mouse in which 
catecholamine-, glucagon- and secretin-stimulated adenylate cyclase activities, and 
thus the rates with which they stimulate lipolysis, would be reduced in vivo. 
Therefore any combination of stimulatory hormones would produce a reduced rate 
of lipolysis compared with lean controls in these systems. That this would not be 
the case for the obese CBA/Ca mouse implies that some other factors must be 
mainly responsible for the observed accummlation of triglyceride. For example, 
persistently elevated activities of cyclic AMP phosphodiesterases could produce 
sufficient reductions in intracellular cyclic AMP levels to cause a net increase in 
triglyceride synthesis: in this respect, an enhanced cyclic AMP phosphodiesterase 
activity has been noted in adipocytes from genetically obese (ob/ob) mice, although 
inhibition of this PDE activity by methylxanthines still results in reduced 
intracellular cyclic AMP levels compared with adipocytes from lean animals 
(Shepherd et al., 1977). Insulin-stimulated lipogenesis is decreased in adipocytes 
from obese animals compared with lean animals (Mercer et al., 1991), unlike 
adipocytes from the genetically diabetic (db/db) mouse which exhibit an enhanced 
insulin stimulation of lipogenesis (Kupiecki & Adams, 1974). However, other 
potential loci for defects which could explain the observed obesity include impaired 
activation or activity of cyclic AMP-dependent protein kinase, a reduced activity of 
hormone-sensitive lipase, the enzyme which catalyses triglyceride breakdown, or 
increased activities of lipogenic enzymes. Further work will need to determine 
which of these steps is responsible for the obese phenotype in the CBA/Ca mouse.
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CHAPTER 6 
Conclusions And Perspectives
The conclusions for each individual chapter of results have already been 
fully discussed. Therefore this section will be used to discuss potentially wider 
implications of the various conclusions that were reached in these studies of 
adenylate cyclase regulation.
The results from Chapter 3 suggest that a greater proportion of Gsa- and 
GjOC-subunits present in liver membranes from genetically Type II diabetic (db/db) 
mice, compared with those from lean animals, are in their free GTP-bound state. 
This was deduced from the discrepancies between relative assessments of G-protein 
a-subunit levels carried out both by immunoblotting and bacterial toxin-catalysed 
ADP-ribosylation, as well as being bome out by an apparently enhanced sensitivity 
of membranes from diabetic animals to stimulation by increasing concentrations of 
Gpp(NH)p. Whilst these studies have been concerned with the regulation of 
hepatic adenylate cyclase activity, the fact that py-subunits may be able to interact 
with several G-protein a-subunits suggests that such drastic reductions in levels of 
py-subunits in diabetic animals may have profound effects on other G-protein- 
linked signalling systems. Examples of such systems include regulation of 
phosphatidylinositol-specific phospholipase C, phospholipase A2 and various G- 
protein-regulated ion channels.
The mechanisms by which Py-subunits can control signalling events have 
been extensively studied for both the adenylate cyclase and retinal cyclic GMP- 
specific PDE systems. These studies have suggested that py-subunits may reduce 
basal (receptor-independent) GDP release from a-subunits since the rate of GDP 
release from holomeric G-proteins is one thousand-fold less than release from free 
a-subunits (Cerione et al., 1985; Bourne et al. 1991). As a result, basal activity 
would be suppressed such that a hormone-stimulated "signal to noise" ratio would 
be maximized. Such a scenario has been proven for the adenylate cyclase system 
using both isolated S49 lymphoma cell membranes (Hildebrandt & Kohnken, 
1990) and purified detergent-solubilised components (Cerione et al., 1985).
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However, both studies have pointed out that these effects are critically dependent on 
the ratio of a-subunits to py-subunits. Hence, depending on the relative abundance 
of various G-protein a-subunits controlling the effector enzymes mentioned above, 
some systems may be more susceptible to altered regulation by reduced levels of 
Py-subunits than others. Indeed, the recent purification of multiple pertussis toxin- 
insensitive G-protein a-subunits from bovine brain by py-affinity chromatography, 
one of which (a42) was shown to be present in liver by immunoblotting, suggests 
that signalling events other than the ones mentioned above will be subject to 
regulation by the concentration of Py-subunits in the plasma membrane (Pang & 
Stemweis, 1990; Strathmann et al., 1989) Also, with the heterogeneity of p- and 
y-subunits becoming more apparent from molecular cloning studies, it may be that 
different py-complexes can interact preferentially with specific a-subunits, thereby 
adding another level of complexity to the system (Levine et al., 1990).
In Chapter 4, studies on the regulation of adenylate cyclase regulation in 
adipocyte membranes from genetically Type II diabetic (db/db) mice demonstrated 
that lipolytic hormone-stimulated adenylate cyclase activity was severely impaired 
for three out of the four Gs-linked hormones tested, with a particularly large 
reduction being noted for p-adrenergic receptor-stimulated activity. Considering 
the fact that a similar reduction was noted in liver membranes from the same 
animals it would be of great interest to determine whether a reduction in P- 
adrenergic receptor-mediated stimulation of adenylate cyclase activity is observed in 
other insulin-sensitive tissues, especially in heart where cyclic AMP is thought to 
play an important role in mediating contraction (Bristow & Ginsberg, 1986). Also, 
as glucose transport is known to be profoundly affected by ligands which elevate 
intracellular cyclic AMP levels, altered responses to hormones which regulate 
adenylate cyclase activity in skeletal muscle, as well as fat and heart, could have 
profound effects on whole body glucose utilisation. This is because the major 
insulin-responsive glucose transporter, GLUT 4, is a substrate for cyclic AMP-
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dependent protein kinase (Gould & Bell, 1990). However, considering the tissue- 
specific nature of the alterations in G-protein expression observed for the diabetic 
(idbldb) mouse, it is possible that each tissue may display unique signalling 
defects.
Since inhibition of adenylate cyclase is relatively unaffected by the observed 
increase in expression of GjOC-1 in adipocyte membranes from diabetic {dbldb) 
animals, there may be consequences for other pertussis toxin-sensitive signalling 
events. One potential candidate is receptor-mediated inositol phosphate generation, 
which is completely abolished by pertussis toxin treatment in rat adipocytes 
(Moreno et al., 1983).
In Chapter 5, it was argued that the heterogeneous nature of the defects in 
adenylate cyclase regulation in adipocyte membranes from obese CBA/Ca animals, 
compared with those from lean animals, suggested the existence of multiple defects 
in both stimulatory and inhibitory mechanisms. Of particular interest was the lack 
of any response to increasing concentrations of glucagon in membranes from obese 
animals. If such a phenomenon was also present in liver membranes from obese 
animals, this could severely perturb hormonal regulation of liver metabolism which 
would, in turn, have profound effects on whole body carbohydrate, lipid and 
protein metabolism. The marked potentiation in P-adrenergic receptor-mediated 
adenylate cyclase activity, if found in other tissues, could, for example, have 
opposite effects on the catecholamine-stimulated inotropic response in heart, and 
thus on the control of glucose transport in heart, fat and muscle compared with the 
scenario described above for the genetically diabetic {dbldb) mouse. Similarly, 
from studies on adipocytes from obese CBA/Ca mice, the observation of a reduced 
'tonic' inhibitory functioning of Gj in cells other than adipocytes could potentially 
produce constitutively elevated intracellular cyclic AMP levels and, in association 
with an insulin-resistant state, result in a net increase in the catabolism of 
carbohydrate and triglyceride reserves.
In conclusion, it can be seen that the development of an insulin-resistant
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state is associated not only with an insensitivity to some of the actions of insulin, 
but also leads to changes in the responses to other hormones which regulate 
metabolism in insulin-sensitive tissues, such as liver and adipose tissues. In 
particular, the work described here on the regulation of adenylate cyclase activity 
shows that these alterations in responsiveness can involve changes in both 
stimulatory and inhibitory mechanisms, although distinct differences are observed 
between different animal models of insulin-resistance. As stated above, detailed 
studies are now necessary to assess any defects in the receptor/G- 
protein/phospholipase C pathway, which plays an important role in regulating 
hepatocyte and adipocyte metabolism in association with insulin and those 
hormones which control cyclic AMP levels. Indeed, considering the evidence 
which suggests that altered functioning of protein kinase C may be an important 
factor in the development of both adenylate cyclase defects and insulin resistance 
(Karasik et al., 1990; Bushfield et al. 1990d), detailed investigations on the 
mechanisms by which intracellular sources of sn-1,2-diacylglycerol are regulated 
in diabetic states may provide important clues as to how the functioning of protein 
kinase C isoforms isoforms is altered. With respect to the alterations in expression 
of G^-subunits found in many of these insulin-resistant syndromes, it has been 
suggested that the insulin receptor is capable of interacting non-covalently with the 
41 kDa pertussis toxin substrate present in liver membranes, which presumably 
represents a mixture of GfL-2 and GjOC-3 (Rothenberg & Kahn, 1988). If this is a 
reflection of a physiologically relevant interaction between the insulin receptor and 
either G^a-2 or GjOc-3 which is involved in insulin receptor signal transduction, 
then either any reduction in the expression or any covalent modifications of these 
proteins could potentially account for some of the post-binding defects seen to 
characterise insulin's action in diabetic states.
However, any relationship between the observations made here, and by 
other workers, on animal model systems and the analogous signal transduction
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systems in human diabetics remains to be rigorously defined.
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